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Abstract 
The thymic stromal microenvironment is crucial for MHC-restricted positive and 
negative selection of T cells in the thymus to generate functional and self-tolerant αβ T 
cells. The studies outlined in this Thesis provide new insights into this important 
process.  
 
It has been known for decades that murine CD4+CD8+ double positive (DP) thymocytes 
form multicellular conjugates with autologous erythrocytes in vitro, a phenomenon 
termed autorosetting. In Chapter 3 the molecular basis of autorosetting is defined. Using 
a flow cytometry assay it was confirmed that DP thymocytes are the major autorosetting 
population in the thymus, whereas peripheral T lymphocytes do not autorosette. The 
autorosetting assay also revealed that CD8β molecules are the main autorosetting 
receptor on DP thymocytes, an anti-CD8β mAb strongly inhibiting autorosetting, a 
finding confirmed using CD8β.KO and CD8α.KO mice. Heparanase treatment of 
erythrocytes greatly diminished autorosetting, thus indicating that heparan sulfate (HS) 
is the key autorosetting ligand on erythrocytes. This finding is consistent with HS-like 
molecules, such as heparin and dextran sulfate (DxS, 5 and 500 kDa), inhibiting 
autorosetting and blocking the binding of mAb to CD8β, with the autorosetting 
inhibition by heparin being 6-O-sulfate dependent. Also, it was found that in the 
periphery, α2-3 O-sialylation of CD8β molecules substantially inhibited autorosetting, 
as α2-3-specific neuraminidase treatment restored autorosetting by peripheral CD8+ T 
lymphocytes. In addition, it was found that serum-derived histidine-rich glycoprotein 
(HRG) totally inhibited CD8-mediated autorosetting by masking HS on erythrocytes. In 
serum extracted from HRG.KO mice, however, another HRG-like molecule appeared to 
inhibit autorosetting. Thus, O-sialylation of CD8β molecules, combined with circulating 
HRG, strictly regulates the CD8-HS interaction by peripheral CD8+ T lymphocytes. 
 
Experiments described in Chapter 4 investigated the functional consequences of the 
CD8-HS interaction by DP thymocytes. Consistent with earlier reports, HS-like 
molecules, particularly DxS500 kDa can induce a sustained uptake of extracellular Ca2+ in 
DP thymocytes, but not in peripheral T lymphocytes. It was found that, like 
autorosetting, the DxS500 kDa-induced Ca2+ flux was severely impaired in CD8β.KO DP 
thymocytes, and further diminished in CD8α.KO thymocytes. Furthermore, treatment of 
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peripheral CD8+ T lymphocytes with an α2-3-specific neuraminidase restored the 
DxS500 kDa-induced Ca2+ flux, this T cell population otherwise being non-responsive to 
DxS500 kDa stimulation. Using mutant mouse strains it was found that the DxS500 kDa-
induced Ca2+ flux was independent of TCR-induced proximal signalling, being 
unaffected by Zap70-deficiency, but was almost totally eliminated in Slp76-deficient 
DP thymocytes. Moreover, DxS500 kDa markedly enhanced thymocytes activation by an 
immobilised anti-CD3ε mAb, as indicated by CD69 upregulation. Collectively, these 
observations suggest that the CD8-HS interaction, which mediates autorosetting, 
induces a sustained Ca2+ flux in DP thymocytes that lowers the threshold required for 
TCR-mediated activation. 
 
Finally, in Chapter 5 the true physiological relevance of the CD8-HS interaction in T 
cell development was examined. It is well known that selection of the T cell repertoire 
in the thymus requires DP thymocytes to scan cortical thymic epithelial cells (cTEC) for 
self-peptide/MHC complexes. To survive, DP thymocytes need to carry a TCR that 
binds weakly to self-peptide/MHC complexes and generates a weak TCR signal, a 
process known as positive selection, with failure to generate an adequate positively 
selecting TCR signal resulting in DP thymocytes dying by neglect. Using flow 
cytometry it was discovered that highly sulfated HS expressed on the surface of cTEC 
participates in the rosetting between cTEC and thymocytes, this process being CD8-
dependent and being markedly inhibited by HS-like molecules, such as heparin and DxS. 
Furthermore, the interaction of thymocyte CD8 with cTEC HS induced a sustained Ca2+ 
flux in the rosetting thymocytes, consistent with this interaction lowering the signalling 
threshold required to positively select DP thymocytes. 
 
In conclusion, this study demonstrates that the CD8-HS interaction (1) enhances the 
interaction of DP thymocytes with cTEC expressing self-peptide/MHC complexes and 
(2) triggers unique CD8-dependent accessory signals, additional to TCR signals, that 
lower the threshold required for positive selection of TCR clones for self-peptide/MHC 
complexes. 
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1         Chapter One 
 
 
 
 
 
 
 
Literature Review 
 
 
 
 
 
 
 
 
The first part of this Chapter provides a general introduction to the contribution of 
heparan sulfate to the mammalian immune system. The second part of this Chapter 
reviews T lymphocytes development and the contribution of the thymus to this process. 
 
 
Chapter 1 
	 2 
1.1 The roles of heparan sulfate in the mammalian immune system 
1.1.1 Introduction 
Heparan sulfate (HS) is a glycosaminoglycan (GAG) that is ubiquitously expressed on 
cell surfaces and in the extracellular matrix (ECM) and basement membrane (BM). 
Each HS molecule is a linear polysaccharide composed of repeating disaccharides of 
hexuronic acid and D-glucosamine that can exhibit immense structural diversity due to 
substitution to varying extents with sulfate groups and epimerization of glucuronic acid 
to iduronic acid, with areas of high sulfation and glucuronic acid epimerisation being 
co-located in ‘hot spots’ throughout the molecule (FIG. 1). HS is structurally related to 
heparin, an extremely highly sulfated form of HS that is restricted to mast cells. The 
biosynthesis and modification of HS chains is thought to take place within the 
endoplasmic reticulum, Golgi apparatus and trans-Golgi network, which in the end 
produce unique HS chains that are covalently attached to a range of core proteins to 
form HS-proteoglycans (HSPG) (FIG. 1) (Kreuger and Kjellen, 2012, Esko and Selleck, 
2002). After synthesis HS chains can be modified by the endoglycosidase, heparanase 
(Peterson and Liu, 2010), and endosulfatases, Sulf1 and Sulf2 (Nagamine et al., 2012, 
Hossain et al., 2010, Uchimura et al., 2006), to regulate HS availability and function. 
Although the core proteins can function independently of the HS chains they carry 
(Kramer and Yost, 2003), HS predominantly dictates the ligand-binding capability and 
therefore the biological roles of HSPG (Sarrazin et al., 2011). Furthermore, while 
different cell types may express similar core proteins, the HS chains these core proteins 
carry can be markedly distinctive, resulting in HSPG with highly divers yet specialised 
roles in mammalian physiology (Sarrazin et al., 2011, Bernfield et al., 1999). In this 
section, some of the contributions of HS to the functioning of the immune system, 
notably leukocyte development, leukocyte migration, immune activation and 
inflammatory processes will be discussed.   
1.1.2 Different cellular location of HS chains 
In general, cell surface HSPGs include members of the transmembrane syndecans 
(syndecan 1-4) and glycosylphosphatidylinositol (GPI)-linked glypicans (glypican 1-6). 
ECM/BM associated HSPGs are comprised of perlecan, collagen type XVIII and agrin. 
These HSPGs are collectively termed ‘full-time’ HSPGs. ‘Part-time’ HSPG include cell 
surface CD44 (isoform 3 is HS-linked) and extracellular betaglycan, testican and 
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neuropilin (Sarrazin et al., 2011, Parish, 2006). Secretory vesicle-associated serglycin is 
a HSPG that is exclusively expressed intracellularly, particularly in mast cells (Kolset 
and Pejler, 2011). Furthermore, HSPGs can also be localised in the nucleus where they 
potentially regulate gene transcription (Richardson et al., 2001, Fedarko and Conrad, 
1986, Buczek-Thomas et al., 2008, Purushothaman et al., 2011, Chen and Sanderson, 
2009). 
 
	
FIG. 1.1: The structure of HSPG. HS chains (blue line) are linear polysaccharides composed 
of repeating disaccharide subunits, which in their unmodified form are D-glucosamine and D-
glucuronic acid (blue box). During synthesis, HS chains are covalently attached to core proteins 
(open circles) at serine (S) residues. A single HSPG molecule may carry multiple HS chains or 
contain other glycosaminoglycans other than HS (not shown). HS modifications include various 
degrees of O- and N-sulfation and epimerisation of D-glucuronic acid to D-iduronic acid by HS-
modifying enzymes (red box) (Kreuger and Kjellen, 2012). The modifications occur in regions 
(hot spots) along the polysaccharide chain, these hot spots being separated by regions of low 
sulfation. Post-synthesis structural alterations are mainly mediated by the endo-β-glucuronidase, 
heparanase, which cleaves HS chains within highly sulfated regions (cleavage site indicated by 
red scissors and arrow) (Peterson and Liu, 2010). 
 
1.1.3 Prevalence of HS in the mammalian immune system 
Due to the structural similarities between HS and heparin, the latter is often used as an 
experimental model for biochemical studies of HS-protein interactions and predicting 
potential HS binding partners. Several heparin-binding proteins are known to carry the 
‘consensus’ heparin/HS-binding motifs XBBXBX or XBBBXXBX (B being the basic 
amino acids arginine, lysine or histidine and X being one of a range of 
aliphatic/aromatic amino acids) (Hileman et al., 1998). If correctly displayed in the 
secondary structure and optimally positioned within the three-dimensional conformation 
of polypeptides, these sequences are hypothetically capable of facilitating strong ionic 
S 
--[GlcNAc(6S)-GlcA-GlcNS(3S,6S)-IdoA(2S)]n-- 
--[GlcNAc-GlcA]n-- 
Core protein 
HS chain (6-70 kDa) 
Heparanase 
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interactions with negatively charged glycosaminoglycans (Cardin and Weintraub, 1989, 
Hileman et al., 1998). Based on this simple amino acid sequence criterion, the Parish 
Laboratory, assisted by Mr Cameron Jack (Genome Discovery Unit, JCSMR, ANU) 
recently screened for protein sequences matching selected G0 terms in the Ensembl 
database (release 72) with a custom Python script for murine gene products that carry 
these motifs and are listed on the UniProt database (www.uniprot.org) as being reported 
to have immunological functions. We identified a total of 235 HS-binding proteins in 
the mouse genome (Table 1.1), a list that includes known HS-binding proteins and 
many potential new ligands for HS. An intriguing feature of this analysis was that 66% 
of the molecules that potentially bind HS are expressed intracellularly, with only 18% 
being exclusively expressed on the cell surface and only 10% being in the extracellular 
compartment. Remarkably, only one HS-binding protein, the HS degrading enzyme 
heparanase, was identified that can be expressed in intracellular and extracellular 
compartments as well as being able to associate with plasma membranes. This finding is 
consistent with the multiple functional roles of the enzyme. 
 
Despite earlier reports claiming that HS negatively regulates gene transcription 
primarily by repressing the activity of p300 and pCAF histone acetyltransferase 
(Buczek-Thomas et al., 2008, Purushothaman et al., 2011), the bioinformatics screen 
implies that intracellular HS plays a more elaborate role in dictating cellular responses 
to various stimuli. Thus, it is predicted that HS interacts with several regulators of 
histone-modifying enzymes, such as Jarid2 (motif: MKRRHI), Kat6a (LHHLRM, 
KKVKK, RRVRK), and Mll1 (LRRFRA, IKKLRA, LKKAKA, VHRIRV, KKVKR, 
RHLKK) alongside key molecules that are involved in signal transduction and 
regulation of gene transcription, notably Vav1 (VKHIKI), STAT5A (KRIKR), STAT-6 
(KKIKR), Bcl-6 (WKKYKF), Bcl-11a (KHMKK), Ciita (LKRLKL), PTBP3 
(VHRVKI, HRFKK), Lck (VKHYKI), IRAK1 (RRAKK), IRAK4 (HHIHR), Foxj1 
(FKKRRL), Syk (RKAHH), ITK/TSK (IKHYHI), Card11 (KRFRK), Zap70 
(KKLFLKR), Jak3 (IHKLKA, AKKLKF, RRIRR) and Cbl-b (RHFHH) and some 
components of the NF-κβ signalling pathway including NFKB2 (YHKMKI), IKBKG 
(MRKRHV) and Nkap (RRAKK, KKAKK, KKYKK). Interestingly, in the RAG-1 
protein, the presence of a HS-binding motif adjacent to a site critical for DNA binding 
(560D, UniProt) (AKRFRY), and overlapping the site that is essential for DNA hairpin 
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formation (971F and 972R, UniProt (Lu et al., 2006)) (RRFRK), may imply a role for 
HS in regulating V(D)J recombination.   
 
 
Table 1.1: Hypothetical HS-interacting proteins.  
Cellular Location Total Protein 
Intracellular 154 
Nlrp3, Nkap, Lrp5, Lyst, Lck, Irak4, Sla2, Mx2, Syk, Oasl2, Tcf3, 
Myo1e, Atp7a, Cplx2, Tusc2, Ak7, Vav3, Blnk, Spta1, Skap1, Fgr, 
Pmaip1, Aim2, Shb, Ddx60, Dapk3, Nfkb2, Apobec3, Ripk2, Nod1, 
Sptb, Oas1d, Mapk14, Ptbp3, March8, Dapk1, Zfp385a, Bcl2, Mecom, 
Chd7, Gpam, Ap3d1, Lcp2, Arid4a, Polr3a, Tnfaip1, Kat6a, Ung, 
Myo9b, Bcl6, Eprs, Sp3, Bag6, Plcg1, Nbn, Pml, Klf1, Rb1, Sfxn1, 
Bcl11a, Farp2, Jarid2, Xrcc6, Itk, Myo1f, Nlrc5, Cyp27b1, Ikzf1, 
Ddx58, Pip4k2a, Ciita, Foxj1, Rnf168, Prkdc, Pms2, Mll1, Stk3, 
Mef2c, Ahctf1, Prkx, Rag1, Batf3, Map3k14, Ilf2, Herc6, Card11, 
Card9, Dlg1, Itch, Dyrk3, Tnip3, Cdk6, Irgm1, Rnf31, Apc, Unc13d, 
Tlr13, Tlr8, Nedd4, Msh6, Pcid2, Sh2b2, Aicda, Myh9, Pik3cd, Zap70, 
Vav1, Stat5a, Tgtp1, Mx1, Enpp2, Dock2, Pgm3, Unc93b1, Plcg2, 
Stxbp2, Ifi44l, Zfp35, Inpp5d, Oas3, Cblb, Ostm1, Bcl11b, Eps8, 
Prkd1, Ctnnbl1, Polr3b, Samhd1, Nlrc4, Tec, Tet2, Map3k5, Pou1f1, 
Ncaph2, Stat6, Smarca4, Fnip1, Jak3, Cactin, Dicer1, Atm, Ikbkg, 
Satb1, Eif2ak2, Stap1, Msh3, Sgpl1, Cdk13, Foxe1, Zc3h8, Spib, 
Maea, March1, Ank1, Mink1 
Plasma membrane 42 
Mpzl2, Adam10, Ntrk1, Icosl, Cxcr5, Cd97, Tlr6, Pde2a, Adam9, Tlr1, 
Ccr3, Treml2, Tril, Tek, Lrrc8a, Il2ra, Selp, Fas, Hfe, Cd83, Cd22, 
Ccbp2, Ctla4, Tlr2, Klre1, Gpr183, Ccr7, Abcc9, Hoxb4, H2-M5, 
Thsd1, Dcstamp, Il7r, Procr, Amica1, Chrnb2, Tnfrsf13c, Csf1r, Tlr4, 
Tyr, Cd93, Eda, Cd40lg 
Extracellular 24 
Masp1, Ccl25, Osm, Il9, Bmp4, Inhba, Pdgfb, Scg2, Hc, Fam20c, 
Wnt2b, Lrrc17, Gas6, C7, Il1a, Wnt5a, Cxcl12, AI182371, C4b, Cxcl5, 
C8b, Ccl17, Serping1, Ccl28 
Intracellular,  
Plasma membrane  
& Extracellular 
1 Hpse 
Intracellular &  
Plasma membrane 
3 Blk, Flt1, Flt3 
Intracellular  
& Extracellular 
2 Isg15, Prg4 
Plasma membrane  
& Extracellular 8 Tgfb1, Vegfa, Enpp3, Ctsg, C8a, Ptpro, Adam17, Enpp1 
List of murine proteins that carry ‘consensus’ heparin/HS-binding motifs.  The motifs adapted for bioinformatics 
screens are the standard motifs, which are primarily XBBBXXBX or XBBXBX (Hileman et al., 1998) 
(http://gduserv.anu.edu.au/~cameron/protein.html). Short motifs are truncated versions of the standard motifs 
XBBBBX, BBXBB or BBXXXBB (B = basic amino acids R, K, H; X = A, V, I, L, M, F, Y, W). Only proteins in the 
UniProt database (www.uniprot.org) that are known to play immunological roles are listed. 
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It is not surprising that cytokines including IL-1α (LKKRRL), IL-9 (HRVKR), TGF-β1 
(VKRKRI) and chemokines such as CCL17 (KHVKK), CCL19 (RRLKK), CCL25 
(ARKRLVHM), CCL28 (VKRRRI), CXCL5 (KKAKR), and CXCL12 (VKHLKI) also 
carry HS-binding motifs, presumably allowing HS to act as their atypical receptors. 
Moreover, HS-binding motifs are also present on the cognate receptors for soluble 
factors such as the cytokine receptors IL-2Rα (HRWRK) and IL-7R (KKVKH) and the 
chemokine receptors CCR3 (WKFFHA), CCR7 (AHRHRA) and CXCR5 (YRRRRL), 
indicating new roles for HS in regulating leukocyte homeostasis and trafficking. In 
addition, HS may regulate the availability of crucial components in the immunological 
synapse as indicated by the presence of HS-binding motifs in the leader sequences of 
ICOSL (WKKLHV) and CTLA-4 (LRRYKA). The presence of HS binding motifs in 
CD22 (KKARR) and CD40L (KKLKR) also suggests additional roles for HS in cell-
cell communication and T cell costimulation.  
 
Examination of the innate immune system reveals that, although HS is already known to 
interact with TLR-4 (Johnson et al., 2002), it appears that HS may also be recognised by 
other TLRs, including cell surface TLR-1, TLR-2, and TLR-6, and endosomal TLR-8 
and TLR-13. To be more precise, the HS binding motifs appear to be in the extracellular 
domains of TLR-4 (RHIFWRR) and TLR-2 (IRRLHA) and in the cytoplasmic domains 
of TLR-1 (HRARH) and TLR-6 (YHKLRA and HRARH). For the endosomal TLRs, 
both motifs (LKKLHL and LKKKHF) are luminal facing for TLR-8, and cytoplasmic 
(HRLRK) and luminal (LKRLKI) for TLR-13. It is possible that HS is involved in 
regulating downstream signalling when the motifs are present in the TLR cytoplasmic 
domains. In contrast, when these motifs are facing the luminal or extracellular space, 
HS may be a ligand or a regulatory component that modulates the interaction between a 
TLR and its cognate ligands. Furthermore, HS-binding motifs are also present on 
inflammasome components such as Nlrp3 (LKKFKM), Nlrc4 (LKKMRL, RHIHR) and 
Aim2 (LKRFKY), implicating a role for HS in regulating the activation of 
inflammatory caspases. In another aspect of innate immunity, several studies have 
reported that heparin and HS are able to interact with several components of the 
complements system, including C1 (Wuillemin et al., 1997), C1q, C1 inhibitor, C2, C4, 
C4b, C4bp, C6, C8, C9, Factor B, Factor D, Factor H (Sahu and Pangburn, 1993), 
MASP-1/2 (Presanis et al., 2004) and complement receptors CR3 (CD11b/CD18) 
(Diamond et al., 1995) and CR4 (CD11c/CD18) (Vorup-Jensen et al., 2007). In support 
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of these observations, we have identified the presence of HS binding motifs in 
complement proteins such as C4b (FRKFHL), Hc/complement C5 (FHKYKV), C7 
(KRLYLKR), C8a (WRKLRY) and C8b (KRYRH) as well as regulatory components 
of the complement machinery including MASP-1 (KHWRR), Serping1 (HKIRK) and 
CD93/complement component C1q receptor (YHKRRA), further highlighting the role 
of HS as a major modulator of the complement system (Zaferani et al., 2013).  
 
However, it should be noted that more in-depth analyses are required to assess the 
validity of these predicted interactions, in particular the demonstration that the predicted 
HS-binding sites are correctly presented within the secondary structure and final three-
dimensional conformation of the putative HS-binding proteins. Also, there are known 
HS-binding proteins that lack the heparin/HS binding motifs used in this analysis, 
suggesting that the list of binding proteins identified in this screen may, in fact, be an 
under estimate. Thus, at face value, the data set implies that a wide range of HS-binding 
proteins participate in the immune system. 
1.1.4 Functional roles of HS in immunity 
Despite the previous section suggesting that there are many unknown HS-protein 
interactions that may control the immune system, there are a number of well-established 
functional roles for HS in immunity. Indeed HSPGs, through their HS chains, are 
involved in a broad spectrum of biological processes, profoundly influencing 
development (Hacker et al., 2005), homeostasis (Bishop et al., 2007) and the 
progression of many diseases (Lindahl and Kjellen, 2013). In the case of the immune 
system, HSPGs are fundamentally involved in regulating cell adhesion, cytokine and 
chemokine function, sensing tissue injury, and mediating inflammatory reactions. Each 
of these functional roles will be briefly discussed below, with specific examples given 
which highlight each function. 
1.1.4.1 Regulator of cell adhesion 
Cell adhesion molecules are important to facilitate and regulate cell-cell signalling, 
migration and activation of leukocytes during development, homing and recruitment to 
inflammatory sites. For example, of particular relevance to leukocytes development in 
the bone marrow is the receptor complex on hematopoietic stem cells (HSC) comprised 
of CD45 and Mac-1 (CD11b/CD18) that has been shown to bind to surface HS on bone 
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marrow-derived stromal cells and facilitate strong adhesion (Coombe et al., 1994). In a 
related study, the HSPG glypican-3 enhances the antagonising effect of tissue factor 
pathway-inhibitor (TFPI) on CD26, the stromal-bound ectopeptidase that is involved in 
cleaving surface CXCL12, a typical ligand for CXCR4 on HSC. As a result, glypican-3 
indirectly supports the directional homing of grafted HSC towards, and their retention 
in, the bone marrow (Khurana et al., 2013). Similarly, in the thymus a particular subset 
of cortical epithelial cells known as thymic nurse cells are reported to express high 
levels of highly sulfated HS that is thought to aid thymocyte adhesion and facilitate T 
cell development (Werneck et al., 1999, Werneck et al., 2000, Oliveira-dos-Santos et 
al., 1998, Oliveira-dos-Santos et al., 1997). 
 
During an inflammatory response, HS positively regulates the recruitment of 
inflammatory cells at three different stages based on the following observations. First, 
endothelial surface HS can reduce neutrophil rolling velocity via L-selectin-mediated 
cell adhesion (Wang et al., 2005). Second, once attached, the HS-mediated Mac-1-
CD44v3 interaction enhances the binding of leukocytes to the endothelial surface to 
drive extravasation (Zen et al., 2009). Finally, within the endothelial ECM/BM, 
collagen type XVIII promotes leukocytes infiltration in again an L-selectin-dependent 
manner (Kawashima et al., 2003, Celie et al., 2005). However, the role of HS in the 
adhesion of leukocytes to the endothelium can occur paradoxically, in a biphasic 
manner. Under physiological conditions, glycocalyx HSPGs of pulmonary endothelial 
cells are known to impede neutrophil adhesion (Schmidt et al., 2012). Following the 
induction of an experimental sepsis model of acute lung injury, the localised production 
of TNF-α activates endothelial cells to produce heparanase, which in turn catalyses the 
partial degradation of HS constituents of the glycocalyx. The loss of HS results in a 
significant increase in neutrophils binding (Schmidt et al., 2012), presumably via 
neutrophils L-selectin binding to residual endothelial HS and via cytokine-induced 
endothelial P- and E-selectin (Giuffre et al., 1997). Additionally, reduction (in wild-type 
mice) or deletion (in knockout mice) of syndecan-1 from murine endothelial cells 
strongly accentuates antigen-specific lymphocytes infiltration into inflammatory sites 
during a delayed-type hypersensitivity reaction (Kharabi Masouleh et al., 2009).  
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1.1.4.2 Modulator of cytokine and chemokine function 
Soluble factors, such as cytokines and chemokines, are crucial to support growth, 
maintain homeostasis, and orchestrate immune cell trafficking across various locations. 
However, some of these molecules are inactive or susceptible to degradation in their 
native, soluble form. Furthermore, these factors need to be timely presented at the right 
site to exert their anticipated functions. HSPGs have been implicated in modulating 
various aspects of cytokine and chemokine function (Handel et al., 2005, Coombe, 
2008).  
 
HSPGs interact with various cytokines primarily on target cells or act as atypical 
cytokine receptors on cytokine presenting cell. The former situation enables HPSGs to 
regulate the availability and influence the interaction between cytokines and their 
cognate receptors on target cells. For example, the binding of cell surface HS to 
cytokines such as IL-7 and IFN-γ proved critical to protect them against proteolysis 
(Clarke et al., 1995, Lortat-Jacob and Grimaud, 1991). Furthermore, the lack of HSPG 
expression on the mouse pro-B cell surface severely impairs IL-7-dependent maturation 
towards pre-B cells suggesting that in this situation HS acts as a primary IL-7 receptor. 
In addition, HSPG can contribute to IL-7 biological activity by presenting IL-7 on 
stromal cells to promote lymphopoiesis in the bone marrow (Borghesi et al., 1999). In 
the thymus, however, the ability of stromal cell HSPGs to bind IL-7 and aid thymocytes 
development is dispensable (Banwell et al., 2000). Depending on the degree of 
sulfation, cell surface HSPG has also been shown to potentiate the IFN-γ-IFN-γ-
receptor interaction (Sadir et al., 1998). Importantly, HSPG also facilitate cytokine 
localisation in specific niches, forming depots where they can be made available to 
target cells. For instance, perlecan binds IL-2, sequestering it from the circulation and 
subsequently depositing the cytokine in the marginal zone and red pulp of the murine 
spleen to modulate murine T lymphocyte homeostasis (Miller et al., 2008). HSPGs also 
facilitate the storing of IL-2 within the vascular smooth muscle wall where cytokine 
availability is regulated through heparanase-mediated ECM degradation (Miller et al., 
2012). 
 
The ability to bind and present a chemokine to target cells is insufficient to drive cell 
migration, the hallmark of chemokine function. HSPGs are not only capable of binding 
and assisting in inducing conformational changes in bound chemokines (Proudfoot et 
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al., 2003, Salanga and Handel, 2011), but also contribute to the establishment of 
immobilised (haptotactic) chemokine gradients in tissues (Laguri et al., 2008). For 
example, HSPG facilitate the oligomerisation of bound RANTES/CCL5, CXCL8, 
MCP-1, and MIP-1, thereby allowing better recognition by their cognate G-protein-
linked transmembrane receptors (Hoogewerf et al., 1997). In addition to the 
sequestration of CXCL2 (Massena et al., 2010), HSPG also mediate transcytosis of 
CXCL8 across the endothelium, presenting both chemokines on the luminal side and 
establishing haptotactic gradients that aid neutrophil recruitment during inflammation 
(Wang et al., 2005). In a separate study, the migration of tissue dendritic cells (DC) to 
regional lymph nodes and the local positioning of DC within lymph nodes was also 
found to be mediated by a HS-dependent haptotactic gradient of CCL21 (Weber et al., 
2013). A similar interaction is believed to facilitate lymphocytes homing through the 
high endothelial venules into peripheral lymphoid organs (Bao et al., 2010, Tsuboi et 
al., 2013), although it is unclear if HS also influences local positioning in specific 
niches. Also, shedding of HSPG, such as syndecan-1 (Hayashida et al., 2009) and 
removal of glucosamine 6-O-sulfate by the endosulfatase, Sulf2 (Uchimura et al., 2006) 
has been implicated in regulating the interaction between HS and various chemokines. 
Furthermore, the tissue-specific inactivation of HS-modifying enzymes can modify 
neutrophil binding to the endothelium, Ndst1 (HS N-deacetylase/N-sulfotransferase) 
deletion severely impairing (Wang et al., 2005), while Hs2st (HS 2-O-sulfotransferase) 
deletion significantly augmenting (Axelsson et al., 2012), neutrophil binding. These 
studies support the concept of regulating HS function by altering the availability of 
enzymes that are involved in HS biosynthesis.   
1.1.4.3 A sensor of tissue injury 
Tissue injury may induce cell necrosis, an event that is often associated with the release 
of various endogenous damage-associated molecular pattern (DAMP)-containing 
molecules that are potent inducers of inflammatory responses and initiators of tissue 
repair mechanisms (Kono and Rock, 2008). Both surface bound HSPG and soluble HS 
participate in sensing tissue injury and also in repair mechanisms. For example, 
endothelial cell surface HS mediates the oligomerisation of the receptor for advanced 
glycation endproducts (RAGE) (Xu et al., 2013) and together form a receptor complex 
that efficiently recognises the chromatin protein, high-mobility group protein B1 
(HMGB1) released from necrotic cells (Xu et al., 2011). As part of the tissue repair 
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mechanism, HS on the surface of professional phagocytes also assists in the clearance 
of necrotic cells (Poon et al., 2010). In fact, soluble HS itself can also function as a 
DAMP (Ihrcke et al., 1993) by interacting with TLR-4 on leukocytes (Johnson et al., 
2002). This interaction has been shown to modulate the release of pro-inflammatory 
cytokines by macrophages (Wrenshall et al., 1999) and markedly induce the maturation 
of DC, as indicated by the up-regulation of MHC-II, CD40, ICAM-1, CD80, CD86 and 
reduced antigen uptake, a typical phenotype of a professional antigen presenting cells 
(Kodaira et al., 2000). Although this is beneficial in triggering immune activation 
following an insult (Johnson et al., 2002), it is also implicated in the underlying 
mechanism of disease progression which can occur in experimental pancreatitis 
(Akbarshahi et al., 2011), sepsis-like syndrome (Johnson et al., 2004), hyperacute 
rejection in graft-versus-host disease (GvHD) (Brennan et al., 2012) and cardiac injury 
(Strand et al., 2013). 
1.1.4.4 Physical barrier to leukocyte migration 
The ECM/BM-associated HS is crucial to form a temporary depot of HS-binding 
soluble factors and to form a physical barrier that supports tissue integrity. In order to 
migrate, particularly through blood vessel walls, leukocytes need to break down the 
ECM/BM barrier and heparanase is primarily involved in this process (Vlodavsky et al., 
1992, Parish, 2006). For example, tissue DC increase the availability of cell surface 
heparanase to aid ECM degradation before migrating into lymphatic vessels leading 
towards regional lymph nodes where they induce antigen-specific responses 
(Benhamron et al., 2006). Subsequent studies have suggested that the matrix 
metalloproteinase, MMP-14, cooperatively works with heparanase to more efficiently 
degrade ECM/BM barriers (Benhamron et al., 2012). During inflammation, infiltrating 
monocytes and neutrophils also exhibit similar modes of degrading ECM/BM barriers 
to aid their extravasation (Matzner et al., 1985, Sasaki et al., 2004). It has also been 
demonstrated that heparanase derived from infiltrating leukocytes is primarily 
responsible for the destruction of the pancreatic islet β-cells that produce insulin, 
thereby providing a novel explanation for the underlying immunopathology of 
autoimmune Type 1 diabetes (Ziolkowski et al., 2012). In a separate study, leukocytes 
were shown to also use endogenous myeloperoxidase to produce oxidants that degrade 
the core protein of perlecan, releasing soluble factors and allowing leukocyte migration 
across ECM/BM barriers (Rees et al., 2010). Although HS can also be degraded by 
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nitric oxide (Vilar et al., 1997, Mani et al., 2000) and reactive oxygen species (Rao et 
al., 2011, Singh et al., 2013, Raats et al., 1997), their direct relevance in the degradation 
of ECM/BM–associated HSPGs and therefore their contribution to leukocytes 
extravasation is yet to be elucidated. 
1.1.5 Concluding remarks 
The evidence presented in the first part of this Literature Review corroborates the 
fundamental importance of HS in the mammalian immune system. HSPGs, primarily 
through their HS side chains, regulate various aspects of the immune system ranging 
from haematopoiesis to homing of leukocytes to peripheral tissues and, most 
importantly, regulating the elicitation of immune responses. Perturbing HS function or 
availability has been proven to results in various abnormal immune phenotypes. 
Furthermore, based on a simple bioinformatics screen presented in Section 1.1.3, it is 
suggested that HS may in fact interact with many more components of the immune 
system than previously realised. A better understanding of HS function across various 
systems is fundamental to exploit its potential in boosting beneficial immune responses 
and also in finding treatments for related immunopathologies.  
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1.2 Intrathymic TCRαβ T lymphocyte development 
As experiments described in this thesis investigated the role of HS in T lymphocyte 
development, in this section the major events in intrathymic T lymphopoiesis that 
through positive and negative selection produce self-tolerant and functional MHC-
restricted TCRαβ T lymphocytes, are reviewed. 
1.2.1 TCRαβ T lymphocytes 
A functional T lymphocyte antigen receptor carried by TCRαβ T lymphocytes is 
composed of an α-chain and a β-chain, each containing a variable (V) and a constant (C) 
region, the V regions being generated via somatic gene recombination during T cell 
development in the thymus. With the exception of the TCRαβ on Natural Killer T 
(NKT) cells that recognises non-MHC ligands (Rossjohn et al., 2012), the vast majority 
of TCRαβ T lymphocytes recognise MHC molecules and can be subcategorised into 
MHC-I restricted CD8+ cytotoxic T lymphocytes (CTL) (Zhang and Bevan, 2011) and 
MHC-II-restricted CD4+ helper T lymphocytes, the latter often being further classified, 
based on the production of signature cytokines following activation, into the Th1 (IFN-
γ), Th2 (IL-4 and IL-13), Th17 (IL-17a, IL-17 and IL-22), Tfh (IL-4 and IL-21) and 
Treg (IL-10) subsets (O'Shea and Paul, 2010, Swain et al., 2012). MHC-I is expressed 
on all nucleated cells and notably at high levels on professional antigen presenting cells 
(APC), such as DCs. The MHC-I molecule is comprised of heterodimeric polypeptide 
chains, namely non-polymorphic β2-microglobulin non-covalently linked to a 
polymorphic α chain, the latter containing α1, α2 and α3 domains. Intracellular derived 
peptides (8-10 amino acids in length) are usually presented by the α1-α2 pocket of 
MHC-I and this allows peptide/MHC-I complexes to be screened by different TCRαβ, 
whereas the α3 loop of MHC-I mediates non-cognate binding to CD8αβ coreceptor 
molecules (FIG. 1.2A), these two binding events being collectively termed Signal 1. 
During an adaptive immune response against an infection, pathogen-derived peptides 
presented by MHC-I on DC provide Signal 1, alongside the ligation of costimulatory 
molecule, such as CD28 on CD8+ T lymphocytes with CD80/CD86 on DC providing 
Signal 2. The resultant activation generates CD8+ T lymphocytes (CTL) that can kill 
target cells expressing cognate peptide/MHC-I complexes via apoptosis. Unlike MHC-I, 
MHC-II expression is restricted to professional APC, including DCs, macrophages and 
B lymphocytes. MHC-II is comprised of a heterodimer of polymorphic α and β 
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FIG. 1.2: Comparison of TCR-peptide/MHC-CD8 and TCR-peptide/MHC-CD4 ternary 
complexes. (A) Hypothetical model of the TCR-peptide/MHC-CD8 complex oriented as if the 
TCR and CD8 molecules are attached to the lymphocytes at the bottom and the MHC-I 
molecules is attached to an opposing APC at the top. The model was constructed by 
superimposing the CD8αβ-H-2Dd complex (Protein data Bank code 3DMM) onto a TCR-H-2Db 
complex (3PQY) through the MHC-I molecule. A portion of the CD8β stalk region was visible 
in the crystal structure and points toward the T cell membrane. The C termini of CD8α and 
CD8β chains are labelled. (B) Crystal structure of a TCR-peptide/MHC-CD4 complex in the 
same orientation as in (A). TCRα, blue; TCRβ, cyan; MHCα, gold; MHCβ/β2m, grey; CD8α, 
green; CD8β, violet; CD4 (D1-D4 domains), red. Adapted from Figure 3, Li et al., (2013). 
 
polypeptides, the α chain containing α1 and α2 domains and the β chain β1 and β2 
domains, with extracellular derived peptides (15-24 amino acids in length) usually 
being presented in a grove composed of the α1-β1 domain. During a CD4+ T 
lymphocyte immune response, TCRαβ interacts with cognate peptide/MHC-IIα1-β1 
complexes and CD4 molecules stabilise this interaction by binding to the β2 domain of 
MHC-II (FIG. 1.2B). As with CD8+ T lymphocytes, Signal 2 is provided by 
costimulatory interactions, such as CD28-CD80/CD86 ligation. Effector CD4+ T 
lymphocytes can encourage antibody production by B lymphocytes and produce 
cytokines to orchestrate various inflammatory responses as well as ‘helping’ the 
induction of CD8+ CTL responses. By the action of regulatory T lymphocytes (Treg), 
CD4+ T lymphocytes can also inhibit T lymphocyte immune responses against both self 
and foreign antigens. Intracellularly, the TCRαβ lacks a signal transduction domain and, 
consequently, is associated with a collection of related signalling molecules termed the 
CD3 complex. Furthermore, a close association of the TCR/CD3 complex with the 
coreceptor molecules CD8 and CD4 is imperative to initiate TCR signalling (FIG. 1.3) 
(Huppa and Davis, 2003, Neefjes et al., 2011, Li et al., 2013, Gascoigne, 2008). 
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FIG. 1.3: Classical model for TCR-CD3-coreceptor 
activity. TCR interacts with an antigenic peptide–MHC 
complex, and the co-receptor (CD4 or CD8) stabilises this 
interaction by bringing the kinase Lck in the proximity of 
the TCR–CD3 complex. Lck can then phosphorylate the 
CD3-associated immunoreceptor tyrosine-based activation 
motifs (ITAMs). Adapted from Figure 1, Gascoigne N.R. 
(2008). 
 
 
 
 
 
 
 
 
 
1.2.2 The thymus  
The thymus is a highly organised epithelial organ with distinct anatomical regions, each 
providing unique microenvironments to facilitate the development of functional MHC-
restricted and self-tolerant TCRαβ T lymphocytes (Miller, 1961, Ciofani and Zuniga-
Pflucker, 2007). The thymus originates from the endodermal gut tube. In mice the 
thymus primordium, indicated by the presence of FoxN1+ thymic epithelial cells (TEC), 
appears between embryonic days 10.5 (E10.5) to E11.5 from the third pharyngeal 
pouch. At this stage the surrounding neural crest-cells (NCC) that eventually form the 
mesenchymal capsule provide signals for the formation, patterning and outgrowth of the 
thymic anlage (Rodewald, 2008, Gordon and Manley, 2011). Early differentiation of the 
progenitor FoxN1+ TEC into cortical or medullary TEC occurs from E12 onwards in an 
autocrine-dependent manner, despite the thymus rudiment still lacking the distinct 
cortical and medullary regions of an adult thymus (Rossi et al., 2006, Hamazaki et al., 
2007). The establishment of the cortical and medullary TEC lineages requires 
thymocyte-derived signals. This coincides with the colonisation of the embryonic 
thymus by lymphoid progenitor cells (LPC) at E12 onwards. The migration of LPC 
across the mesenchymal capsule into the foetal thymus is guided by CCL21 and CCL25 
(expressed by the Gcm2+ parathyroid primordium and FoxN1+ TEC), which are the 
cognate ligands for CCR7 and CCR9 on LPC (Liu et al., 2005, Liu et al., 2006). TEC-
thymocyte ‘crosstalk’ promotes TEC lineage commitment (Ritter and Boyd, 1993, van 
Ewijk et al., 1994, Su et al., 2003), however, thymocyte-derived signals are dispensable 
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at the initial stage, as blocking initial LPC colonisation has a negligible effect on TEC 
development, but is more important in subsequent stages of TEC development (Klug et 
al., 2002). Thus, the committed cortical-TEC (cTEC: CD205+, β5t+ and keratin K8+) 
and medullary-TEC (mTEC: lectin UEA-1+, keratin K5+, AIRE+/-, MHC-II+, CD80+, 
MTS10+, ERTR5+ and claudin cld-3,4+) (Gray et al., 2002, Seach et al., 2012, Anderson 
and Takahama, 2012) inhabit and define the cortical and medullary regions of the 
thymus, respectively. Finally, the functional thymus architecture is co-inhabited by 
fibroblasts, endothelial cells, DCs and macrophages (Gray et al., 2002). At this stage 
onwards LPC appear to enter the thymus in distinct waves rather than in a continuous 
manner via the vasculature (Foss et al., 2001). The process of extravasation via the 
vasculature is mediated by the interaction of endothelial P-selectin with LPC P-selectin 
glycoprotein 1 (PGSL-1) and endothelial VCAM-I with the LPC α4β2/VLA4 integrin 
(Rossi et al., 2005, Scimone et al., 2006). Furthermore, the seeding of the thymus at the 
corticomedullary junction (CMJ) is guided by chemokines produced by thymic stromal 
cells (Krueger et al., 2010, Zlotoff et al., 2010). 
1.2.3 Intrathymic TCRαβ T lymphocyte development 
T lymphocytes are generated from bone marrow (BM) hematopoietic stem cells (HSC) 
that migrate to the thymus (Orkin and Zon, 2008) (FIG. 1.4). Multipotent LPC/early 
thymic progenitors (ETP) have the potential to differentiate into natural killer (NK) 
cells, DCs, macrophages and B lymphocytes (Bell and Bhandoola, 2008, Wada et al., 
2008). In the context of an adult thymus, LPC/early thymic progenitors (ETP) enter at 
the CMJ (Lind et al., 2001) and migrate outwards to the subcapsular zone (SCZ), then 
back inwards to the cortex and into the medulla, guided by chemokines and the ECM 
(Savino et al., 2002, Savino et al., 2004), while intimately interacting with stromal cells 
which provide distinct  cues for sequential developmental stages (FIG. 1.5) (Lind et al., 
2001, Anderson and Jenkinson, 2001, Takahama, 2006, Klein et al., 2014).   
1.2.3.1 DN stage: ETP settling, TCRαβ lineage selection and β-selection 
Uncommitted ETP lack CD4 and CD8 molecules, hence, collectively they are termed 
double negative (DN) thymocytes. DN cells are classified into four major subsets (DN1, 
DN2, DN3 and DN4), based on CD117 (c-Kit), CD44, CD25, CD24 (heat stable 
antigen, HSA) and CD27 expression (Godfrey et al., 1993, Koch and Radtke, 2011). 
The DN2 and DN3 subsets can be further subdivided into two additional developmental
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FIG. 1.4: Overview of thymic T cell development. The individual stages of T cell maturation 
from earliest lymphoid progenitor cells (LPC) to the CD4 single positive (SP) and CD8 SP 
thymocytes. The expression of CD4 and CD8 surface molecules separates the CD4+CD8+ 
double positive (DP) and SP negative from the CD4-CD8- double negative (DN) cells. The 
surface CD44 and CD24 expression characterises the four major DN cell populations: 
CD44+CD25- (DN1), CD44+CD25+ (DN2), CD44-CD25+ (DN3) and CD44-CD25- (DN4) cells. 
The earliest LPC is derived from a hematopoietic stem cell (HSC) in the bone marrow. HSCs 
undergo a gradual differentiation process and become more restricted to the lymphoid lineage. 
LPC arrive at the thymus and develop to the early thymic progenitor (ETP) cell stage, a 
subpopulation of the heterogeneous DN1 subset that retains the potential to give rise to dendritic 
cells (DCs), natural killer (NK) cells and macrophages (MΦ). The DN2 and the DN3 cells can 
be subdivided further into two additional developmental cell stages on the basis of CD117 and 
CD27 cell surface marker expression, respectively (Table 1.2). Critical checkpoints during T 
cell maturation are indicated in bracketed numbers and are the (1) DN1 checkpoint, where 
Notch signalling inhibits alternative cells fate potentials; (2) the β-selection checkpoint, where 
the transition from DN3a to DN3b marks the progression along T cell receptor αβ lineage; and 
finally (3) the positive and negative selection checkpoint, where DP thymocytes commit to 
either MHC-I-restricted CD8 SP or MHC-II-restricted CD4 SP cell fate. Dashed arrows indicate 
differentiation routes that have been elucidated mainly by in vitro differentiation assays. 
Adapted from Figure 1, Koch and Radtke (2011).  		
cell stages on the basis of CD117 and CD27 cell surface marker expression, 
respectively (Table 1.2). The migration of ETP/DN1 thymocytes towards the SCZ is 
guided by cTEC, with CXCR4-CXCL12 (Plotkin et al., 2003), CCR7-CCL21/CCL19 
and CCR9-CCL25 (Krueger et al., 2010, Zlotoff et al., 2010) interactions having been 
implicated in the process. The survival, differentiation and T lineage commitment of 
DN1 thymocytes is dependent on cTEC and mesenchymal fibroblast-derived IL-7, stem 
cell factor (SCF), FMS-like tyrosine kinase 3 ligand (Flt3L) (Wang et al., 2006) and 
Delta like ligand 4 (DLL4) (Hozumi et al., 2008, Koch et al., 2008). DN1 thymocytes 
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commit to the DN2 stage as a result of DLL4-induced Notch1 signalling which 
supresses NK and B cell lineage genes (Schmitt et al., 2004, Garcia-Ojeda et al., 2013) 
and drives RAG-mediated TCRγ, TCRδ and TCRβ gene rearrangements, the former two 
preceding monoallelic Vβ gene assembly (Capone et al., 1998, Livak et al., 1999, Agata 
et al., 2007).  
 
Table 1.2: Stages of T cell development correlate with specific location in the thymus, 
distinct cell-surface phenotypes and TCR requirement. 
Developmental 
stage Cell surface phenotype Location 
TCRβ 
rearrangement 
TCRα 
rearrangement 
ETP / DN1 CD117
hiCD44hiCD25- 
CD24-/loCD27hi CMJ Germline Germline 
DN2a CD117
hiCD44hiCD25+ 
CD24hiCD27hi Cortex Germline Germline 
DN2b CD117
intCD44hiCD25+ 
CD24hiCD27int Cortex DJH Germline 
DN3a CD117
-/loCD44-/loCD25+ 
CD24hiCD27-/lo SCZ DJH, VDJH Germline 
DN3b CD117
-/loCD44-/loCD25int 
CD24hiCD27hi SCZ VDJ
+ Germline 
DN4 CD117
-/loCD44-/loCD25-
/loCD24hiCD27hi SCZ VDJ
+ Germline 
DP CD4
+CD8+ 
TCRβintpreTCRα+ Cortex VDJ
+ VJ 
Abbreviation: CMJ, corticomedullary junction; D, diverse; DN, double negative; DP double positive; ETP, early 
thymic progenitor; H, heavy chain; J, joining; SCZ, subcapsular zone; TCR, T cell receptor; V, variable.  
Adapted from Table 1, Koch and Radtke (2011). 
 
 
Studies have indicated that strong IL-7 and TCRγδ signals favour the TCRγδ lineage, 
whereas Notch1 and weak pre-TCRαβ signals favour the TCRαβ lineage choice (Laky 
et al., 2003, Garbe et al., 2006, Kreslavsky et al., 2008). Thus, a strong TCRγδ signal or 
a weak pre-TCRαβ signal results, respectively, in prolonged or transient ERK 
activation, thus skewing the commitment towards either the TCRγδ or TCRαβ T lineage 
(Lee et al., 2014). This selection process occurs as DN2 thymocytes progress into the T-
lineage committed DN3 stage upon arriving at the SCZ and this migration is guided by 
thymocyte CCR9 interacting with CCL25 displayed by cTEC (Benz et al., 2004). DN3 
thymocytes express the pre-TCR complex, which is comprised of a monoallelic TCRβ 
chain, an invariant pre-TCRα chain and the CD3 complex (Saint-Ruf et al., 1994). 
Studies have shown that the pre-TCR signal (cell autonomous after dimerisation of the 
TCRβ and pre-TCRα chains (FIG. 1.6B) (Kortum et al., 2013)), the cTEC-derived 
Notch1 signal and the CXCR4 signal are indispensible, in combination with the IL-7 
signal (Boudil et al., 2015), for the survival, proliferation and differentiation (β-
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selection) (Ciofani and Zuniga-Pflucker, 2005, Golec et al., 2013, Kreslavsky et al., 
2012, Maillard et al., 2006, Trampont et al., 2010, Mandal et al., 2008) of DN3 
thymocytes into DN4 stage thymocytes and, subsequently, into the CD4+CD8+ double 
positive (DP) stage, these developmental stages coinciding with Rag gene reactivation 
to facilitate V(D)J recombination at the TCRα locus (Petrie et al., 1993, Shinkai et al., 
1993, Wilson et al., 1994, Yannoutsos et al., 2001). 
1.2.3.2 DP stage: repertoire selection and CD4/CD8-lineage choice in the cortex 
In addition to its contributions to early thymopoiesis, the thymic cortex is renowned for 
its role in the deletion of ‘useless’ TCRαβ clones, repertoire selection and the deletion 
of potentially autoreactive TCRαβ T lymphocytes (Shah and Zuniga-Pflucker, 2014, 
Klein et al., 2014). DP (CD3+TCRβlopreTCRα+) thymocytes undergo continuous TCRα 
gene rearrangement until the pre-TCRα is MHC-selectable (Petrie et al., 1993). Pre-
selection DP thymocytes undergo a slow (3-8 µm/min) ‘random walk’ in the cortex 
(Witt et al., 2005, Bousso et al., 2002), which is guided by cTEC-derived CXCL12 and 
CCL25 gradients (Love and Bhandoola, 2011), while scanning self-peptides being 
presented by MHC molecules on cTEC (Capone et al., 2001, Laufer et al., 1996) and on 
migratory SIRPα+CD8α- DCs (Wu and Shortman, 2005). Unique antigen presentation 
machineries bestow cTEC with distinct abilities to process low affinity ‘private’ self-
peptides from macroautophagy-derived self-antigens for presentation on MHC-I and 
MHC-II molecules to DP thymocytes (Klein et al., 2014). For example, the expression 
of the thymoproteosome subunit, β5t (Psmb11), at high levels in cTEC is essential for 
the positive selection of CD8+ T lymphocytes (Murata et al., 2007, Nitta et al., 2010) by 
increasing the repertoire of TCR ligands for presentation by MHC-I (Sasaki et al., 
2015). In fact, a recent study reported that peripheral CD8+ T lymphocytes generated in 
a β5t-deficient environment exhibited aberrant homeostasis and immune responses to 
infections (Takada et al., 2015). Similarly, the lysosomal proteases cathepsin-L and 
thymus-specific serine protease (TSSP), which are highly expressed by cTEC, are found 
to be essential for the positive selection of CD4+ T lymphocytes by similarly by 
increasing the repertoire of TCR ligands for presentation by MHC-II molecules 
(Nakagawa et al., 1998, Honey et al., 2002, Gommeaux et al., 2009, Klein et al., 2014).  
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FIG. 1.5: Stromal cell interactions during T cell development. (A) Successive stages of DN 
T cell development are accompanied by an outward movement of thymocytes towards the 
subcapsular zone. Subsequent to β-selection at the DN3 stage, DP thymocytes 'randomly walk' 
through the outer cortex, which possibly facilitates the 'scanning' of cortical thymic epithelial 
cells (cTECs) for positively selecting ligands. At this stage, DP thymocytes may be engulfed by 
cTECs and form so-called thymic nurse cells; however, the molecular control and physiological 
relevance of this process remains to be established. Interactions between DP thymocytes and 
cortical conventional dendritic cells (cDCs) may lead to negative selection. It remains unknown 
whether these cortical cDCs exclusively belong to the migratory signal-regulatory protein-α 
(SIRPα)-expressing subset. Positively selected CD4 or CD8 lineage-committed thymocytes 
relocate into the medulla by directed migration. Upon reaching the medulla, SP thymocytes 
again assume a 'random walk' motion pattern. Through this random migration, SP thymocytes 
may now 'scan' resident and migratory cDCs, plasmacytoid dendritic cells (pDCs), medullary 
thymic epithelial cells (mTECs) and B cells. It is estimated that SP thymocytes engage in 
around five contacts with antigen-presenting cells (APCs) per hour, so that during their 4- to 5-
day residency in the medulla, thymocytes may serially interact with several hundred APCs. 
Solid arrows indicate main migratory pathways that are involved in thymocyte selection. 
Dashed arrows indicate other relevant migratory pathways. (B) Key functional properties of 
thymic APCs that are discussed in this literature review. AIRE, autoimmune regulator; BCR, B 
cell receptor; TRA, tissue-restricted antigen. Adapted from Figure 1, Klein et al., (2014). 
A B
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1.2.3.2.1 TCR signalling pathways involved in repertoire selection 
The quality of TCR signalling is determined by the strength of the TCRαβ/coreceptor-
self-peptide MHC interaction (FIG. 1.6), which is the key determinant in repertoire and 
lineage selection (Werlen et al., 2003, Fu et al., 2014). The TCR complex consists of 
TCR αβ chains and the CD3 complex (composed of CD3γε, CD3δε and CD3ζζ 
subunits), with the CD3ς subunit containing an immunoreceptor tyrosine-based 
activation motif (ITAM) in its cytoplasmic domain. The Src family PTK p56Lck (Lck) is 
constitutively phosphorylated (Nika et al., 2010) and is key to the initiation of TCR 
signalling. TCR binding to self-peptide/MHC complexes recruits Lck-bound to 
CD4/CD8 to the proximity of the TCR/CD3 complex, with resultant phosphorylation of 
the CD3ζ chain ITAM. This provides a docking site for Zap70 recruitment, which is 
phosphorylated by Lck (Y319) and trans-phosphorylated by adjacent Zap70 (Y493), 
with pZap70 then phosphorylating the adaptor protein LAT. Subsequently, pLAT 
recruits two sets of molecular complexes to regulate Ras activation, namely the [PLC-
γ1-Gads-ITK-Slp76] complex and the [Grb2-Sos] complex. Slp76, Gads and ITK 
regulate the phosphorylation of PLC-γ1, pPLC-γ1 then cleaving PIP2 into IP3 and DAG. 
IP3 initiates the release of ER-stored Ca2+, which can trigger the uptake of extracellular 
Ca2+. The resultant rise in intracellular Ca2+ activates the phosphatase calcineurin to 
dephosphorylate the transcription factor pNFAT and NFAT then translocates into the 
nucleus and dimerises with AP-1 family transcription factors to regulate gene 
transcription. The increase in intracellular Ca2+ also induces DAG to recruit PKCθ and 
RasGRP1 to the plasma membrane, PKCθ activating the NF-κB pathway and RasGRP1 
activating the downstream Ras-MEK-MAPK/ERK1/2 cascade. The Grb-Sos complex 
can form a positive feedback loop to activate Ras thus promoting the Ras/ERK1/2 
pathway and augmenting AP-1 activity in regulating gene transcription (Gascoigne and 
Palmer, 2011, Fu et al., 2014, Kortum et al., 2013, Feske et al., 2012).  
 
TCR signalling in pre-selection DP thymocytes is extremely sensitive, small changes in 
upstream pathways significantly tipping the signalling threshold either for or against 
cell survival (Davey et al., 1998). At the cell surface, N-glycosylation enhances the 
retention of CD4 and CD8 molecules at the plasma membrane consequently augmenting 
the recruitment of CD4/CD8-bound Lck to initiate TCR signalling and activation of the 
downstream ERK1/2 cascade following an encounter with low affinity TCR ligand 
thereby promoting positive selection (Zhou et al., 2014). Biphasically, through an 
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FIG. 1.6: Canonical TCR signal transduction to Ras-MAPK in T cell development. (A) 
After TCR binding and engagement of the upstream kinases Lck and Fyn activated Zap70 
triggers phosphorylation of LAT. Phosphorylated LAT (pLAT) associates with two molecular 
complexes that regulate Ras activation: [PLC-γ1−GADS−ITK-SLP-76] and [Grb2-Sos] 
complexes. On pLAT, pPLC-γ1 cleaves PIP2 generating IP3 and DAG, the former stimulates 
release of Ca2+ from intracellular stores and DAG then recruits PKCθ and RasGRP1 to the 
membrane, and the combined actions of Ca2+, DAG, and PKCθ activate RasGRP1. The Ras 
guanine nucleotide exchange factors (GEFs) Sos1 and Sos2 are also recruited to LAT via the 
adapter Grb2. Sos proteins have basal RasGEF activity, which can be enhanced by the binding 
of activated Ras (Ras-GTP) to an allosteric binding pocket on Sos. Ras-GTP binding to Sos 
potentially allows for the engagement of a positive feedback loop, primed by either RasGRP1 or 
basal Sos activity, to produce high levels of Ras activation. Ras signals to multiple downstream 
effector pathways including the Raf−MAPK/ERK kinase MEK cascade. (B) Integrated model 
of Ras activation during thymocyte development. At the DN3 stage, ligand-independent pre-
TCR signals are transmitted to Ras and ERK by the combined actions of Sos1, RasGRP1, and 
RasGRP4 to stimulate proliferation and differentiation to the DP stage. In the thymic cortex, 
positively selecting signals are transmitted from the TCR to Ras via RasGRP1. Downstream of 
Ras, ERK activation is required for efficient positive selection. To promote negative selection, 
higher-potency ligands trigger Ras activation via either RasGRP1 or Sos1. Here, activation of 
ERK seems to be dispensable, and activation of other MAPKs; JNK, p38, and ERK5 are likely 
more important. RasGEFs whose individual deletion blocks thymocyte development for a given 
signal are shown in red, whereas RasGEFs that require combined deletion with a second 
RasGEF to cause a developmental block are shown in blue. Proteins whose role at a given 
developmental checkpoint have not been demonstrated by developmental studies are shown in 
green. Adapted from Figure 1 and Figure 2, Kortum et al., (2013).  
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unknown mechanism, N-glycosialylation also appears to attenuate persisting TCR-
induced Ca2+ signalling when encountering high affinity TCR ligands, thus inhibiting 
negative selection (Zhou et al., 2014). Intracellularly, it has been shown that low affinity 
TCR ligands generate weak signals by favouring intermittent Zap70 and LAT 
activation, slow and low level intracellular Ca2+ rises and, hence, moderate Ras/ERK 
activation, as the Grb-Sos complexes remain localised within the Golgi apparatus. In 
contrast, high affinity/avidity TCR ligands induce a strong signal, characterised by rapid 
activation of Zap70 and LAT, robust yet transient intracellular Ca2+ rises and 
accentuated Ras/ERK activation, implicitly due to an exaggerated pLAT-bound Grb-
Sos complex-mediated positive feedback loop. Downstream, high affinity/avidity TCR 
ligands induce robust activation of the MAPKs ERK1/2, JNK1/2, p38 and ERK5, the 
latter three being strongly associated with cell death. Thus, only low affinity TCR 
ligands promote DP thymocytes survival and maturation into SP thymocytes (FIG. 
1.6B) (Daniels et al., 2006, Hernandez et al., 2010, Kortum et al., 2013).  
 
Several signalling molecules are appreciated for their roles in fine-tuning the 
intracellular translation of analogue-to-digital TCR signalling in DP thymocytes. Thus, 
Grb2-bound Tespa1 in the LAT signalling platform is implicated in the release of ER-
stored Ca2+ required for effective induction of the ERK/AP-1 and Ca2+/NFAT pathways 
essential for T cell survival (Wang et al., 2012). Also, the LAT-Grb2-bound Themis-
SHP1/2 complex expands the threshold for weak TCR ligands to promote T cell 
survival by exerting a negative feedback which dampen upstream Lck activity (Fu et al., 
2013, Fu et al., 2014, Paster et al., 2015). Downstream, the calcineurin/NFAT-pathway 
favours T cell survival by enhancing ERK activity in response to very weak, but not 
strong, TCR signalling (Gallo et al., 2007, Neilson et al., 2004).  
 
As TCR on DP thymocytes encounter compatible self-peptide/MHC complexes, the 
thymocytes cease their ‘random walk’ and begin to tightly interact with cTEC (Witt et 
al., 2005, Bousso et al., 2002). In addition to providing TCR signals (FIG. 1.6A) cTEC 
express unique cell surface molecules that can provide ‘accessory signals’ to aid the 
selection of DP thymocytes and their development into CD4 SP and CD8 SP 
thymocytes (Anderson et al., 1994). It is likely that these accessory signals are delivered 
as DP thymocytes tightly interact with cTEC to form rosette-like structures (Kyewski et 
al., 1982, Oliveira-dos-Santos et al., 1997), the most extreme example of this interaction 
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being thymic nurse cells (TNC) (FIG. 1.5) (Wekerle and Ketelsen, 1980, Wekerle et al., 
1980), despite TNC formation not being required for positive selection (Nakagawa et 
al., 2012). This heterotypic cell-cell interaction, however, is not restricted to cTEC, as 
other stromal cells, including DCs and macrophages, have been observed to rosette with 
thymocytes (Shortman et al., 1989, Shortman and Vremec, 1991, Oliveira-dos-Santos et 
al., 1998). The molecular mechanisms underpinning these interactions are not fully 
understood, although thymocyte Thy-1/CD90 (He et al., 1991), cTEC CD326/EpCAM 
(Nelson et al., 1996) and several thymocyte-cTEC cell adhesion receptor-ligand pairs 
have been implicated, such as the α4β1/VLA4 integrin-VCAM-1 (Salomon et al., 
1997), CD2-LFA-3 and LFA-1 integrin-ICAM-1 interactions (Singer, 1990, Paessens et 
al., 2008). A separate study showed that thymocytes unable to synthesise a TCR (Rag-/-, 
p56Lck-/-, TCRβ-/- and to a lesser extent, TCRα-/- mice), CD44 or CD4 resulted in reduced 
TEC-thymocyte rosette formation (Oliveira-dos-Santos et al., 1998). In addition, as 
mentioned in Section 1.1.4.1, an in vitro study implicated highly sulfated HS expressed 
on cTEC in thymocyte adhesion, although the HS-specific receptor on thymocytes and 
the physiological role of this interaction in thymocyte development is yet to be 
elucidated (Britz and Hart, 1983, Werneck et al., 1999, Werneck et al., 2000). 
1.2.3.2.2  Positive and negative selection of DP thymocytes 
The Bcl-2 family of anti-apoptotic proteins, including Bcl-2, Bcl-xL and Mcl-1, are 
critical to maintain mitochondrial outer membrane integrity (Ma et al., 1995, Harris and 
Thompson, 2000, Dunkle et al., 2010), and the survival of pre-selection DP thymocytes, 
with pre-selection DP thymocytes having limited time to attain the much needed TCR 
survival signals as they test the ability of their nascent TCRαβ to recognise self-
peptide/MHC complexes. Also, at this time pre-selection DP thymocytes gradually lose 
their sensitivity for cTEC-derived IL-7 signalling (Ribeiro et al., 2013), as SOCS-1 
suppresses IL-7R expression by these cells (Yu et al., 2006), consequently reducing the 
expression of Bcl-2 (Munitic et al., 2004). In the absence of TCR signals 
downregulation of Bcl-2, Bcl-XL and Mcl-1 results in oligomerisation of the pro-
apoptotic proteins Bax and Bak on the mitochondrial wall, favouring the release of 
mitochondrial cytochrome c and activation of the intrinsic cell death pathway 
(Hernandez et al., 2010, Zhang et al., 2005). The majority of the nascent TCRαβ 
molecules either fail to bind or very weakly bind to self-peptide/MHC complexes such 
that an inadequate TCR survival signal is generated and they are destined towards 
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apoptosis-mediated ‘death by neglect’ (Starr et al., 2003b, Szondy et al., 2012, Yates, 
2014), a fate that can be enhanced by glucocorticoids produced by cTEC and 
thymocytes (Wyllie, 1980). Studies have also revealed that TCR ligation by a non-MHC 
ligand (anti-TCR cross-linking) without a concomitant CD4/CD8 signal (Van Laethem 
et al., 2007), or CD8 ligation (anti-CD8 cross-linking) in the absence of a TCR signal 
(Grebe et al., 2004), may also favour T cell death by neglect. Thus, the deletion of CD4 
(Rahemtulla et al., 1991) or CD8 (Fung-Leung et al., 1991) molecules, whilst retaining 
an intact TCR that permitted the survival and further development of post-DN 
thymocytes the resultant T cells lacked helper or cytotoxic functions, respectively. 
Collectively, these observations emphasise the importance of simultaneous TCR and 
CD4/CD8 coreceptor engagement by self-peptide/MHC complexes for the survival and 
subsequent lineage specification of DP thymocytes (FIG. 1.7) (Werlen et al., 2003, Van 
Laethem et al., 2012). Also, it should be noted that throughout the thymus, F4/80+ 
macrophages play a key role in clearing dying T cells and maintaining a non-
inflammatory milieu by producing TGF-β, PGE2, PAF and adenosine (Surh and Sprent, 
1994, Fadok et al., 1998, Koroskenyi et al., 2011, Szondy et al., 2012). 
 
The binding of weak to intermediate affinity TCRs and adequate CD4/CD8 coreceptors 
to self-peptide/MHC complexes generates weak to moderately strong TCR signals 
(FIG. 1.6B) that favour the survival of DP thymocytes (‘positive selection’) (Daniels et 
al., 2006). This leads to the upregulation of IL-7R expression which restores the 
sensitivity of the T cells to cTEC-derived IL-7, thus leading to the upregulation of Bcl-2 
expression (Linette et al., 1994, Yu et al., 2006, Munitic et al., 2004). A recent study 
confirmed that recruitment of CD8/CD4-bound Lck to the proximity of the TCRαβ/CD3 
complex initiates TCR signalling that favours survival of DP thymocytes with weak to 
intermediate TCRαβ-MHC interactions that generate weak to adequate TCR-signals 
(FIG. 1.7) (Van Laethem et al., 2012, Van Laethem et al., 2013). These TCR signalling 
events coincide with the repression of Rag to cease TCRα gene rearrangements 
(Borgulya et al., 1992, Wilson et al., 1994) and an increase in TCRαβ, CD69 and CD5 
expression levels with CD69 and CD5 expression being directly proportional to TCR 
signal strength and TCR affinity for self-peptide/MHC complexes, respectively 
(Yamashita et al., 1993, Merkenschlager et al., 1997, Davey et al., 1998, Azzam et al., 
1998, Hare et al., 1999).  
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FIG. 1.7: Co-receptor basis of MHC-specific thymic selection. TCR signalling requires the 
juxtaposition of Lck with TCR (FIG 1.3 and FIG. 1.6A). In immature pre-selection DP 
thymocytes, all available tyrosine kinase Lck is co-receptor-associated and bound to the tails of 
both CD4 and CD8 co-receptors. Consequently, TCRs on pre-selection DP thymocytes can only 
access Lck when they bind to the identical peptide/MHC complexes as CD4 and CD8 co-
receptors. TCRs that bind MHC-independent native ligands cannot access co-receptor-
associated Lck because the CD4 and CD8 co-receptors only bind to extracellular MHC 
complexes. Thus, only MHC-specific TCRs transduce thymic selection signals with the result 
that thymic selection is strictly MHC-specific. However, genetic deletion of both CD4 and CD8 
co-receptors makes Lck freely available to all TCRs, so that TCRs that bind to any ligand in the 
thymus can transduce selection signals and be expressed on mature T cells in the periphery. 
Consequently, deletion of both CD4 and CD8 co-receptors allows the generation of mature T 
cells expressing MHC-independent TCRs with antibody-like recognition specificities. 
According to this perspective, the TCR repertoire is intrinsically diverse with specificity for 
both native and MHC-dependent ligands. However, MHC restriction is imposed on this diverse 
TCR repertoire by CD4 and CD8 co-receptors during thymic selection because of their dual 
specificity for intracellular Lck and extracellular MHC. Adapted from Figure 2, Van Laethem et 
al., (2012). 
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Another notable change in DP thymocytes during and after positive selection is the level 
of cell surface N- and O-glycosialylation (Daniels et al., 2002, Bi and Baum, 2009). As 
mentioned in Section 1.2.3.2.1 the marked increase in N-glycosialylation from the DN 
to the DP stage is strongly associated with the enhanced retention of Lck-bound CD4 
and CD8 molecules at the plasma membrane to potentiate and fine-tune TCR proximal 
signalling. Subsequently, SP thymocytes and naïve peripheral T lymphocytes showed 
lower levels of N-glycans to maintain peripheral tolerance (Zhou et al., 2014, 
Rabinovich and Toscano, 2009) that can be reversed by T cell activation (Comelli et al., 
2006). Moreover, of relevance to this thesis, CD8αβ molecules are heavily O-sialylated 
following positive selection. The addition of α2-3 sialic acids to the core-1-O-glycans, 
associated with the stalk region of the CD8β chain by the activity of ST3Gal-I 
sialyltransferase is strongly associated with a reduced ability of the CD8 molecules on 
post-selection DP thymocytes to bind MHC-I molecules (Moody et al., 2001, Daniels et 
al., 2001, Moody et al., 2003, Merry et al., 2003). Similar to N-glycosialylation, O-
sialylation can be reversed by activation, consequently restoring the coreceptor function 
of CD8 molecules (Pappu and Shrikant, 2004, Starr et al., 2003a). Additional to its role 
in peripheral tolerance, O-sialylation of CD8 molecules is crucial to maintain normal 
homeostasis of peripheral CD8+ T lymphocytes (Priatel et al., 2000).  
 
High affinity TCR clones are potentially autoreactive and are destined to clonal deletion 
to avoid autoimmunity, a process termed ‘negative selection’ (Palmer, 2003). Studies 
have implicated strong TCR signals and an extended CD4/CD8 coreceptor-bound Lck 
recruitment following a high affinity TCRαβ-self-peptide/MHC complex interaction to 
favour negative selection (FIG. 1.6B) (Daniels et al., 2006, Stepanek et al., 2014). This 
strong interaction eventually leads to activation-induced apoptosis in DP thymocytes 
with the pro-apoptotic proteins Bim (also known as Bcl2l11) and the nuclear steroid 
receptor Nur77 playing major roles in the process, independently antagonising the anti-
apoptotic activity of Bcl-2 (Bouillet et al., 2002, Calnan et al., 1995). A strong TCR 
signal results in Bim neutralising the Bcl-2 pro-survival signal in a dose-dependent 
manner (O'Connor et al., 1998) and Nur77 recruiting a related member protein, Nor-1, 
translocating to the mitochondria and together interacting with Bcl-2 and altering the 
conformation of the protein such that it becomes a pro-apoptotic molecule (Thompson 
and Winoto, 2008). Although negative selection is thought to mainly take place in the 
thymic medulla, an early study revealed a high proportion of thymocytes actually 
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undergoing active apoptosis in the cortex in situ (Surh and Sprent, 1994). While this 
may reflect DP thymocytes dying by neglect, recent observations revealed that 
approximately 55-75% of these apoptotic cells are TCR-signalled DP thymocytes 
undergoing negative selection and, in fact, this population is greater than that observed 
undergoing medullary clonal deletion (Daley et al., 2013, Stritesky et al., 2013). Thus, 
this finding implicates cortical thymic stromal cells in instigating the screening for and 
deletion of potentially autoreactive TCR clones. The migratory CD11c+SIRPα+CD8α- 
classical DC (FIG. 1.5) (Wu and Shortman, 2005) is believed to mediate this important 
role due to its efficiency in capturing and presenting blood-borne self-antigens to DP 
thymocytes in the thymus. In fact, ablating the CCR2/CCL8-dependent migration of 
these DCs to the thymus substantially abrogated negative selection of T cell clones 
specific for blood-borne antigens (Baba et al., 2009). Another study revealed that 
negative selection in the cortex is mainly occurring in the vicinity of these DCs, the 
targeted ablation of DCs resulting in severely abrogated deletion of strongly self-
reactive TCR clones, with cTEC being incapable of substituting for this function 
(McCaughtry et al., 2008).  
 
Apparently, however, not all DP thymocytes experiencing strong TCR signals face 
negative selection. An early observation revealed an escape route from negative 
selection, in which high affinity transgenic TCRs became internalised before 
undergoing secondary TCRα rearrangement (McGargill et al., 2000), although a recent 
study insists that negative selection is the most physiological outcome for high affinity 
transgenic TCR clones (Kreslavsky et al., 2013). Another study revealed that β5t+ cTEC 
facilitate TCR rearrangement in DP thymocytes associated with TNC, but this feature is 
prominent with non-transgenic/polyclonal TCR thymocyte populations (Nakagawa et 
al., 2012). Thus it was hypothesised that this phenomenon is relevant to rescuing DP 
thymocytes from death by neglect or mediating ‘facilitated’ positive selection of TCR 
clones with an inadequate affinity for self-peptide/MHC complexes rather than allowing 
DP thymocytes to escape from negative selection (Klein et al., 2014). 
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1.2.3.2.3  CD4/CD8-lineage choice in post-selected DP thymocytes 
Positively selected DP thymocytes that survive negative selection undergo CD4/CD8-
lineage choice, a process elegantly explained by the ‘kinetic signalling’ model of CD4-
CD8 differentiation (FIG. 1.8) (Singer et al., 2008). Despite CD4/CD8 coreceptor 
signals dictating the outcome of the positive selection process, the same signals 
however, are insignificant for CD4/CD8-lineage commitment (Erman et al., 2006). 
Post-selection TCRαβhiBcl-2hi DP thymocytes (Punt et al., 1996) cease expression of 
the Cd8 gene, but not the Cd4 gene and enter a CD4+CD8- transcriptional stage 
(CD4+CD8lo surface phenotype). Initially, a persisting TCRαβ/CD4-self-peptide/MHC-
II signal biases the thymocytes towards CD4-lineage commitment by preventing the 
suppression of CD4-lineage genes and upregulating the transcription factors GATA3, 
TOX and Th-POK; Th-POK being the key suppressor of CD8-lineage genes and the 
transcription factor, RUNX3 (Luckey et al., 2014). Consequently, CD4+CD8lo DP 
thymocytes commit and differentiate into CD4 SP thymocytes. Alternatively, TCRαβ 
recognition of self-peptide/MHC-I ceases downstream TCR signalling, which leads to 
the downregulation of GATA-3 and Th-POK expression. Signals from IL-7, IL-15 
(McCaughtry et al., 2012) and possibly other common γc cytokines dominate to trigger 
‘coreceptor reversal’, leading to the downstream effect of terminating CD4-lineage gene 
expression and upregulation of RUNX3 expression (Brugnera et al., 2000). This, in turn 
results in the suppression of Th-POK activity and the reinitiation of CD8-lineage gene 
expression and, thus, the CD4+CD8lo DP thymocytes commit and differentiate into CD8 
SP thymocytes (Brugnera et al., 2000, Yu et al., 2003, Singer et al., 2008, Park et al., 
2010).  
 
Positively selected thymocytes also regain enhanced motility (>13 µm/min) that allows 
them to migrate to the medulla (Witt et al., 2005, Bousso et al., 2002). It has been 
reported that post-selection thymocytes show a marked increase in PlexD1 expression, 
which upon its interaction with its medullary-TEC (mTEC)-derived ligand, Sema3e, 
induces cessation of CCR9-mediated thymocytes migration in the cortex (Choi et al., 
2008) and relaxes VLA4-VCAM-1-mediated adhesion of thymocytes to cTEC (Choi et 
al., 2014). Coincidentally, the upregulation of CCR7 and CCR4 expression by TCRαβhi 
SP thymocytes drives chemotaxis towards the mTEC-derived CCL19/CCL21 and 
CCL5/CCL17/CCL22 chemokine gradients, respectively (Ueno et al., 2004, Laan et al., 
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2009), and this migration is thought to be aided by a passive inward flow of interstitial 
fluid (Takahama, 2006). 
 
 
	
FIG. 1.8: The kinetic signalling model for CD4/CD8-lineage choice. Regardless of the 
specificity of their TCR, positively selecting TCR signals induce DP thymocytes that are 
transcriptionally Cd4+Cd8+ to terminate Cd8 gene expression and to convert into Cd4+Cd8- 
intermediate thymocytes. Because of the absence of Cd8 gene transcription, Cd4+Cd8- 
intermediate thymocytes appear phenotypically as CD4+CD8lo cells, and these are the cells in 
which lineage choice is made. Persistence of TCR signalling in Cd4+Cd8- intermediate 
thymocytes blocks IL-7-mediated signalling and induces differentiation into mature CD4 SP 
thymocytes. Cessation or disruption of TCR signalling in Cd4+Cd8- allows IL-7-mediated 
signalling, which induces Cd4+Cd8- intermediate thymocytes to undergo co-receptor reversal, 
gain a Cd4-Cd8+ phenotype and differentiate into CD8 SP thymocytes. Adapted from Figure 3, 
Singer et al., (2008). 
 
1.2.3.3 SP stage: establishing central tolerance, final maturation and egress 
In addition to the aforementioned mTEC derived signals relocating SP thymocytes to 
the medulla, signals received by mTEC from positively selected DP and SP thymocytes 
contribute to the formation and maintenance of a functional thymic medulla (Anderson 
and Takahama, 2012). Thus, RANKL derived from positively selected DP thymocytes 
and CD40L and LTβ from SP thymocytes are crucial for the formation of a thymic 
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medulla, these molecules binding to their cognate receptors RANK, CD40 and LTβR, 
respectively, on mTEC, perturbation of these signals being associated with autoimmune 
phenotypes in mice (Hikosaka et al., 2008, Akiyama et al., 2008, Boehm et al., 2003). 
The thymic medulla is the key to establishing central tolerance due to the participation 
of mTEC, DCs and thymic B lymphocytes in the clonal deletion of autoreactive SP 
thymocytes or the deviation of CD4 SP thymocytes towards MHC-II-restricted 
CD4+CD25+FoxP3+ natural regulatory (Treg) lymphocytes (Xing and Hogquist, 2012, 
Hsieh et al., 2012, Klein et al., 2014, Hadeiba and Butcher, 2013).  
 
In establishing central tolerance, AIRE regulates the promiscuous gene expression of 
tissue-restricted antigens (TRA) by mTEC. The presentation of MHC-restricted TRA in 
combination with the appropriate cytokine and costimulatory signals can induce the 
negative selection of high affinity TRA-reactive SP thymocytes (Liston et al., 2003, 
Anderson et al., 2005). AIRE also controls the transfer of mTEC-derived TRA to 
thymus resident SIRPα-CD8α+ DCs (Perry et al., 2014) that can cross-present TRA to 
CD8 SP thymocytes and induce clonal deletion (Gallegos and Bevan, 2004, Proietto et 
al., 2008). The transfer of mTEC-derived TRA to SIRPα-CD8α+ DCs is physiologically 
feasible due to their close proximity (Klein et al., 2014), this colocalisation being due to 
mTEC-derived XCL1 (lymphotactin) attracting DCs to the medulla near mTEC via its 
receptor, XCR1, which is unique to SIRPα-CD8α+ DCs. The study also showed that 
perturbing the XCL1-XCR1 interaction leads to the mislocalisation of SIRPα-CD8α+ 
DCs, alters Treg cellularity and the deficient mice develop autoimmune phenotypes (Lei 
et al., 2011). In addition to the ability of the migratory SIRPα+CD8α- DCs to mediate 
negative selection of TCR clones strongly reactive to blood-borne self-antigen (Section 
1.2.3.2.2 and FIG. 1.5) (Baba et al., 2009), a separate study showed that SIRPα+CD8α- 
migratory DC are superior to SIRPα-CD8α+ resident DC in inducing Treg development 
(Proietto et al., 2008). Moreover, plasmacytoid DC can also acquire blood-borne 
antigens from the periphery and migrate to the thymus in a CCR9-dependent manner to 
exert central tolerance via negative selection but lack the ability to support Treg 
development (Hadeiba et al., 2012). Finally, thymic B lymphocytes also share 
functional redundancies with mTEC and thymic DCs in inducing central tolerance. For 
example, a recent study proposed that AIRE- peripheral B lymphocytes homing to the 
thymus initiate a cognate interaction (TRA-specific) with autoreactive CD4 SP 
thymocytes to gain a CD40 signal, which leads to the upregulation of AIRE, MHC-II 
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and CD80, the B lymphocytes thus becoming ‘licensed’ to delete cognate autoreactive 
CD4 SP thymocytes (Yamano et al., 2015).  
 
Immature SP thymocytes that survive negative selection then undergo final stages of 
maturation towards becoming long-lived and functionally competent MHC-restricted T 
lymphocytes in the periphery. Hogquist et al. (2015) separates these highly complex 
maturation process into distinct phases: semi-mature (SM: CD69+MHC-I-, susceptible 
to activation-induce apoptosis), mature-1 (M1: CD69+MHC-I+, cells able to survive 
antigen induced-apoptosis and proliferate on antigenic stimulation) and mature-2  (M2: 
CD69-MHC-I+, competent to proliferate upon antigenic stimulation and express surface 
molecules that allow thymus egress) (Hogquist et al., 2015). Eventually, M2 SP 
thymocytes express Krupple-like factor (KLF)-2 (Carlson et al., 2006) that induces the 
expression of sphingosin-1-phosphate (S1P) receptor-1, the receptor for S1P. High 
expression levels of S1P on the endothelium of the thymic periphery drives SP 
thymocytes to egress from the thymus and undergo further maturation in the periphery 
(Matloubian et al., 2004). 
1.2.4 Concluding remarks 
Based on the findings summarised above it is clear that T lymphocyte development and, 
in particular, positive and negative selection, is a highly complex process that requires 
diverse extracellular cues, with distinct microenvironments in special anatomical 
regions of the thymus being critical to guide and drive T cell development in a timely 
manner. Perturbing the normal symbiotic ‘cross-talk’ between the developing 
thymocytes and thymic stromal cells results in the impaired development of all thymic 
components, uncontrolled development of lymphoid malignancies, severe 
immunodeficiency and autoimmune diseases. Understanding the optimal conditions for 
T cell development is important to characterise factors predisposing individuals to 
immunodeficiencies and autoimmunity, and developing therapies that reverses these 
undesirable processes. 
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1.3 Experimental aims 
Previous studies by my supervisor’s laboratory (the Parish laboratory) demonstrated 
that HS mimetics inhibit a MHC-restricted interaction (i.e., autorosetting) between DP 
thymocytes and autologous erythrocytes (Parish et al., 1984). In this PhD Thesis it is 
postulated that autorosetting is mimicking an important HS-dependent cell adhesion 
process in the thymus that plays a role in promoting a tight interaction between 
thymocytes and TECs (Werneck et al., 1999), particularly in the cortex, where DP 
thymocytes reside. In another study, my supervisor’s laboratory demonstrated that HS 
mimetics could trigger a sustained intracellular Ca2+ flux in a subset of DP thymocytes 
(Tellam and Parish, 1987, Weston et al., 1991). Hence, it was predicted that the HS-
induced Ca2+ flux and the autorosetting phenomenon are linked, the interaction of DP 
thymocytes with HS on cTEC providing an ‘accessory signal’ (Anderson et al., 1994) 
that is important in T lymphocyte development.  
 
Therefore, the main aims of this PhD project were: 
a) To identify the receptor(s) on DP thymocytes that binds HS and mediate 
autorosetting. 
b) To determine the functional significance of HS binding by DP thymocytes. 
c) To investigate the physiological role of HS recognition by thymocytes on T 
lymphocyte development.   
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2        Chapter Two 
 
 
 
 
 
 
 
Materials and Methods 
 
 
 
 
 
 
 
 
This chapter describes the materials and methods used for experiments described within 
this thesis  
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2.1 General reagents 
2.1.1 Reagents, media and buffers 
Details of reagents, including cell-labelling fluorescence dyes, enzymes, culture media, 
kits, buffers and anticoagulant solutions used in this thesis are as listed in Table 2.1. 
2.1.2 Sulfated polysaccharides 
Sulfated polysaccharides used in this thesis are listed in Table 2.2. Modified heparins 
were synthesised and donated by Dr. Craig Freeman (JCSMR, ANU, Canberra). 
2.1.3 Antibodies 
Table 2.3 details all the antibodies used in the experimental procedures.  
 
2.2 Purification of human plasma histidine-rich glycoprotein (hHRG) 
Human Histidine-Rich Glycoprotein (hHRG) was purified from human plasma, as 
previously described (Rylatt et al., 1981). Whatman P-11 phosphocellulose (50 g) 
(Whatman, Kent, UK) was rehydrated in a mixture of 0.2 M HCl and ethanol (1:1 
vol/vol) with occasional stirring for 60 min. The phosphocellulose was sequentially 
washed with 1 L of distilled-distilled water (ddH2O), 1 L of NaOH (0.1 M) and 1 L of 
ddH2O before being resuspended in 1 L of 1 mM EDTA for 30 min with occasional 
stirring. The phosphocellulose was then washed in 1 L of ddH2O and resuspended in 0.5 
M NaCl loading buffer (10 NaH2PO4, 1 mM EDTA, pH6.8). The subsequent steps were 
performed at 4°C to prevent protein degradation. The phosphocellulose was loaded onto 
a Econo-Column® (2.5 x 20 cm) (Bio-Rad, Richmond, CA) and sequentially washed 
with fresh 90 mL of 0.5 M NaCl loading buffer containing 50 mg/mL BSA, then three 
times with 90 mL of 0.5 M NaCl loading buffer (without BSA), 90 mL of 2 M NaCl 
loading buffer, before final equilibration with 0.5 M NaCl loading buffer. Perfabloc 
(200 µg/mL) (Roche Diagnostics, Indianapolis, IN), 4 µg/mL of aprotinin (Boerhringer, 
Mannheim, Germany), 1 mM EDTA and 0.5 M NaCl was added to 0.5 L of human 
plasma (Red Cross, The Canberra Hospital, Canberra, Australia) and the plasma 
centrifuged (20,000 g, 20 min, 4°C) in a Sorval RC-5B Centrifuge (Dupont, 
Wilmington, DE). The plasma supernatant was collected and mixed with an equal 
volume of 0.5 M NaCl loading buffer and then loaded onto the equilibrated 
phosphocellulose P-11 column. Unbound proteins were sequentially washed from the 
 
Materials & Methods 
	 37 
column with 1 L of 0.5 M NaCl loading buffer and then 0.3 L of 0.7 M NaCl loading 
buffer. Finally, column-bound HRG was eluted with 2 M NaCl loading buffer and then 
concentrated in 0.5 M NaCl/10 mM NaH2PO4 storage buffer using a Diaflo 
Concentrator 202 with YM-30 Diaflo Ultrafiltration Membrane (Amicon, Baverly, 
MA). The purified human HRG was aliquoted and stored at -80°C until use. 
 
2.3 Bradford protein assay 
The Bradford Protein assay was used to estimate protein concentration. BSA standards 
and protein samples were diluted in PBS to a final volume of 100 µL and loaded onto a 
flat-bottomed 96-well microplate (NUNC™, Thermo Fisher Scientific, Waltham, MA). 
A 100 µL aliquot of concentrated Bradford Reagent dye (Bio-Rad, Richmond, CA) was 
added to each BSA standard and protein sample and the plate incubated at RT for 5 min. 
The absorbance at 595 nm was measured on Thermomax microplate reader using 
SoftMaxPro 4.0 software (Molecular Devices, Sunnyvale, CA).  
 
2.4 Sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE)  
Protein samples were mixed with an equal volume of reducing SDS (2x) sample buffer 
(125 mM Tris-HCl, 20 % Glycerol, 4% SDS, 0.01% bromophenol blue, 10% 
dithiothreitol, pH 6.8) and boiled for 5 min. Samples were electrophoresed (80 volts, 90 
min) on a 4-20 % gradient pre-cast polyacrylamide MiniGel (NuSep, Homebush NSW, 
Australia) using Mini-Protean II apparatus (Bio-Rad, Richmond, CA) in SDS-HEPES 
running buffer (NuSep, Homebush NSW, Australia). To estimate the molecular weight 
of protein samples, 5 µL of pre-stained protein standards (Bio-Rad, Richmond, CA) 
were simultaneously run.  
 
2.5 Coomassie blue protein staining 
Following SDS-PAGE the polyacrylamide gel was stained with Coomassie Blue 
staining solution (0.4% Coomassie Blue, 50% methanol, 10% acetic acid) for 30 min at 
RT. The gel was sequentially destained with destaining solution-I (50% methanol, 10% 
acetic acid) for 30-60 min and then destaining solution-II (7% ethanol, 5% acetic acid) 
until the protein bands were discretely observable.  
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Table 2.1: Reagents used in experimental procedures. 
Name Details 
General reagents  
2-mercaptoethanol (2-ME) Gibco BRL, Grand Island, NY 
Bovine Serum Albumin (BSA) ≥98% Sigma-Aldrich, St. Louis, MO 
Complete EDTA-free protease inhibitor Roche Diagnostics, Indianapolis, IN 
Dimethyl sulfoxide (DMSO) Cambridge Isotope laboratories, Tewksbury, MA 
Foetal calf serum (FCS) Serana/Fisher Biotec, Australia.  Heat-inactivated (56°C/30 min). 
HEPES Gibco BRL, Grand Island, NY 
L-glutamine Life Technologies, Carlsbad, CA 
Recombinant mouse Histidine-Rich 
Glycoprotein (rec. mHRG) R&D Systems, Minneapolis, MN 
Streptavidin-FITC BD Bioscience, San Jose, CA 
Streptavidin Microbeads Miltenyi Biotec, Bergisch Gladbach, Germany 
Cell labelling dyes  
CFDA-SE Exλ/Emλ: 495/519 nm. Life Technologies, Carlsbad, CA 
Cell Proliferation Dye eFluor® 670 (CPD670) Exλ/Emλ: 647/670 nm. eBioscience, San Diego, CA 
CellTrace Violet (CTV) Exλ/Emλ: 405/450 nm. Life Technologies, Carlsbad, CA 
Hoechst-33342 Exλ/Emλ: 350/461 nm. Life Technologies, Carlsbad, CA 
Hoechst-33258 Exλ/Emλ: 350/461 nm. Life Technologies, Carlsbad, CA 
Digestion enzymes  
Collagenase Type IV (filter-sterilised) Worthington, Lakewood, NJ 
Collagenase/Dispase Roche Diagnostics, Indianapolis, IN 
DNAse I Roche Diagnostics, Indianapolis, IN 
Heparanase (human platelet) Purified by Dr. Craig Freeman (Freeman and Parish, 1997) 
Heparinase I (Flavobacterium heparinum) Sigma-Aldrich, St. Louis, MO 
Neuraminidase Type II (Vibrio cholerae) Sigma-Aldrich, St. Louis, MO 
Kits  
Qproteome Murine Albumin Depletion Kit QIAGEN, Limburg, Netherlands 
ReadiLink 647/674 Antibody Labelling Kit Bio-Rad, Richmond, CA 
Lectins  
Maackia amurensis lectin II (MAL-II), 
biotinylated Vector Laboratories, Burlingame, CA  
Peanut agglutinin (PNA), biotinylated Sigma-Aldrich, St. Louis, MO 
Ulex europaeus agglutinin I (UEA-I), 
Fluorescein and Rhodamine Red-conjugated Vector Laboratories, Burlingame, CA  
Media, buffers and anticoagulant solution  
Alsever’s Solution 
D-glucose 20.5 g/L, Na3C6H5O7.2H2O 8g/L, NaCl 4 g/L, 
Citric acid 0.55 g/L, pH 6 ±1 in ddH2O. 
Filter-sterilised (0.22 µm) 
Dulbecco’s Phosphate Buffered Saline (PBS) Ca2+/Mg2+-free. Sigma-Aldrich, St. Louis, MO 
FACS buffer PBS, 0.1 % BSA (weight/vol) or 0.5 % FCS (vol/vol),  pH 7.0-7.4 
HEPES buffered saline (HBS) NaCl 8 g/L, KCl 0.4 g/L, CaCl2 0.2 g/L, MgCl2.6H2O 0.2 g/L, D-glucose 1.8 g/L, HEPES 10 mM in ddH2O 
Hank’s Balanced Salt Solution (HBSS) 
NaCl 8 g/L, KCl 0.4 g/L, MgSO4.7H2O 0.1 g/L, MgCl2.6H2O 
0.1 g/L, CaCl2 0.112g/L, D-glucose 1g/L, phenol red 0.02 
g/L, NaH2PO4.2H2O 0.078 g/L, KH2PO4 0.06 g/L in ddH2O 
MACS buffer PBS, 2 mM EDTA, 0.5% FCS (vol/vol), pH 7 
Minimal Essential Medium (MEM-F15) F15 MEM powder (Gibco BRL, Grand Island, NY) 9.61 g/L and NaHCO3 2.2 g/L in ddH2O 
Normal saline NaCl 9 g/L in double-distilled water 
BD Pharm Lyse™ Erythrocyte Lysing Buffer 
(10X) 
BD Bioscience, San Jose, CA 
Diluted to 1x in ddH2O  
RPMI-1640 Life Technologies, Carlsbad, CA  No phenol red/HEPES/L-glutamine  
Complete RPMI-1640 medium 
(Supplemented with) 
10% FCS (vol/vol), 10 mM HEPES, 2 mM L-glutamine,  
1 mM sodium pyruvate, 50 µM 2-mercaptoethanol 
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Table 2.2: Sulfated polysaccharides used in experimental procedures. 
Name Details 
Dextran sulfate 5 kDa ∞ 
Sigma-Aldrich, St. Louis, MO Dextran sulfate 500 kDa ∞ 
Heparin (Bovine Lung) ∞ 
Heparin, fluoresceinated ∞⌘ Provided by Dr. Craig Freeman 
 
Modified heparins (Synthesised and donated by Dr. Craig Freeman)§ 
Modification Structure 
Nil (Unmodified precursor) -[IdoA(2S)-(α1,4)-GlcNS(6S)]n- 
 
De-COO- -[IdoA(2S)-(α1,4)-GlcNS(6S)]n- 
 
De-2S -[IdoA-(α1,4)-GlcNS(6S)]n- 
 
De-NS/re-NAc -[IdoA(2S)-(α1,4)-GlcNAc(6S)]n- 
 
De-2S, de-NS/re-NAc -[IdoA-(α1,4)-GlcNAc(6S)]n- 
 
De-6S -[IdoA(2S)-(α1,4)-GlcNS]n- 
 
De-NS -[IdoA(2S)-(α1,4)-GlcNH(6S)]n- 
 
De-S, re-NS -[IdoA-(α1,4)-GlcNS]n- 
 
De-S -[IdoA(2S)-(α1,4)-GlcNH]n- 
 
  
∞ Sulfated polysaccharides were solubilised in ddH2O to 20 mg/mL.  
⌘  Fluoreseinated heparin powder derived from porcine mucosa heparin (Calbiochem, La Jolla, CA) was solubilised 
to 20 mg/mL in ddH2O, then aliquoted and stored at -20°C. 
§ All modified heparins were synthesised from porcine mucosa heparin (Calbiochem, La Jolla, CA) and provided at 
20 mg/mL in ddH2O. Stored at -20°C. 
 
Heparin modification: de-COO=decarboxylated, de-S=2,6-O-desulfated, de-2S=2-O-desulfated, de-6S=6-O-
desulfated, de-NS=N-desulfated, re-NAc=N-reacetylated 
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Table 2.3: Details of primary antibodies used in experimental procedures. 
Specificity Isotype Clone Format Conc. Used (final) Source 
CD2 Rat IgG2b RM2-5 Biotin, FITC 5 µg/mL ∞ BD 
CD3ε Ar. Ham IgG1 145-2C11 Purified, FITC 5 µg/mL ∞ BD 
CD4 Rat IgG2a RM4-5,  
Biotin, FITC, PE, 
AF700 
1 µg/mL   
5 µg/mL ∞⌘ BD, Biolegend 
CD8α Rat IgG2a 53-6.7 Biotin, FITC, APC, APC-eF780 
1 µg/mL   
5 µg/mL ∞⌘ BD, eBioscience 
CD8β.2 Rat IgG1 53-5.8 Biotin, FITC 1 µg/mL   5 µg/mL ∞ BD, Biolegend 
CD11a Rat IgG2a M17/4 Purified 5 µg/mL ∞ BD 
CD11b Rat IgG2b M1/70 Biotin, AF700,  1 µg/mL   5 µg/mL ⌘ Biolegend 
CD11c Ar. Ham IgG1 N418 Biotin, APC-Cy7 
1 µg/mL   
5 µg/mL ⌘ Biolegend 
CD16/CD32 Rat IgG2b 2.4G2 Purified 5 µg/mL  BD 
CD44 Rat IgG2b IM7 Purified 5 µg/mL ∞ BD 
CD45 Rat IgG2b 30-F11 Purified 5 µg/mL ∞ BD 
CD45.1 Mouse IgG2a A20 FITC, PE-CF594 0.4 µg/mL   BD 
CD45.2 Mouse IgG2a 104 PerCP-Cy5.5 0.4 µg/mL   BD 
CD45R/B220 Rat IgG2a RA3-6B2 Biotin 5 µg/mL ⌘ BD 
CD62L Rat IgG2a MEL-14 Biotin 5 µg/mL ∞ BD 
CD69 Ar. Ham IgG1 H1.2F3 PE, BV605 1 µg/mL   5 µg/mL ∞ BD, Biolegend 
CD90.2 Rat IgG2a 53-2.1 Biotin, PE 5 µg/mL ∞⌘ BD, Biolegend 
CD326/EpCAM Rat IgG2a G8.8 Biotin, PE-Cy7 2 µg/mL  ⌘ Biolegend 
H2-Kb Mouse IgG2a AF6-88.5 PE, FITC 1 µg/mL   Biolegend 
Heparan sulfate Mouse IgM F58-10E4 Purified, FITC, ReadiLink 647/674¶ Varied   
Seikagaku Corp., 
US Biological, 
AMSBIO 
Ly49G Rat IgG2a 4D11 Purified 5 µg/mL ∞ BD 
Ly-51 Rat IgG2a 6C3 PE 40 ng/mL   Biolegend 
NKG2D Rat IgG1 CX5 Purified 5 µg/mL ∞ BD 
TCR β chain Ar. Ham IgG2 H57-597 Biotin 5 µg/mL ∞ Biolegend 
TER-119 Rat IgG2b TER-119 Biotin 5 µg/mL ⌘ BD, Biolegend 
 
¶ Purified anti-HS mAb (50 µL aliquot, 1 mg/mL) conjugated to ReadiLink 647/674 (Bio-Rad) using custom 
Ab conjugation kit according to manufacturer’s instructions. 
 
 Application 
  Fluorescence flow cytometry 
∞ Surface marker blocking 
⌘ MACS-enrichment 
 Fc-Block (blocking of non-specific antibody binding) 		
2.6 Western blotting 
Following SDS-PAGE (Section 2.4) protein samples were electrophoretically (100 
volts, 60 min) blotted onto a Hybond ECL nitrocellulose membrane (Amersham 
Biosciences, Buckinghamshire, UK) using a Mini-Protean II apparatus and a Mini Tran-
Blot Electrophoretic Transfer Cell Kit (Bio-Rad, Richmond, CA) in transfer buffer 
containing 5 mM Tris, 38.5 mM glycine, 20% methanol. The membrane was incubated 
in PBS/5% skim milk powder at 4°C for 16 hr before the target protein was probed with 
specific Ab diluted in PBS/0.1% BSA at 4°C for 90 min. The membrane was 
 
Materials & Methods 
	 41 
extensively washed in PBS/0.5% Tween-20 before being incubated with HRP-
conjugated detection Ab, diluted in PBS/0.1% BSA at 4°C for 90 min. After the 
membrane was extensively washed in PBS/0.5% Tween-20, immunoreactive proteins 
were detected using an ECL™ Western blotting reagent (Amersham Biosciences, 
Buckinghamshire, UK) and imaged using a LAS-1000 Chemiluminesence and a 
Fluorescence Imaging System (Fuji Photo Co. Ltd, Japan). 
 
2.7 Animals  
The strain, phenotype and sources of mice used in this thesis are detailed in Table 2.4. 
Mice were housed in a certified PC2 facility and daily maintained by the staff of 
Australian Phenomics Facility (APF) or the candidate. All animal procedures were 
performed under approval from the Animal Experimentation Ethics Committee of the 
Australian National University, Canberra.  
 
Table 2.4: Mouse strains used in experimental procedures. 
Mouse Strain Phenotype / Reference Source/Donor 
C57BL/6 (B6) Wild type. CD45.2  APF, ANU  
B6.SJL Wild type. CD45.1 
CD4-/- CD4 deficient ENU mutant (unpublished) Dr. Anselm Enders, APF/ANU 
CD8α.KO CD8α chain deficient (Mak et al., 1992) Jackson Laboratories, USA 
CD8β.KO CD8β chain deficient (Crooks and Littman, 1994) Prof. Alfred Singer, NIH, USA 
CD4-/-xCD8β.KO CD4 and CD8β double deficient (unpublished) APF, ANU 
CD45.KO CD45 deficient (Kishihara et al., 1993) Dr. Zuopheng Wu, APF/ANU 
H2-Kb/Db.KO MHC-I deficient (Perarnau et al., 1999) Dr. G. Karupiah, APF/ANU 
β2m.KO MHC-I deficient (Koller et al., 1990) 
β2mxMHC-II.KO MHC-IxMHC-II double deficient  (MHC-II.KO: (Madsen et al., 1999)) 
Dr. Stephen Daley, APF/ANU Slp76-/- 
Slp76 deficient ENU mutant  
(ENUstrain.T-wimp (Siggs et al., 2015)) 
Zap70-/- Zap70
 deficient ENU mutant 
(ENUstrain.MrTLess (Siggs et al., 2007)) 
 
2.8 Preparation of mouse blood  
2.8.1 Collection of mouse blood 
A maximum blood volume of 1% of total body weight or ~100-200 µL from a 20-25 g 
adult mouse (8-10 week old) was collected from the lateral cantus into a microfuge tube 
using a non-heparinised haematocrit tube (Hirschmann Läborgerate GmbH & CO. KG, 
Eberstadt, Germany). 
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2.8.2 Isolation of mouse serum 
The blood was incubated at 37°C in a humidified cell incubator with 5% CO2 in air for 
30 min and allowed to clot before being centrifuged at 7000 g for 20 min. The serum 
was collected, aliquoted and stored at -80°C until use. 
 
2.9 HRG detection by enzyme-link immunosorbent assay (ELISA) 
Mouse serum was diluted 1/500 in PBS/1% BSA before being loaded (100 µL/well) 
into a nickel-coated (Ni-NTA) HisSorb 96-well plate (QIAGEN, Limburg, Netherlands) 
and plates then incubated at RT for 2 hr. Unbound proteins were removed by flicking 
out the supernatant from the plates and washing the plates three times with 200 µL per 
well of PBS/0.5% Tween-20. A goat anti-mouse HRG pAb (R&D Systems, 
Minneapolis, MN) in PBS/1%BSA was added to each well (0.5 µg/mL, 100 µL/well) 
and the plates incubated at RT for 2 hr. After extensive washing in PBS/0.5% Tween-
20, HRP-conjugated rabbit anti-goat pAb (DAKO, Glostrup, Denmark) in PBS/1% 
BSA was added to each well (6.5 µg/mL, 100 µL/well) and incubated at RT for 45 min. 
Immunolabelled HRG was detected by adding ABTS Peroxidase Substrate (100 
µL/well) (1 Component system) (KPL, Gaithersburg, MA) for 20-30 min at RT. The 
absorbance at 405 nm was measured on a Thermomax microplate reader using 
SoftMaxPro 4.0 software (Molecular Devices, Sunnyvale, CA). 
 
2.10 Depletion of mouse serum albumin 
Mouse serum albumin was removed from mouse serum using a Qproteome® Murine 
Albumin Depletion Kit (QIAGEN, Limburg, Netherlands) according to the 
manufacturer’s instructions. Briefly, 25 µL of mouse serum was diluted 1:4 in 75 µL of 
50 mM NaCl binding buffer (supplemented with 50 mM Na2HPO4, 10 mM Imidazole 
and complete EDTA-free protease inhibitor (Roche Diagnostics, Indianapolis, IN)) and 
loaded onto a Qproteome® Depletion Spin Column that was pre-equilibrated in the 
same buffer. The column was incubated at RT for 5 min before briefly being 
centrifuged (500 g, 10 s). The albumin-depleted eluted serum fraction was collected, 
aliquoted and stored at -80°C until use. 
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2.11 Depletion of mouse serum HRG 
Mouse serum HRG was depleted using Cobalt (Co2+)-affinity chromatography (Patel et 
al., 2013). All steps were performed at 4°C to prevent protein degradation. A 40 µL 
aliquot of Co2+-Sepharose bead (TALON Metal affinity resin, Clontech, Palo Alto, CA) 
was washed by centrifugation (500 g, 4 min) to remove storage buffer. Beads were then 
equilibrated with 50 µL of 50 mM NaCl binding buffer (prepared as described in 
Section 2.10). The beads were centrifuged (500 g, 4 min) and supernatant removed 
ready for serum application. A 10 µL aliquot of mouse serum was diluted 1:6 by the 
addition of 50 µL of 50 mM NaCl binding buffer and this was then added to washed 
beads. In some experiments, the albumin-depleted serum fraction (prepared as described 
in Section 2.10) was used. The beads were incubated at 4°C for 16 hr then centrifuged 
(500 g, 4 min) before the supernatant was collected, aliquoted and stored at -80°C until 
use.  
 
2.12 Lymphocyte preparation 
2.12.1 Preparation of single-cell lymphocyte suspension 
Animals were humanely euthanised by CO2 asphyxiation or cervical dislocation. The 
lymphoid organs were dissected out aseptically and placed in ice-chilled serum-free 
HBSS or RPMI-1640, gently pressed through a 70 µm cell strainer (BD, San Jose, CA) 
and pelleted via centrifugation (300 g, 5 min). Where necessary, erythrocytes were 
depleted by adding 5 mL of 1x BD Pharm Lyse™ lysing buffer, incubated at RT for 7 
min followed by three washes (300 g, 5 min) in 10 mL RPMI-1640/5% FCS. The cells 
were resuspended in an appropriate assay buffer and kept on ice until use. 
2.12.2 Manual enrichment of peripheral lymphocytes  
Peripheral CD4+ (pCD4) and CD8+ (pCD8) T and B220+ B lymphocytes were enriched 
from pooled lymph nodes and spleens by negative selection via magnetic-activated cell 
sorting (MACS) (Quah et al., 2004). Briefly, erythrocytes-depleted leukocytes in 1 mL 
of MACS buffer were incubated with a biotin-conjugated mAb cocktail (Table 2.5) at 
RT for 15 min. The cells were washed three times (300 g, 5 min), resuspended in 0.5 
mL of MACS buffer containing 14 µL of Streptavidin-Microbeads (Miltenyi Biotec, 
Germany) and incubated at RT for 15 min. Excess Streptavidin-Microbeads were 
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removed by pelleting cells by centrifugation (300 g, 5 min) and removal of the 
supernatant. Cells were then resuspended in 0.5 mL MACS buffer and loaded onto a 
magnetised LS Column (Miltenyi Biotec, Germany). The eluted cells were collected 
and pelleted via centrifugation (300 g, 5 min) and the supernatant removed. Cells were 
then washed three times, each by resuspending the cell pellet in 10 mL of buffer 
followed by centrifugation (300 g, 5 min, 4°C) and removal of the supernatant. The 
cells were resuspended in an appropriate buffer and kept on ice until use. 
 
Table 2.5: MAb cocktails used in manual MACS enrichment of peripheral lymphocytes. 
Target cell MAb cocktail (5 µg/mL each) 
Peripheral CD4+ T cells (pCD4) Anti-CD8α, CD11b, CD11c, B220, TER-119 
Peripheral CD8+ T cells (pCD8) Anti-CD4, CD11b, CD11c, B220, TER-119 
Peripheral B cells (B220) Anti-CD90, CD4, CD8α, CD11b, CD11c, TER-119 
* All mAbs are biotinylated and are detailed in Table 2.3 
 
2.12.3 Cell counting and viability 
A 10 µL aliquot of cell suspension was diluted 1:2 in 10 µL of 0.1% Trypan Blue (BDH 
Poole Chemicals, London England) and loaded onto a haemocytometer. The cells were 
viewed at x40 magnification using a standard Olympus B light microscope (Olympus 
Optical, Tokyo, Japan) to determine cell number and viability. Alternatively, 10 µL of a 
cell suspension was diluted in 490 µL of PBS and loaded into a sample cup and cell 
number and cell viability determined using VI-CELL® cell viability analyser (Beckman 
Coulter, Pasadena, CA).  
 
2.13 Antibody labelling and analysis of leukocytes 
2.13.1 Blocking of non-specific antibody binding FcR 
Cells were resuspended (106-107 cells/mL) in ice-chilled FACS buffer and incubated 
with a rat anti-mouse CD16/CD32 mAb (5 µg/mL) (Mouse BD Fc Block™, clone 
2.4G2) on ice for 20 min in a total volume of 1 mL.  
2.13.2 Cell surface antibody labelling 
Cells were labelled with fluorochrome-conjugated mAbs (Table 2.3) in 1 mL of FACS 
buffer on ice and in the dark for 30 min. Cells were then pelleted by centrifugation and 
washed three times (300 g, 5 min). Samples were then resuspended in ice-chilled FACS 
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buffer ready for flow cytometry. Where necessary, Hoechst-33258 (1 µg/mL) was 
added to distinguish dead cells. 
2.13.3 Multiparametric analysis of cells by flow cytometry 
Cells were acquired at a constant event rate (<1000 events/sec) on a BD LSRFortessa™ 
flow cytometer using BD FACSDiva™ software (Franklin Lakes, NJ). A total of 1-
5x105 viable (Hoechst-33258-) cells were acquired and recorded after excluding cell 
debris and cells clumps based on forward (FSC-A) and side (SSC-A) light scattering. 
Post-acquisition analysis was performed using FlowJo software (version 8.8.7) (Tree 
Star Inc. Ashland, OR). 
 
2.14 Lymphocyte-erythrocyte autorosetting assay 
2.14.1 Fluorescent labelling of lymphocytes 
Lymphocytes (4x106 cells/mL) in HBSS/0.5% FCS (pre-equilibrated to RT) were 
incubated with Hoechst-33342 (4 µg/mL) (Life Technologies, Carlsbad, CA) at RT for 
30 min and then used for autorosetting assay. In some experiments the cells were then 
labelled with fluorescent mAbs, as described in Section 2.13.2, and washed (300 g, 5 
min and removal of supernatant) before being resuspended in HBSS/0.5% FCS.  
2.14.2 Preparation of CFSE-labelled erythrocytes  
An adult mouse (8-10 week old) was intravenously (i.v.) injected via its lateral tail vein 
with 25 µL of 20 mM CFDA-SE in DMSO (Life Technologies, Carlsbad, CA) mixed 
with 100 µL of sterile PBS using a BD Ultra-Fine™ 0.3 mL insulin syringe (12.7 mm, 
31G gauge needle) (Coupland et al., 2010). Blood from mice was collected (as 
described in Section 2.8.1) 4-16 hr after CFDA-SE injection, into an equal volume of 
Alsever’s Solution, rested for 20 min at RT away from light before being washed (700 
g, 5 min) four times in normal saline. The blood was resuspended (%, vol/vol) in ice-
chilled HBSS/0.5% FCS and was kept on ice until use.  
2.14.3 Standard autorosetting assay 
A fluorescence-based autorosetting assay was used, modified from a prior method used 
by the Parish Laboratory (Parish et al., 1982, Sia and Parish, 1980a). In U-bottomed 96-
well microplates (Linbro®, MP Biomedicals, Santa Ana, CA) 50 µL of Hoechst-33342 
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labelled lymphocytes (4x106 cells/mL) and 50 µL of CFSE-labelled erythrocytes (2%, 
vol/vol) were mixed. To induce autorosetting the mixtures were briefly centrifuged (200 
g, 1 min, 4°C) and the pelleted cells then incubated on ice for 45 min. The cell pellets 
were gently transferred to 1.2 mL cluster tubes using wide-bore pipette tips (Axygen® 
Corning, Tewksbury, MA) and were immediately analysed on a bench-top analytical 
flow cytometer. The cells were acquired at medium event rate (~3000 events/sec) while 
recording a minimum of 10,000 viable (Hoechst-33342lo) cells and autorosetting 
depicted by Hoechst-33342lo cells acquiring CFSE+ profiles (%Araw) gated to include ≥2 
bound erythrocytes (1 CFSE+ peak/erythrocyte) per thymocyte. Non-rosetting cell 
mixtures were also examined as a control, which involved analysis of lymphocyte and 
erythrocyte samples immediately after mixing the two populations (and therefore before 
true rosette formation) to measure background ‘coincidence’ (%C) values of cell 
mixtures (Snow, 2004). %True autorosetting was calculated by %Araw-%C. 
 
2.15 Lymphocyte-erythrocyte autorosetting inhibition experiments  
Hoechst-33342 labelled lymphocytes (4x106 cells/mL) were incubated with either 
blocking mAbs (0.005-5 µg/mL) (Table 2.3) or sulfated polysaccharides (0.001-100 
µg/mL) (Table 2.2) and CFSE-labelled erythrocytes (2%, vol/vol) were incubated with 
either purified hHRG or mouse serum at pre-determined concentrations. Cells were 
incubated with inhibitors on ice for 60 min. Cell autorosetting was then examined 
without removing the excess inhibitors. 
 
2.16 Analysis of cell surface heparan sulfate on erythrocytes 
2.16.1 Heparanase treatment of erythrocytes 
CFSE-labelled erythrocyte suspensions (2%, vol/vol) were incubated with platelet-
derived human heparanase (HPSE, 4 µg/mL) (provided by Dr. Craig Freeman, ANU) or 
bacterial heparinase I/heparitinase III from Flavobacterium heparinum (HPNSE, 5 
U/mL) (Sigma-Aldrich, St. Louis, MO) in a 37°C/5% CO2 humidified cell incubator for 
60 min and subsequently kept on ice until use.  
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2.16.2 Assessment of erythrocyte cell surface heparan sulfate  
A CFSE-labelled erythrocytes suspension (0.06%, vol/vol) was incubated with a 
ReadiLink 647/674-conjugated anti-heparan sulfate mAb (0.125–4 µg/mL) (clone F58-
10E4) on ice for 60 min. Cell surface HS labelling was examined by flow cytometry.  
 
2.17 Assessment of lymphocyte sialylation profiles 
2.17.1 Neuraminidase treatment of lymphocytes 
Lymphocytes (3x107 cells/mL) in HBSS or RPMI-1640 (supplemented with 0.5% FCS) 
(pre-equilibrated to 37°C) were incubated with 0.1 U/mL of bacterial neuraminidase 
(Neu) type II from Vibrio cholerae (Sigma-Aldrich, St. Louis, MO) in a 37°C/5% CO2 
humidified cell incubator for 60 min (Moody et al., 2001, Daniels et al., 2001). The 
cells were washed three times (300 g, 5 min) and resuspended in the appropriate assay 
buffer. 
2.17.2 Cell surface lectin labelling 
Lymphocytes (1x107 cells/mL) in ice-chilled PBS/0.1% BSA were incubated with 0.2 
µg/mL of biotin-conjugated peanut agglutinin (PNA) (Sigma-Aldrich, St. Louis, MO) or 
Maackia amurensis lectin II (MAL-II) (Vector Laboratories, Burlingame, CA) (Brennan 
et al., 2006) on ice for 30 min. The cells were washed twice (400 g, 5 min) in ice-chilled 
PBS/0.1% BSA and then Streptavidin-FITC (1 µg/mL) was added to the cells and 
incubated on ice for 20 min. The cells were then washed twice (400 g, 5 min) with ice-
chilled PBS/0.1% BSA before resuspension in 50 µL of PBS/0.1% BSA. Lectin binding 
was analysed by flow cytometry.  
 
2.18 Inhibition of antibody binding by sulfated polysaccharides 
Lymphocytes (1x107 cells/mL) suspended in ice-chilled PBS/0.1% BSA were incubated 
with sulfated polysaccharides (0.1-100 µg/mL) for 60 min on ice prior to labelling with 
fluorescent mAbs (Table 2.3), including anti-CD45, anti-CD4, anti-CD8α or anti-CD8β 
mAbs (5 µg/mL each), for 30 min on ice. The cells were then washed four times (400 g, 
5 min, 4°C) before being resuspended in 50 µL of ice-chilled PBS/0.1% BSA and 
analysed by flow cytometry. Inhibition of mAb binding by sulfated polysaccharides was 
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represented by ‘% control mAb binding’ calculated using the following formula (Parish 
and Warren, 1991). 
 
GMFI mAb-reacted cells with sulfated polysaccharide
GMFI mAb-reacted cells without sulfated polysaccharide
× 100 
 
2.19 Heparin binding assay 
Lymphocytes (1x107 cells/mL) in ice-chilled PBS/0.1% BSA were incubated with 0.1 
mg/mL of FITC-heparin (donated by Dr. Craig Freeman, ANU) on ice for 30 min. The 
cells were washed four times (400 g, 5 min) and resuspended in 50 µL of PBS/0.1% 
BSA before being analysed by flow cytometry.  
 
2.20 Flow cytometric intracellular Ca2+ flux assay 
The loading of lymphocytes with intracellular Ca2+ indicator fluorescent dyes and the 
flow cytometric analysis of intracellular Ca2+ flux were performed as detailed below. 
2.20.1 Loading of lymphocytes with Ca2+ indicator dye 
Lymphocytes (3x107 cells/mL) in MEM-F15 or RPMI-1640 medium were incubated 
with Indo-1 AM (5 µM) (Tellam and Parish, 1987, Weston et al., 1991) at 37°C for 60 
min. After three washes (300 g, 5 min and removal of supernatant) with MEM-F15 or 
RPMI-1640 medium supplemented with 5% FCS the cells were resuspended (4x106 
cells/mL) in ice-chilled RPMI-1640/0.5% FCS (pH 7.4) supplemented with 10 mM 
HEPES. The cell suspension was kept on ice and used within 3 hr post-loading. 
2.20.2 Measurement of intracellular Ca2+ flux by flow cytometry 
Intracellular Ca2+ flux was monitored on a BD LSR-1™ flow cytometer using BD 
CellQuest™ Pro software. Ca2+ flux assessed as an increase in the ratio of fluorescence 
(GMFI) of Ca2+-bound over Ca2+-unbound Indo-1 (Table 2.7). The cells were pre-
equilibrated and maintained at 37°C during analysis using an external sheath connected 
to a heated waterbath. After the exclusion of cellular debris and clumped cells on the 
basis of FSC/SSC light scattering the basal Ca2+ level was monitored for 2 min before a 
stimulus was added and a change in Ca2+ level was monitored for 20 min at a constant 
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flow rate (~500 events/sec). Also, a 2 min (endpoint) intracellular Ca2+ level was 
measured after the kinetic assessment.  
 
Table 2.6: Calcium indicator dyes. 
Dye Loading conc. 
Flow 
cytometer 
Excitation 
laser 
Detection BP filter (nm) Ca2+ Flux 
(Ratio) Ca2+-bound Ca2+-free 
Indo-1 AM 5 µM LSR I 325 nm (UV) 424 ± 22 510 ± 10 424/510 
     
Fluo-4 AM 2.5 µM 
LSRFortessa 
488 nm (Blue) 530 ± 30  
530/695 Fura-Red AM 5 µM 488 nm (Blue)  695 ± 40 
Calcium indicator dyes (Life Technologies, Carlsbad, CA) were solubilised in DMSO to make 2 mM stock solution 
and stored at -20°C, protected from light. 
 
2.21 Thymocyte activation assay 
Thymocyte activation was assessed based on the upregulation of CD69 after an 
exposure to a stimulus (Davey et al., 1998, Yamashita et al., 1993). Thymocytes (2x106 
cells/mL) in RPMI-1640/10% FCS medium (supplemented with 25 mM HEPES, 1 mM 
L-glutamine/2 µM 2-ME) were loaded (200 µL /well), with or without sulfated 
polysaccharide, into a flat-bottomed 96-well plate (Linbro®, MP Biomedicals, Santa 
Ana, CA) and incubated at 37°C for 4 hr. For TCR/CD3 stimulation, 96-well 
microplates were pre-coated with an anti-CD3ε mAb (clone 145-2C11) diluted in PBS 
(50 µL/well, 0.4–10 µg/mL) (pH 8.0) at 4°C for 16 hr. Each well was rinsed three times 
with 200 µL of PBS to remove unbound mAb and thymocytes were then loaded, with or 
without sulfated polysaccharides and incubated at 37°C for 4 hr. The cells were washed 
three times (400 g, 5 min, 4°C) and subsequently labelled with a PE or BV605-
conjugated anti-CD69 mAb (1 µg/mL) in ice-chilled PBS/0.1%BSA on ice for 20 min. 
Excess anti-CD69 mAb was removed via centrifugation (400 g, 5 min, 4°C) and 
removal of the supernatant. The cells were then resuspended in ice-chilled 
PBS/0.1%BSA containing Hoechst-33258 (1 µg/mL) to discriminate dead cells. CD69-
labelling was analysed by flow cytometry.  
 
2.22 Identification of rosetting thymic stromal cells  
2.22.1 Enzymatic digestion of thymic fragments 
Four thymuses from 3 week old C57BL/6 mice were isolated and placed in serum-free 
RPMI-1640 (RT) medium. Aseptically, the connective tissue was removed and each 
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lobe cut into smaller fragments and placed in 5 mL of RPMI-1640 in a BD Falcon™ 50 
mL tube. The fragments were agitated using wide-bore transfer pipette and were 
allowed to sediment (~1 min) before removing the supernatant. The fragments were 
sequentially enzymatically digested (10 min/cycle), in which the uppermost 5 mL of the 
supernatant was collected after each 10 min cycle and fresh enzymes suspension applied 
to the remaining cell suspension. This was repeated until all fragments were fully 
disintegrated. The process included four cycles in type-IV collagenase solution (1 
mg/mL) (Worthington, Lakewood, NJ) and two cycles in collagenase/dispase solution 
(1 mg/mL) (Roche Diagnostics, Indianapolis, IN), all in the presence of DNAse-I (100 
µg/mL) (Roche Diagnostics, Indianapolis, IN) in 5 mL of serum-free RPMI-1640 at 
37°C. Finally, the supernatants were pooled and pelleted (100 g, 10 min) before being 
resuspended in 1 mL of RPMI-1640. 
2.22.2 Enrichment of pre-formed thymic rosettes  
Pre-formed thymic rosettes were enriched via two-step unit gravity sedimentation 
procedure above a FCS cushion, as described previously (Kyewski et al., 1982, 
Oliveira-dos-Santos et al., 1997). Briefly, thymic digests (as prepared in Section 2.22.1) 
were gently applied to the top of a FCS (12 mL) layer in a 14 mL BD Falcon™ tube. 
Denser multicellular conjugates were allowed to sediment at unit gravity for 60 min, the 
pelleted cells collected and centrifuged once (100 g, 10 min), the supernatant removed 
and the cell pellet resuspended in ice-chilled PBS/0.1% BSA/2 mM EDTA buffer and 
kept on ice until analysis. 
2.22.3 Cell surface labelling of stromal cells 
Enriched thymic stromal cells (106-107 cells/mL) from Section 2.22.2 were incubated 
with mouse BD Fc Block™ (5 µg/mL) at 4°C for 20 min before being labelled with 
fluorescently conjugated anti-EpCAM mAb (2 µg/mL), anti-Ly-51 mAb (40 ng/mL) 
and the lectin UEA-1 (2 µg/mL) (Table 2.3). The cells were washed once (400 g, 10 
min and removal of supernatant) before being resuspended (5x106 cells/mL) in ice-
chilled RPMI-1640/0.5 % FCS, pH 7.0 and were kept on ice until use. 
2.22.4 Assessment of stromal cell surface heparan sulfate  
Enriched thymic stromal cells (106-107 cells/mL) from Section 2.22.2 were incubated 
with a ReadiLink 647/674-conjugated anti-heparan sulfate mAb (clone F58-10E4) (1 
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µg/mL) on ice for 60 min and washed once by centrifugation (300 g, 5 min and removal 
of supernatant) before being resuspended in ice-chilled PBS/0.1% FCS. Cell surface HS 
labelling was examined by flow cytometry.  
  
2.23 Stromal-thymocyte rosetting assay 
2.23.1 Manual enrichment of EpCAM+ thymic epithelial cells (TEC) 
TEC were enriched from thymic digests (as prepared in Section 2.22.1) by two-step 
positive selection of EpCAM+ cells using MACS. Thymic digest in 1 mL of MACS 
buffer was filtered through a 100 µm cell strainer (BD, San Jose, CA) and incubated 
with a biotin-conjugated anti-EpCAM mAb (CD326, clone G8.8) (5 µg/mL) at RT for 
15 min. After two washes (300 g, 5 min and removal of supernatant) the cells were 
incubated with Streptavidin-Microbeads (20 µL) in 0.5 mL of MACS buffer at RT for 
15 min. Excess Streptavidin-Microbeads were removed by centrifugation (300 g, 5 min) 
and removal of supernatant and the cells resuspended in 0.5 mL of MACS buffer. Cells 
were then loaded onto a magnetised LS Column. Unlabelled cells were eluted three 
times with MACS buffer, the column detached from the magnet and the content flushed 
into a fresh pre-equilibrated magnetised LS column. Unlabelled cells were then 
similarly eluted with MACS buffer as above. Finally, the column bound cells were 
flushed from unmagnetised columns with 5 mL of MACS buffer and washed four times 
(300 g, 5 min and removal of supernatant) in RPMI-1640/5% FCS. The cells were 
resuspended in ice-chilled RPMI-1640/0.5% FCS (pH 7.0) and were kept on ice until 
use. The phenotype of enriched TEC was confirmed by flow cytometry, as described in 
Section 2.22.3 and 2.22.4. 
2.23.2 Fluorescent labelling of thymocytes  
Thymocytes (108 cells/mL) in 1 mL of RPMI-1640/5% FCS (pre-equilibrated to RT) 
were incubated with Cell Proliferation Dye eFluor® 670 (CPD670, 100 nM) or 
CellTrace™ Violet (CTV, 500 nM) at RT for 5 min (Quah and Parish, 2012). The cells 
were washed four times (300 g, 5 min and removal of supernatant) before being 
resuspended to 5x107 cells/mL in ice-chilled RPMI-1640/0.5% FCS (pH 7.0). Cells 
were kept on ice until use. 
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2.23.3 Stromal-thymocyte rosetting assay 
A stromal-thymocyte rosetting assay was used based on the standard autorosetting assay 
described in Section 2.14.3. In a U-bottomed 96-well microplate (Linbro® MP 
Biomedicals, Santa Ana, CA), equal volumes (50 µL) of CPD670 labelled thymocytes 
(5x107 cells/mL) (Section 2.32.2) and pre-labelled EpCAM+ MACS-enriched stromal 
cells (5x106 cells/mL) (Section 2.32.1) were mixed (10:1 cell ratio) and briefly 
centrifuged (200 g, 1 min, 4°C) before being incubated on ice for 45 min. The cell 
aggregates at the bottom of each well were gently transferred to 1.2 mL cluster tubes 
using wide-bore pipette tips and immediately analysed on a bench-top analytical flow 
cytometer using similar configurations to those used to examine autorosetting (Section 
2.14.3), with at least 20,000 EpCAM+ cells being recorded whilst maintaining a 
constant flow rate (~3000 total events/sec). Rosetting was assessed as EpCAM+ stromal 
cells acquiring a CPD670+ profile (%Rraw), equivalent to ≥3 bound thymocytes (1 
CDP670+ peak/thymocyte) per stromal cell. In parallel, an equivalent non-rosetting cell 
mixture was analysed to determine the level of coincidence (%C) as described in 
Section 2.14.3. %True rosetting was calculated by %Rraw-%C. 
 
2.24 Analysis of intracellular Ca2+ flux in rosetting thymocytes 
Thymocytes were incubated with Fluo-4 AM (2.5 µM) and Fura-Red™ AM (5 µM) 
dyes (Bailey and Macardle, 2006) in RPMI-1640/5%FCS at 37°C for 60 min and then 
labelled with the dye CTV (500 nM) at RT for 5 min. After three washes (300 g, 5 min 
and removal of supernatant) in ice-chilled RPMI-1640/10% FCS, the cells were 
resuspended in ice-chilled RPMI-1640/0.5% FCS/10 mM HEPES buffer. Stromal-
thymocyte rosetting was induced as described in Section 2.23.3 in a U-bottomed 96-
well microplate and the cells were gently transferred into a 1.2 mL cluster tube and the 
extent of rosetting and intracellular Ca2+ levels in bound thymocytes (gated as described 
in Section 2.23.3) at 5, 10 and 30 min post-incubation (1 min snapshot per time point) 
simultaneously monitored using BD LSRFortessa™ and BD FACSDiva™ software 
(Franklin Lakes, NJ). Ca2+ flux was assessed as an increase in the ratio of fluorescence 
(GMFI) of Ca2+-bound Fluo-4 over Ca2+-unbound Fura-Red (Table 2.7). To study 
rosette-induced Ca2+ mobilisation at 37°C, the cell suspensions were pre-heated at 37°C 
for 5 min, rosetting induced (200 g, 1 min) and cells then incubated in a 37°C/5% CO2 
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humidified cell incubator. During analysis, the cells were maintained at 37°C using an 
external sheath connected to a heated waterbath.  
 
2.25 Statistical analysis 
Statistical significance was measured using Student’s t-test (unpaired, 2-tailed) or One-
way or Two-way ANOVA with GraphPad Prism 5.0 Software (GraphPad Software, San 
Diego, CA). 
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Chapter Three 
 
 
 
 
 
 
 
Mechanisms and Regulators of Murine Autorosetting 
 
 
 
 
 
 
 
3.1 Abstract 
Autorosetting, the binding of lymphocytes to two or more autologous erythrocytes, is 
unique to thymocytes and much less evident with peripheral T lymphocytes. Previous 
studies have implicated MHC-I recognition and interaction with negatively charged 
polysaccharides on erythrocytes in autorosette formation. In this Chapter, a flow 
cytometry-based assay for quantifying autorosetting is described, the assay confirming 
that double positive (CD4+CD8+) thymocytes are the major autorosetting population in 
the thymus, whereas peripheral T lymphocytes do not autorosette. Using the new 
autorosetting assay a wide range of mAbs against different thymocytes cell surface 
antigens were tested and a CD8β-specific mAbs shown to strongly inhibit autorosetting, 
a finding confirmed with CD8α and CD8β knockout mice. It was also shown that 
heparanase treatment of erythrocytes prevented autorosetting, indicating that heparan 
sulfate (HS) is the autorosetting ligand on erythrocytes and consistent with sulfated 
polysaccharides, such as heparin and dextran sulfate, inhibiting autorosetting and 
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blocking the binding of mAbs to CD8β, with inhibition of autorosetting by heparin 
being 6-O-sulfate dependent. Also it was found that sialylation of CD8β on peripheral 
CD8+ T lymphocytes substantially limits autorosetting, with neuraminidase treatment 
restoring autorosetting by these T lymphocytes. Additional studies confirmed that 
histidine-rich glycoprotein (HRG) from serum, a HS-binding molecule, inhibits 
autorosetting, although serum from HRG knockout mice still inhibited autorosetting via 
a HRG-like molecule. Thus, sialylation of CD8, combined with blocking of the HS 
ligand by serum-derived HRG and potentially related molecules, strictly regulates the 
CD8-HS interaction by peripheral CD8+ T lymphocytes. 
 
3.2 Introduction 
In mice, certain subsets of T lymphocytes are able to form rosettes with autologous and 
allogeneic erythrocytes, in vitro, a phenomenon termed autorosetting. It has been 
previously demonstrated that autorosetting lymphocytes are predominantly immature, 
hydrocortisone-sensitive thymocytes or 20-50% of the total thymocytes population. 
Moreover, peripheral lymphocytes usually display much lower levels of autorosetting 
(Charreire and Bach, 1975, Braganza et al., 1975, Kolb, 1977). Thus, at face value, 
autorosetting seems to be a developmentally regulated process. 
 
The molecular basis of autorosetting is poorly understood. Early studies showed that 
murine autorosetting is more efficient when the lymphocytes and erythrocytes are MHC 
compatible, implying a level of MHC-I-restriction. However, autorosetting with 
allogeneic erythrocytes is clearly evident, indicating that the interaction is 
predominantly MHC-I independent (Primi et al., 1979, Charreire et al., 1980, Sia and 
Parish, 1980a). Furthermore, certain monosaccharides and complex sulfated 
polysaccharides can totally inhibit autorosetting by murine thymocytes (Parish et al., 
1984), suggesting that besides MHC-I recognition, the binding of negatively charged 
glycans on the erythrocyte surface plays a major role in autorosetting.  
 
Autorosetting can be regulated extrinsically by serum. Early studies revealed that mouse 
serum can totally inhibit autorosetting (Charreire and Bach, 1975, Kolb, 1977, Ghanta 
et al., 1978, Hsu et al., 1980), subsequent investigations showing that this inhibitory 
activity can be entirely ascribed to histidine-rich glycoprotein in serum (HRG) (Rylatt et 
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al., 1981). As HRG from several species totally inhibits autorosetting (Sia et al., 1982), 
it is likely to disrupt MHC-independent aspects of autorosetting. 
 
Despite the information outlined above, little is known about the molecular basis of 
autorosetting, in particular the nature of the autorosetting receptor on T lymphocytes. 
This Chapter describes experiments that attempted to resolve this issue. 
 
3.3 Results 
3.3.1 Establishment of a flow cytometry-based autorosetting assay 
Previously, chromogenic dyes were used to distinguish lymphocytes from erythrocytes 
and rosettes were manually scored using a light microscope (Lay et al., 1971, Baxley et 
al., 1973, Sandilands et al., 1974, Charreire and Bach, 1975, Sia and Parish, 1980a). 
Here, a multicolour flow cytometric autorosetting assay was developed in which 
erythrocytes were labelled in vivo with CFDA-SE (Coupland et al., 2010) (FIG. 3.1A), 
the DNA-binding fluorescent dye, Hoechst-33342, was used to label viable 
lymphocytes in vitro (FIG. 3.1B), the two cell populations mixed and autorosetting 
induced by centrifugation as previously described (Sia and Parish, 1980a) (FIG. 3.1C). 
Whilst the conventional flow cytometer configuration involves a narrow core stream, 
which facilitates analysis at the single-cell level (FIG. 3.2A), here the core stream was 
broadened to allow the detection of large rosettes at high speed (~3000 events/sec). 
Unfortunately, this increased the level of ‘coincidence’, namely lymphocytes and 
erythrocytes being simultaneously excited by the laser (Snow, 2004, Fent et al., 2008) 
and thus, being falsely identified as rosettes (FIG. 3.2B and C). To overcome this 
problem, lymphocytes and erythrocytes were mixed immediately before flow cytometry 
to obtain %coincidence values, true autorosetting values being determined by 
subtracting %coincidence from %uncorrected autorosetting values. Increasing 
concentrations of erythrocytes (0.03-2%, vol/vol) were allowed to autorosette with a 
constant concentration of thymocytes (2x106 cells/mL), true autorosetting being 
maximal with 1% erythrocytes (FIG. 3.3) and thus, being the default lymphocyte-to-
erythrocyte ratio applied throughout this study.  
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FIG. 3.1: Multicolour flow cytometric lymphocyte-erythrocyte autorosetting assay. (A) 
Preparation of CFSE-labelled erythrocytes. On day 0, one C57BL/6 mouse (8 week old) was 
injected (i.v.) with 5 mM CFDA-SE (Exλ/Emλ: 495/519 nm). The blood was retro-orbitally 
collected 16 hr later on day 1 into Alsever’s solution (pH 6.0) and the erythrocytes washed and 
resuspended in HBSS/0.5% FCS (4°C). (B) Preparation of fluorescently labelled lymphocytes 
in vitro. Lymphocytes from a syngeneic C57BL/6 mouse were labelled with 4 µg/mL of 
Hoechst-33342 (Exλ/Emλ: 350/461 nm) in HBSS/0.5% FCS at RT, allowing live/dead 
discrimination of nucleated cells (see lower flow cytometry plot). (C) Induction of autorosetting. 
Equal volumes (50 µL) of lymphocyte (4x106 cells/mL) and erythrocyte suspensions (0.06-4%, 
vol/vol) were mixed in U-bottom 96-well plates, then briefly centrifuged (200 g, 1 min) before 
being incubated on ice for 60 min. Cell pellets were gently resuspended, transferred into cluster 
tubes and analysed on an analytical bench-top flow cytometer. 
 
3.3.2 Organ distribution of autorosetting lymphocytes 
It was previously reported that immature, cortisone-sensitive, thymocytes are the main 
autorosetting cells in the thymus, whereas peripheral lymphocytes autorosette at much 
lower levels (Charreire and Bach, 1975, Kolb, 1977, Sia and Parish, 1980a, Sia and 
Parish, 1980b). Using the flow cytometry based autorosetting assay, it was confirmed 
that thymocytes (54.6% autorosetting) were the main autorosetting population, whereas 
autorosetting by spleen (6.1% autorosetting) and various lymph node (LNs) 
populations, namely pooled axillary and brachial, inguinal and mesenteric LN derived 
lymphocytes, was low to negligible (1.8%, 0.2 % and 0.6% autorosetting, respectively) 
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(FIG. 3.4A). Furthermore, double positive (DP) and CD8 single positive (SP) 
thymocytes were the main autorosetting subsets (65.4% and 22.1% autorosetting, 
respectively), whereas double negative (DN), CD4 SP thymocytes, peripheral CD4+ and 
CD8+ T lymphocytes, and peripheral B lymphocytes (B220+) autorosetted at low to 
negligible levels (2.5%, 0.4%, 4.8%, 4.9% and 1.2% autorosetting, respectively) (FIG. 
3.4B).  
 
	
FIG. 3.2: Configuration of flow cytometer for detection of rosettes. (A) Conventional setup 
for single-cell analysis. A flow cell with a narrow core stream allows separation and detection 
of individual cells. (B) Flow cell configuration for detection of multicellular conjugates in a 
lymphocytes rosetting cell mixture. (i) A broad core stream allows the entry of multicellular 
complexes. (ii) Representative histogram of autorosetting of viable Hoechst-33342-labelled 
thymocytes. Gate set to detect ≥2 erythrocytes/thymocyte (%Araw). (C) Measurement of 
background noise (‘coincidence’) in a non-rosetting cell mixture, which involves mixing 
lymphocytes and erythrocytes immediately before flow cytometry analysis. (i) A broad core 
stream allows simultaneous detection of signals from erythrocytes and lymphocytes, averaging 
1 unbound erythrocyte per lymphocyte. (ii) Representative histogram of coincidence in a non-
rosetting cell mixture, with the gate set to detect ≥2 erythrocytes/thymocyte (%C). True 
autorosetting values represent %Araw - %C (i.e., 68%-5.2%) = 62.8% in example shown. 
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FIG. 3.3: Flow cytometric analysis of autorosetting between thymocytes and autologous 
erythrocytes. Equal volumes (50 µL) of erythrocyte (0.06-4%, (vol/vol)) and Hoechst-33342 
labelled thymocyte (4x106 cells/mL) suspensions were mixed. Each set of cell mixtures was 
either immediately analysed by flow cytometry to provide a coincidence control (grey 
histogram) or induced to autorosette (red histogram) by brief centrifugation (200 g, 1 min) and 
incubation on ice for 60 min, prior to evaluation (i.e., viable Hoechst-33342+ thymocytes 
acquiring CFSE+ profiles) by flow cytometry. (A) Representative fluorescence histograms 
depicting autorosetting and coincidence plots for different erythrocyte concentrations. Gate 
includes thymocytes associating with ≥2 erythrocytes. (B) Percentage (%) of uncorrected 
autorosetting (Araw), coincidence control values (C) and true autorosetting of thymocytes (Araw-
C) with increasing concentrations of erythrocytes (%, vol/vol). Data are mean % autorosetting ± 
SD of triplicate samples. 
 
3.3.3 Identification of CD8 as the autorosetting receptor on lymphocytes 
Initially, a wide range of mAbs specific for lymphocytes cell surface antigens were 
examined for their ability to inhibit autorosetting. It was found that the presence of 
mAbs to CD11a, Ly-49G, NKG2D, CD44, CD62L, CD90.2, CD2, CD3ε, CD4 and 
CD45 individually did not inhibit autorosetting. Interestingly, only an anti-TCRβ mAb 
appeared to partially inhibit autorosetting compared to untreated control (50.2% vs. 
64.3% autorosetting, P < 0.001) (FIG. 3.5A). Moreover, autorosetting was comparable 
between CD4.KO, CD45.KO and WT thymocytes (FIG. 3.5C), the data suggesting that 
besides TCRβ, these molecules do not independently contribute to autorosetting.  
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FIG. 3.4: Lymphoid organ and lymphocyte subset distribution of autorosetting 
lymphocytes. (A) Autorosetting by lymphocytes from various lymphoid organs. (Lymph node 
(LN): Axil./Brac. = axillary/brachial (pooled); Ing. = inguinal; Mes. = mesenteric). (B) 
Comparison of the ability of various lymphocyte subsets to autorosette. (Subset: DN = double 
negative (CD4-CD8-); DP = double positive (CD4+CD8+); SP = single positive (CD4+ or CD8+) 
thymocytes; pCD4 = peripheral CD4+ cells; pCD8 = peripheral CD8+ cells; B220 = 
predominantly peripheral B cells). Data are mean % autorosetting ± SD of triplicate samples. 
 
Based on the lymphoid organ and T lymphocyte subset distribution of autorosetting 
cells (Section 3.3.2) and the potential involvement of MHC-I in autorosetting, it was 
hypothesised that the CD8 molecule that is known to bind MHC-I (Norment et al., 
1988), could be involved in autorosetting. This hypothesis was tested by examining the 
ability of anti-CD8 mAbs to inhibit autorosetting. Indeed, an anti-CD8β mAb 
significantly inhibited autorosetting, compared to an isotype control (10.5% vs. 65.4% 
autorosetting, P < 0.001), and to a lesser extent, an anti-CD8α mAb was also 
significantly inhibitory, compared to an isotype control (46.8% vs. 62% autorosetting, P 
< 0.001). Moreover, combining the anti-CD8α and anti-CD8β mAbs was significantly 
more inhibitory than the anti-CD8β mAbs alone and diminished autorosetting to 
background levels, i.e., 2.6% autorosetting (FIG. 3.6A). Moreover, both anti-CD8 
mAbs inhibited autorosetting in a concentration-dependent manner (FIG. 3.6B). To 
unequivocally demonstrate that CD8 plays a major role in autorosetting, autorosetting 
by CD8.KO thymocytes was examined. It was found that both CD8α.KO and CD8β.KO 
thymocytes showed a dramatically and significantly reduced ability to autorosette, 
compared to the WT control (3% and 7.8% vs. 64.3% autorosetting, P < 0.001), with 
the CD8α.KO thymocytes showing significantly lower autorosetting than the CD8β.KO 
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thymocytes (P < 0.05) (FIG. 3.6C). There was also significantly reduced autorosetting 
by DP and CD8 SP thymocytes from CD8β.KO mice, compared to DP and CD8 SP 
thymocytes from WT mice (6.6% and 3% vs. 65.4% and 22.1% autorosetting, P < 
0.0001), highlighting the significant role of CD8β in autorosetting (FIG. 3.6D). 
		
 
 
FIG. 3.5: Contribution of leukocyte surface molecules to autorosetting. (A) Analysis of 
autorosetting thymocytes in the absence (i.e., untreated control) or presence of 5 µg/mL of anti-
CD11a, anti-Ly-49G, anti-NKG2D, anti-CD44, anti-CD62L, anti-CD69, anti-CD90.2, anti-CD2, 
anti-CD3ε or anti-TCRβ mAbs. Data are mean ± SD of triplicate samples. ***, P < 0.001. (1-
way ANOVA with Dunnett’s multiple comparisons test to untreated control). (B) Thymocytes 
autorosetting in the presence of 5 µg/mL of anti-CD4 or anti-CD45 mAb, compared to isotype 
controls. In (A) and (B), thymocytes were pre-incubated with mAb/isotype controls on ice for 
30 min prior to the autorosetting assays which were performed in the presence of the mAbs. (C) 
Autorosetting by WT, CD45.KO and CD4.KO thymocytes. Data are mean % autorosetting ± 
SD of triplicate samples. NS, not significant (Student’s t-test). 	
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FIG. 3.6: Contribution of CD8 molecules to thymocytes autorosetting. Autorosette inhibition 
by anti-CD8α and anti-CD8β.2 mAb, individually and combined at (A) 5 µg/mL, or (B) titrated 
at 0.005-5 µg/mL, compared to isotype controls. (C) Autorosetting by WT, CD8α.KO and 
CD8β.KO thymocytes. (D) Autorosetting by WT and CD8β.KO, DP and CD8 SP thymocytes. 
(E) Autorosetting by CD8β.KO thymocytes in the presence of 5 µg/mL of an anti-CD8α mAb 
or an isotype control. In (A), (B), and (E) thymocytes were pre-incubated with mAb/isotype 
controls on ice for 30 min prior to the autorosetting assays which were performed in the 
presence of the mAbs. An additional control was untreated cells (control). Data are mean % 
autorosetting ± SD of triplicate samples. NS, not significant. *, P < 0.05. ***, P < 0.001. ****, 
P < 0.0001 (1-Way ANOVA with Tukey’s multiple comparisons test). 	
Furthermore, addition of an anti-CD8α mAb to CD8β.KO thymocytes further reduced 
autorosetting (2.6% vs. 7.7% of isotype control, P < 0.05), corroborating the supportive 
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role of CD8α in autorosetting (FIG. 3.6E). Collectively, the data suggest that the CD8αβ 
heterodimer is the key autorosetting receptor, with CD8β being the major participant in 
autorosetting but being aided by CD8α. In this context, it should be noted that the cell 
surface expression of CD8β is dependent on CD8α (Blanc et al., 1988, Gorman et al., 
1988, Norment and Littman, 1988), which explains why autorosetting by CD8α.KO 
thymocytes is so dramatically reduced. 
3.3.4 Identification of the autorosetting ligand on erythrocytes 
Based on earlier data suggesting that H-2L/H-2D molecules on erythrocytes contribute 
to autorosetting (Sia and Parish, 1980a) it was postulated that MHC-I on the erythrocyte 
surface is a potential autorosetting ligand. To test this hypothesis, the ability of MHC-I 
deficient, H-2Kb/Db.KO and β2-microglobulin.KO erythrocytes to autorosette was 
evaluated. Surprisingly, both H-2Kb/Db.KO and β2m.KO erythrocytes were comparable 
to WT erythrocytes in their ability to autorosette (FIG. 3.7). Hence, despite MHC-I 
being implicated in autorosetting, it is most unlikely to be the primary autorosetting 
ligand on erythrocytes.  
 
 
 
 
 
FIG. 3.7: MHC-I molecules are dispensable for autorosetting. Comparison of the ability of 
WT, β2m.KO or H-2Kb/Db.KO erythrocytes to autorosette with syngeneic thymocytes. Data are 
mean % autorosetting ± SD of triplicate samples. NS, not significant. (1-Way ANOVA with 
Dunnett’s multiple comparisons test to WT). 
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FIG. 3.8: Heparan sulfate on the surface of erythrocytes acts as an autorosetting ligand. (A) 
Concentration-dependent autorosetting inhibition by the sulfated polysaccharides heparin and 
DxS (5  & 500 kDa) (IC50 = concentration of sulfated polysaccharide required to inhibit 
autorosetting by 50%).  (B) Autorosetting by bacterial heparinase-I (HPNSE) and mammalian 
heparanase (HPSE)-treated erythrocytes. Erythrocytes were treated with 5 U/ml of HPNSE (F. 
heparinum) or 4 µg/mL of platelet-derived HPSE at 37°C for 60 min. Data in (A) and (B) are 
mean % autorosetting ± SD of triplicate samples. (C) Availability of surface HS on HPNSE and 
HPSE-treated erythrocytes, as measured by anti-HS (clone 10E4) mAb binding at 2 µg/mL. 
Data are GMFI ± SD of triplicate samples. ***, P < 0.001 (1-way ANOVA with Dunnett’s 
multiple comparisons test to mock treated control). (D) Mapping of structural requirements of 
heparin to inhibit autorosetting. Thymocytes, untreated control or pre-treated with bovine lung 
heparin, porcine intestinal mucosa heparin or modified porcine intestinal mucosa heparins (10 
µg/mL) were examined for autorosetting (Modification: de-COO- = decarboxylated; de-S = 
desulfated (complete); de-2S = de-2-O-sulfated; de-6S = de-6-O-sulfated; de-NS = de-N-
sulfated; re-NAc = re-N-acetylated; re-NS = re-N-sulfated). In (A) and (D) thymocytes were 
pre-incubated with inhibitors on ice for 30 min prior to the autorosetting assays which were 
performed in the presence of the inhibitors. NS, not significant. *, P < 0.05. **, P < 0.01. ***, P 
< 0.001 (1-way ANOVA with Dunnett’s multiple comparisons test to untreated control in (i), or 
porcine intestinal heparin in (ii)). Data are mean % autorosetting ± SD of triplicate samples. 
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In a separate study, autorosetting receptors were previously shown to have high affinity 
for sulfated polysaccharides, particularly heparin and dextran sulfate (DxS), with their 
presence totally inhibited autorosetting (Parish et al., 1984). These findings suggested 
that the autorosetting ligand is most likely to be a negatively charged polysaccharide. 
Indeed, it was consistently shown using the flow cytometry based autorosetting assay 
that heparin and DxS (5 and 500 kDa) inhibited autorosetting, with DxS500 kDa (IC50 = 
1.5 µg/mL) being the most inhibitory, followed by heparin (IC50 = 1.8 µg/mL) and DxS5 
kDa (IC50 = 38.9 µg/mL) being the least inhibitory (FIG. 3.8A). Heparin and DxS are 
physiologically not membrane-bound molecules and thus it was postulated that 
erythrocyte surface heparan sulfate (HS) (Trybala et al., 1993, Vogt et al., 2004), which 
closely resembles heparin in structure, is most likely to be the autorosetting ligand. To 
test this hypothesis, erythrocytes were treated with bacterial heparinase-I (HPNSE) or 
human platelet heparanase (HPSE) and the effect of the treatments on autorosetting was 
evaluated. Remarkably, HPNSE and HPSE treated erythrocytes showed a greatly 
impaired ability to autorosette, compared to mock treated erythrocytes (5.5% and 6.2% 
vs. 51.7% autorosetting, P < 0.001) (FIG. 3.8B). The residual autorosetting by HPNSE 
and HPSE treated erythrocytes is most likely due to the remaining HS chains, as 
indicated by the anti-HS mAb (clone 10E4) exhibiting substantial binding to treated 
erythrocytes (FIG. 3.8C). It should be emphasised, however, that the 10E4 HS-binding 
mAb interacts with a HS epitope not easily removed by HPNSE or HPSE treatment and 
probably binds to HS stubs remaining after digestion (Parish C.R. pers. comm.). Thus, 
overall these data highlight HS as the key autorosetting ligand on erythrocytes. 
 
Since HS is the autorosetting ligand and heparin is a highly sulfated version of HS, the 
structural features of HS involved in autorosetting were determined by using chemically 
modified heparins as inhibitors. Initially, both bovine lung and porcine intestinal 
mucosa heparin were found to totally inhibit autorosetting at 10 µg/mL, although 
chemically modified porcine intestinal mucosa heparin was used in all subsequent 
experiments. Completely desulfated (de-S) heparin was not inhibitory, compared to 
untreated thymocytes (62.7% vs. 67.8% autorosetting, P > 0.05), indicating that 
sulfation is essential for autorosetting receptor recognition, neither the carboxyl groups 
nor the sugar backbone of heparin/HS directly interacting with the autorosetting 
receptor. Decarboxylation (de-COO-) and de-2-O-sulfation (de-2S) of heparin appeared 
to significantly and partially reduce the autorosetting inhibitory activity of heparin 
 
Autorosetting: Mechanisms & Regulators 	
	 67 
(12.4% and 19.7% autorosetting, P < 0.05 and P < 0.01, respectively). N-linked 
desulfation (de-NS) of heparin, which replaced the negatively charge N-linked sulfate 
groups with positively charged amines appeared to be non-inhibitory but re-acetylation 
of the positively charged N-linked amines (de-NS/re-NAc) considerably restored 
autorosetting inhibition (69% to 23.5% autorosetting, P < 0.001). Moreover, 
autorosetting inhibition by de-2-O-sulfated, de-NS/re-NAc (de-2S, de-NS/re-
NAc) heparin was comparable to the precursor compound de-NS/re-NAc heparin (24% 
and 23.5% autorosetting, respectively), suggesting that the 2-O-sulfate group needs to 
act cooperatively with N-linked sulfates in order to interact with the autorosetting 
receptor. Similarly, re-N-sulfated de-S (de-S/re-NS) heparin did not inhibit 
autorosetting, suggesting that N-linked sulfate groups alone are insufficient to bind to 
the receptor. Remarkably, removal of 6-O-sulfate groups (de-6S) from heparin 
completely destroyed the ability of heparin to inhibit autorosetting (FIG. 3.8D). These 
data suggest that autorosetting is influenced by the net negative charge of the HS ligand, 
with the 6-O-sulfate group being an essential epitope for autorosetting to occur. 
3.3.5 Direct evidence that CD8 interacts with HS-like molecules 
Based on the data presented in Section 3.3.3 and Section 3.3.4, it was concluded that 
CD8β and, to a lesser extent, CD8α interact with HS. The CD8-HS interaction was 
further investigated, either indirectly, by measuring the ability of sulfated 
polysaccharides that resemble HS (i.e., heparin and DxS) to competitively inhibit anti-
CD8 mAbs binding or based on FITC-heparin binding to thymocytes. For comparison, 
the effect of the sulfated polysaccharides on the binding of an anti-CD45 mAb was 
examined as CD45 was previously reported to bind heparin/HS (Parish et al., 1988a, 
Coombe et al., 1994). Likewise, an anti-CD4 mAb was assessed as CD4 was previously 
shown to carry a polyanion binding site that may interact with sulfated polysaccharides 
(Parish and Warren, 1991). 
 
The fluorescence histograms in FIG. 3.9A illustrate the shift in fluorescence intensity of 
the mAbs binding to thymocytes in the presence of the different sulfated 
polysaccharides at 0.1-100 µg/mL. The inhibition of mAb binding by the sulfated 
polysaccharides is presented as %control mAb binding in FIG. 3.9B. Remarkably, anti-
CD8β mAb binding was almost totally inhibited by DxS500 kDa at 1-100 µg/mL, to a 
lesser extent by heparin and the least by DxS5 kDa. Furthermore, a less dramatic but 
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similar pattern of sulfated polysaccharide inhibition was observed with anti-CD8α mAb 
binding, whereas anti-CD4 mAb binding was only inhibited by DxS500 kDa and anti-
CD45 mAb binding was only marginally affected by the presence of the different 
sulfated polysaccharides. 
 
	
FIG. 3.9: Analysis of anti-CD45, anti-CD4, anti-CD8α and anti-CD8β mAb binding to 
thymocytes in the presence of the sulfated polysaccharides heparin and dextran sulfate (5 
& 500 kDa). (A) Representative fluorescence histograms and (B) graphical presentations of the 
extent of anti-CD45, anti-CD4, anti-CD8α or anti-CD8β mAb binding to thymocytes in the 
absence or presence of 0.1-100 µg/mL of the sulfate polysaccharides heparin and DxS (5 & 500 
kDa), as examined by flow cytometry. Thymocytes were incubated with the respective 
inhibitors (0.1-100 µg/mL) on ice for 30 min, then without removing the inhibitors, 
fluorescently-tagged mAbs (5 µg/mL) were added and the cells were incubated on ice for 
another 30 min before being washed and analysed by flow cytometry. Data are mean % control 
mAb binding ± SD of triplicate samples. 
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FIG. 3.10: Binding of heparin to thymocytes requires CD8 molecules. Binding of FITC-
heparin to (A) thymic or peripheral T cell subsets, with subset labelling as in FIG. 3.4B, (B) 
CD8β.KO DP and CD8 SP thymocytes, compared to WT thymocytes and (C) CD8α.KO, 
CD8β.KO and CD4.KO, compared to WT thymocytes. FITC-heparin binding (1 µg/mL) was 
performed on ice for 60 min before the cells were washed and analysed by flow cytometry. 
FITC-heparin binding is expressed as mean fold increase in fluorescence relative to a 
background autofluoresence control ± SD of triplicate samples. NS, not significant. **, P < 0.01. 
***, P < 0.001. ****, P < 0.0001, based on Student’s t-test in (B) and 1-Way ANOVA with 
Tukey’s multiple comparisons test in (C). 
 
Surprisingly, it was found that different lymphocytes populations varied markedly in 
their ability to bind FITC-heparin. Thus, FITC-heparin binding was highest on DP 
followed by CD8 SP thymocytes (13.6 and 7.6-fold background, respectively), with 
binding being much less on DN and CD4 SP thymocytes and peripheral CD4+ and 
CD8+ T lymphocytes (1.7, 3.6, 1.9 and 3.3-fold background respectively) (FIG. 3.10A). 
Importantly, consistent with the autorosetting data (FIG. 3.6D), DP and CD8 SP 
thymocytes from CD8β.KO mice displayed substantially reduced FITC-heparin binding 
compared to WT DP and CD8 SP thymocytes (12.1 vs. 2.4-fold background, P < 
0.0001 and 5.0 vs. 1.8-fold background, P < 0.01, respectively) (FIG. 3.10B), this 
reduction in FITC-heparin binding being comparable in CD8α.KO and CD8β.KO 
thymocytes (2.4 vs. 3.4-fold background, P > 0.05) (FIG. 3.10C). Additionally, 
consistent with autorosetting (FIG. 3.5C), there was comparable binding of FITC-
heparin to CD4.KO and WT thymocytes (11.4 vs. 11.5-fold background, P > 0.05) 
(FIG. 3.10C), indicating that CD4, despite binding polyanions, does not contribute to 
FITC-heparin binding by thymocytes. Collectively, these data are consistent with CD8 
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being the dominant heparin and, presumably, HS binding molecule on the surface of DP 
and CD8 SP thymocytes.  
3.3.6 Sialylation influences the interaction of CD8 with HS-like molecules 
Previous studies have reported a developmentally regulated α2-3 sialylation of the stalk-
like region of the CD8β molecule expressed by CD8 SP thymocytes and peripheral 
CD8+ T lymphocytes (Moody et al., 2001, Merry et al., 2003). This modification 
changes the conformation of the CD8 molecule and consequently impairs the ability of 
the molecule to bind to MHC-I and act as a coreceptor for TCR signalling (Daniels et 
al., 2001, Moody et al., 2003). Therefore, it is possible that a similar modification of 
CD8 is responsible for the weak autorosetting (FIG. 3.4) and FITC-heparin binding 
(FIG. 3.10A) of peripheral CD8+ T lymphocytes. To test this hypothesis, cells were 
treated with neuraminidase (type II from V. cholerae) to enzymatically remove surface 
α2-3 sialic acid residues and the impact of desialylation on FITC-heparin binding and 
autorosetting studied. The glycosylation status of the treated lymphocytes was further 
examined based on the binding of the α2-3 sialic acid specific Maackia amurensis lectin 
II (MAL-II) (Wang and Cummings, 1988) and the Galβ1-3GalNAc-Ser/Thr core 1 O-
glycan specific peanut agglutinin (PNA) (Pereira et al., 1976). Thus, the MAL-II and 
PNA lectins can be used to monitor α2-3 sialic acid removal by neuraminidase, MAL-II 
detecting sialic acid loss and PNA measuring the exposure of subterminal galactose 
residues following sialic acid cleavage. 
 
Initially, it was noted that with untreated cells, the level of MAL-II binding was highest 
on peripheral CD4+ and CD8+ T lymphocytes, binding being progressively lower on 
CD8 SP, CD4 SP, DP and DN thymocytes. Conversely, PNA binding was highest on 
DP thymocytes, with the other lymphocyte subsets exhibiting little or no binding of 
PNA. Neuraminidase treatment resulted in a dramatically reduced MAL-II binding to 
all lymphocyte subsets except DN thymocytes and, at the same time, PNA binding to all 
lymphocytes subsets was greatly elevated, altogether these data being reflective of 
successful enzymatic desialylation (FIG. 3.11A and B). At the thymic level, 
neuraminidase treated DP, CD8 SP and CD4 SP thymocytes showed significantly 
enhanced FITC-heparin binding and autorosetting. Remarkably, neuraminidase-treated 
peripheral CD8+ T lymphocytes displayed the highest improvements in FITC-heparin 
binding (2.6 to 16.7-fold background, P < 0.001) and autorosetting (3.7% to 41% 
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autorosetting, P < 0.001). In contrast, neuraminidase treated peripheral CD4+ T 
lymphocytes displayed no significant improvement in autorosetting (3.7 % to 5.6% 
autorosetting, P > 0.05) despite significantly increased FITC-heparin binding (2.6 to 
4.9-fold background, P < 0.01) (FIG. 3.11C and D). These data are consistent with CD8 
sialylation reducing the heparin/HS binding and autorosetting potential of the molecule. 
 
To more directly demonstrate that CD8β sialylation influences heparin/HS recognition 
or autorosetting advantage was taken of lymphocytes from CD8β deficient mice. 
Interestingly, MAL-II and PNA binding by CD8β.KO DP and CD8 SP thymocytes was 
significantly lower than by WT cells (P < 0.05), whilst comparable lectin binding by 
both WT and CD8β.KO peripheral CD8+ T lymphocytes was observed. In contrast, 
following neuraminidase treatment, a significant difference in MAL-II and PNA 
binding to CD8β.KO and WT lymphocytes was only evident with peripheral CD8+ T 
lymphocytes (P < 0.01) (FIG. 3.12A and B). These data suggest that CD8β can either 
directly or indirectly influence the sialylation status of developing T cells. Importantly, 
the enhanced FITC-heparin binding and autorosetting observed following 
neuraminidase treatment of WT cells was dramatically reduced with CD8β.KO DP and 
CD8 SP thymocytes and peripheral CD8+ T lymphocytes (FIG. 3.12C and D). 
Furthermore, the enhanced autorosetting of neuraminidase treated DP and CD8 SP 
thymocytes and peripheral CD8+ T lymphocytes was shown to be dependent on 
recognition of erythrocyte HS as HPNSE and HPSE treatment of erythrocytes 
dramatically reduced the ability of these cells to autorosette (FIG. 3.13). Collectively, 
these data demonstrate the importance of developmentally controlled sialylation of 
CD8β in regulating the CD8-HS interaction. 
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FIG. 3.11: Analysis of the influence of the sialylation status of lymphocytes on their 
heparin binding ability and autorosetting capacity. Measurement by flow cytometry of 
lymphocyte desialylation following V. cholerae neuraminidase treatment based on the binding 
of FITC-labelled (A) Maackia amurensis lectin II (FITC-MAL-II) (α2-3 sialic acid specific) and 
(B) peanut agglutinin (FITC-PNA) (Galβ1-3GalNAc-Ser/Thr core 1 O-glycan specific). (C) 
The effect of desialylation on FITC-heparin binding as detected by flow cytometry. FITC-
MAL-II, FITC-PNA and FITC-heparin binding were performed at 1 µg/mL on ice for 60 min, 
before the cells were washed and examined by flow cytometry. Data in (A-C) are expressed as 
mean fold increase in fluorescence relative to a background autofluoresence control ± SD of 
triplicate samples. (D) Comparison of the extent of autorosetting by untreated and 
neuraminidase-treated T cells. Lymphocytes subset labelling as defined in FIG. 3.4B. Data are 
mean % autorosetting ± SD of triplicate samples. NS, not significant. **, P < 0.01. ***, P < 
0.001. ****, P < 0.0001 (Student’s t-test). 
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FIG. 3.12: Analysis of the contribution of CD8β to the sialylation status of CD8+ T cells and 
impact of CD8β-deficiency on heparin binding and autorosetting following desialylation. 
Comparison of the binding of (A) FITC-MAL-II, (B) FITC-PNA and (C) FITC-heparin to 
untreated and V. cholerae neuraminidase-treated WT, CD8β.KO, DP, CD8 SP thymocytes and 
peripheral CD8+ T cells, and (D) the effect of such treatment on autorosetting. Lymphocyte 
subsets defined as in FIG. 3.4B and the lectins MAL-II and PNA defined as in FIG. 3.11. Data 
in (A-C) are expressed as mean fold increase in fluorescence relative to a background 
autofluoresence control ± SD of triplicate samples. Data in (D) are mean % autorosetting ± SD 
of triplicate samples. NS, not significant. *, P < 0.05. **, P < 0.01. ***, P < 0.001. ****, P < 
0.0001 (Student’s t-test). 	
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FIG. 3.13: Surface HS is required for erythrocytes to autorosette with neuraminidase-
treated T cells. Autorosetting between different neuraminidase-treated lymphocyte populations 
as defined in FIG. 3.4 and mock treated control, bacterial heparinase-I (HPNSE) or mammalian 
heparanase (HPSE)-treated erythrocytes as detected by flow cytometry. HPSE and HPNSE 
treatments were performed as described in FIG. 3.8C. Data are mean % autorosetting ± SD of 
triplicate samples. ***, P < 0.001 (1-way ANOVA with Dunnett’s multiple comparisons test to 
untreated control). 
 
3.3.7 Autorosetting inhibition by serum derived HRG 
Autorosetting inhibition by sera from various mammalian species (Charreire and Bach, 
1975, Kolb, 1977, Ghanta et al., 1978, Hsu et al., 1980) has been shown previously to 
be ascribed to HRG (Rylatt et al., 1981, Sia et al., 1982). Here, it was confirmed that 
purified human HRG strongly inhibited mouse thymocytes autorosetting (IC50 = 2.53 
µg/mL) (FIG. 3.14A). Based on earlier studies it would be expected that HRG deficient 
serum would not inhibit autorosetting, hence, the ability of HRG.KO (Tsuchida-
Straeten et al., 2005) and WT mouse sera to inhibit autorosetting was evaluated. 
Western blotting and ELISA analyses confirmed the absence of detectable HRG in 
HRG.KO sera (FIG. 3.14B). Surprisingly, autorosetting inhibition by the HRG.KO sera 
was found to be considerably more efficient than the WT sera, i.e., autorosetting was 
reduced by 50% by HRG.KO sera diluted 1/512 compared with a 1/64 dilution of WT 
sera (~8 fold difference) (FIG. 3.14C). Despite Coomassie blue staining of SDS-PAGE 
gels showing no obvious difference in total protein constituents of WT and HRG.KO 
sera (FIG. 3.14D, top panel), it is possible that in the absence of HRG, the levels of 
another serum factor that inhibits autorosetting has been elevated.  
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FIG. 3.14: Autorosetting inhibition by histidine-rich glycoprotein (HRG) and by a 
compensatory HRG-like serum protein. (A) Autorosetting inhibition of mouse thymocytes by 
different concentrations (6.4 ng/ml - 20 µg/mL) of purified human serum HRG (hHRG). (B) 
Detection of HRG in WT and HRG.KO mouse sera in three different mice by Western blotting 
(top panel) and ELISA (bottom panel) using polyclonal rabbit anti-hHRG. Recombinant mouse 
HRG (rec. mHRG) and hHRG are used as controls in the Western blot. (C) Autorosetting 
inhibition by WT and HRG.KO mouse sera. (D) Analysis of total protein content (top panel) by 
Coomassie Blue staining and detection by Western blotting (middle panel) and ELISA (bottom 
panel) of HRG in untreated and Co2+-bead binding protein preparations from WT and HRG.KO 
mouse sera. (E) Autorosetting inhibition by Co2+-bead depleted WT and HRG.KO mouse sera. 
Data in (A), (C) and (E) are mean % autorosetting ± SD of three replicates. ELISA data in (B) 
and (D) are mean absorbance ± SD of three replicates. In (E), NS, not significant. ***, P < 
0.001 (1-Way ANOVA with Tukey’s multiple comparisons test). 
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Due to its histidine-rich domain, HRG is readily depleted from plasma by Co2+-affinity 
chromatography (Patel et al., 2013). Indeed, the absence of detectable HRG in WT 
mouse sera by Western blotting and ELISA and the detection of HRG in the Co2+-beads 
binding fraction of WT sera by Western blotting (FIG. 3.14D middle and bottom 
panels) confirms that Co2+-affinity chromatography completely depletes HRG from 
mouse serum. Furthermore, Co2+-bead-depleted WT serum was unable to inhibit 
autorosetting but unexpectedly, Co2+-bead-depleted HRG.KO serum also lacked 
autorosetting inhibitory activity (FIG. 3.14E). SDS-PAGE analysis of the Co2+-bead-
binding fractions from WT and HRG.KO sera revealed seven identical Coomassie blue 
staining protein bands of 15 kDa to >150kDa, despite an extra band (i.e., HRG) being 
predicted to be present in the WT serum fraction (FIG. 3.14D, top panel). Detailed 2D-
SDS-PAGE and mass spectrometry studies need to be performed to resolve this issue. 
 
3.4 Discussion 
In this Chapter a flow cytometry-based autorosetting assay was developed to investigate 
the molecular basis of murine autorosetting. Using the assay the main findings were: (i) 
autorosetting cells are primarily DP and to a lesser extent CD8 SP thymocytes, whereas 
autorosetting by peripheral T lymphocytes is negligible, (ii) autorosetting is mediated 
by the CD8αβ heterodimer on thymocytes, with CD8β making a major contribution to 
erythrocyte binding, (iii) CD8 interacts with highly sulfated HS on the erythrocytes 
surface, this interaction specifically requiring the presence of 6-O-sulfate groups, (iv) 
sialylation of CD8β on peripheral CD8+ T lymphocytes results in the masking of the HS 
binding site on CD8 molecules, a process that can be reversed by neuraminidase 
treatment and, finally, (v) it was confirmed that HRG in serum inhibits autorosetting 
although other, biochemically similar, molecules in plasma appear to be inhibitory. 
 
Consistent with previous reports (Charreire and Bach, 1975, Kolb, 1977, Sia and Parish, 
1980a, Sia and Parish, 1980b), the data shown in FIG. 3.4 confirmed that the thymus is 
the primary depot for autorosetting lymphocytes, 60-80% of DP and 20% of CD8 SP 
thymocytes autorosetting, whereas few peripheral CD8+ T lymphocytes (i.e., less than 
5%) autorosetted. At face value, it is conceivable that autorosetting is developmentally 
controlled, being enabled at a certain point during DP thymocyte maturation, but 
eventually being disabled in CD8 SP thymocytes and severely impeded in peripheral 
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lymphocytes. Although previous reports claimed that up to 20% of peripheral 
lymphocytes autorosetted, only 6% of peripheral lymphocytes autorosetted in this study, 
a discrepancy that is likely to be due to the technical advantages of the flow cytometry-
based autorosetting assay. Firstly, Hoechst-33342 labelling allowed the analysis of 
autorosetting to be entirely on viable lymphocytes, eliminating the artifactual binding of 
erythrocytes by dead/dying cells which could have occurred in earlier studies. Secondly, 
the shear force of the flow cytometer sheath fluid would disperse weakly formed 
autorosettes. It should also be noted that the subset-specific analysis of autorosetting in 
the current assay eliminated the dilution effect of non-rosetting populations, presumably 
encounted in earlier studies. Thus, the data presented in this Chapter were generated by 
a highly objective assay that only counted stable autorosettes formed by viable 
lymphocytes and, consequently, was ideally placed to facilitate the identification of the 
autorosetting receptor on thymocytes and its ligand on erythrocytes.  
 
Earlier studies suggesting that autorosetting is MHC-I restricted (Primi et al., 1979, 
Charreire and Bach, 1975, Sia and Parish, 1980a), which indirectly implicated CD8 in 
autorosetting as this molecule binds MHC-I. Indeed, based on the ability of anti-CD8 
mAbs to inhibit autorosetting and the failure of CD8-deficient thymocytes to autorosette 
(FIG. 3.6), it was established that the CD8αβ heterodimer is the autorosetting receptor, 
with CD8β being the key autorosetting component of the heterodimer. Although partial 
inhibition of autorosetting by an anti-TCRβ mAb (FIG. 3.5) would suggest that TCRβ 
participates in autorosetting, this results is probably due to steric hindrance as the TCR 
complex is located proximal to the CD8αβ molecule (Devine et al., 2006). 
Unfortunately, the study of autorosetting by TCR-deficient thymocytes is not feasible as 
TCR-deficiency results in aberrant thymocytes development (Mombaerts et al., 1992). 
Moreover, MHC-I molecules on erythrocytes are not the main autorosetting ligand 
interacting with the CD8αβ heterodimer on thymocytes as their absence in KO mice did 
not affect autorosetting (FIG. 3.7). A possible explanation for this discrepancy is that 
the high shear forces in the flow cytometry assay used in this thesis to measure 
autorosetting eliminated the contribution of weak TCR-MHC-I interactions to the 
formation of autorosettes. 
 
Consistent with an earlier report (Parish et al., 1984), it was confirmed that the sulfated 
polysaccharides heparin and DxS completely inhibited autorosetting (FIG. 3.8A). These 
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data suggested that analogous molecules on the erythrocyte surface, namely HS, could 
function as an autorosetting ligand, a role ultimately confirmed by the failure of HPNSE 
and HPSE treated erythrocytes to autorosette (FIG. 3.8C). In addition, inhibition of the 
binding of anti-CD8 mAbs to lymphocytes by heparin and DxS (FIG. 3.9) suggested 
that HS may interact with the CD8αβ heterodimer, particularly CD8β. Indeed, the 
impaired ability of CD8 deficient thymocytes to bind FITC-heparin was consistent with 
the CD8αβ heterodimer directly binding heparin/HS (FIG. 3.10B and C). Furthermore, 
this HS interaction is 6-O-sulfate dependent and is optimal when maximum negative 
charges are available on the heparin/HS chains (FIG. 3.8D).  
 
CD8β is developmentally α2-3 sialylated (FIG. 3.11A and B), the ST3Gal-1 
sialyltransferase being upregulated in CD8 SP thymocytes and peripheral CD8+ T 
lymphocytes, with this modification being previously reported to alter the conformation 
of the CD8αβ heterodimer (Moody et al., 2003). Additional to the blocking effect on 
MHC-I binding (Daniels et al., 2001), results presented in this Chapter indicate that α2-
3 sialylation of CD8αβ impedes the interaction of CD8 on thymocytes and peripheral 
CD8+ T lymphocytes with HS. Thus, biochemical desialylation of CD8 by 
neuraminidase treatment strikingly augmented thymocyte and restored peripheral CD8+ 
T lymphocyte autorosetting (FIG. 3.11C and D). Hence, α2-3 sialylation not only limits 
the ability of CD8 molecules on peripheral CD8+ T lymphocytes to bind heparin/HS, as 
desialylation of DP thymocytes also enhances heparin/HS binding by CD8 as well as 
autorosetting. Moreover, data shown in FIG. 3.13 unequivocally show that autorosetting 
by neuraminidase treated peripheral CD8+ T lymphocytes is HS-dependent.  
 
The data shown in FIG. 3.14A confirmed that serum-derived HRG strongly inhibits 
autorosetting, consistent with earlier reports from the Parish Laboratory (Rylatt et al., 
1981, Sia et al., 1982). Although not tested in this study, HRG is likely to block 
autorosetting by binding to erythrocyte HS (Jones et al., 2004), thus preventing it from 
binding to CD8β. Whilst HRG is the major serum component that is responsible for 
autorosetting inhibition by WT serum, the enhanced ability of HRG deficient serum to 
inhibit autorosetting suggests the dominance of a substitute inhibitor in the HRG.KO 
mice (FIG. 3.14C). Western blotting revealed that HRG was absent from HRG.KO sera 
but Co2+-affinity chromatography, which depleted HRG from WT serum, also removed 
the unknown autorosetting inhibitor from HRG.KO serum. Thus, it is possible that the 
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autorosetting inhibitor in HRG.KO serum is an isoform of HRG not recognised by the 
generic anti-HRG polyclonal Ab used for Western blotting, being produced from an 
artifactual transcript encoded by the altered HRG gene in HRG.KO mice. Further work 
is required to resolve this issue. 
 
In summary, using a new flow cytometry-based autorosetting assay, the molecular 
mechanisms that facilitate and control murine autorosetting have been characterised. 
The CD8αβ heterodimer, but mainly CD8β, on DP thymocytes binds directly to highly 
negatively charged HS chains, carrying 6-O-sulfate groups, on erythrocytes. During 
development in the thymus, and in the periphery, α2-3 sialylation of CD8β impedes the 
ability of CD8 to bind HS, an inhibitory effect that is reversed by enzymatic 
desialylation. Thus, together with circulating HRG, the ability of CD8 to interact with 
HS is constantly and tightly suppressed in peripheral CD8+ T lymphocytes.  
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Functional Significance of Murine Autorosetting 
 
 
 
 
 
 
 
4.1 Abstract 
In Chapter 3 it was shown that murine autorosetting is mediated by CD8 on DP 
thymocytes interacting with HS on erythrocytes. Earlier studies by the Parish 
Laboratory discovered that certain sulfated polysaccharides, particularly DxS500 kDa, that 
resemble HS and inhibit autorosetting, can induce a sustained Ca2+ flux in a 
subpopulation of immature murine thymocytes corresponding to DP thymocytes. In this 
Chapter it was initially confirmed that DxS500 kDa induces a Ca2+ flux in DP thymocytes, 
but not in peripheral T lymphocytes, that is dependent on the uptake of extracellular 
Ca2+. Furthermore, the extent of the DxS500 kDa-induced Ca2+ flux was severely impaired 
in CD8β.KO DP thymocytes, this effect being more evident in CD8α.KO DP 
thymocytes, where both CD8β and CD8α molecules were absent. It was also shown that 
neuraminidase treatment markedly restored the DxS500 kDa-induced Ca2+ flux in 
peripheral CD8+ T lymphocytes. Also, using mutant mouse strains it was discovered 
that the DxS500 kDa-induced Ca2+ flux was independent of TCR-induced proximal 
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signalling, being unaffected by Zap70-deficiency, but was substantially impaired in 
Slp76-deficient DP thymocytes. Finally, DxS500 kDa was able to markedly enhance 
thymocytes activation by an immobilised anti-CD3 mAb, as measured by CD69 
upregulation. Collectively, these data suggest that the CD8-HS interaction observed 
with thymocytes autorosetting, induces a Ca2+ flux in DP thymocytes that lowers the 
threshold required for TCR-mediated activation of DP thymocytes. 
 
4.2 Introduction 
In developing thymocytes proper ligation of the TCR by self-peptide/MHC leads to the 
initiation of downstream signalling events, including a substantial rise in cytoplasmic 
Ca2+, which may activate relevant transcription factors that are then translocated to the 
nucleus to either suppress or activate genes controlling cellular activation, proliferation, 
and cytokine production (Gascoigne and Palmer, 2011, Fu et al., 2014). The binding of 
CD8/CD4 to the non-cognate regions of MHC-I and MHC-II, respectively, may aid the 
process by increasing the avidity of TCR-ligand binding and fine-tuning downstream 
signalling (Li et al., 2013). In particular, CD8β has been shown to position the CD8αβ 
heterodimer proximal to the TCR-CD3 complex, consequently, enhancing 
peptide/MHC-I binding and, intracellularly, promoting the formation of a signalling 
platform involving Lck and LAT (Bosselut et al., 2000, Arcaro et al., 2001). 
 
The release of Ca2+ from intracellular stores and the influx of extracellular Ca2+ via an 
array of plasma membrane Ca2+ channels contributes to the rise in cytoplasmic Ca2+ in 
developing thymocytes. Following TCR activation, phosphorylated Slp76 regulates 
ITK-mediated phosphorylation of PLC-γ1, which then converts PIP2 to IP3 and DAG. 
IP3 then binds to IP3 receptors on endoplasmic reticulum (ER) to trigger the release of 
ER-stored Ca2+. In parallel, the binding of Ca2+ to STIM1 on ER membranes changes 
the conformation of STIM1, which enables its interaction with CRAC/ORAI1 channels 
and trigger the uptake of extracellular Ca2+ across the plasma membrane (Feske et al., 
2012). Furthermore, plasma membrane voltage-gated Na+ channels (VGSC) (Lo et al., 
2012), purinergic P2X channels (Freedman et al., 1999) and voltage-dependent Ca2+ 
channels (Cav1.4) (Omilusik et al., 2011) have been linked with the influx of 
extracellular Ca2+ in stimulated thymocytes. In the cytoplasm, Ca2+ may also activate 
Ca2+-calmodulin dependent pathways, notably calcineurin, a Ca2+-dependent 
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phosphatase which dephosphorylates phosphorylated-NFAT. Dephosphorylated NFAT 
is then translocated to the nucleus to participate in gene transcription (Adachi et al., 
2000). 
 
The Parish laboratory has shown previously that certain sulfated polysaccharides that 
inhibit autorosetting, particularly DxS500 kDa, can induce a sustained Ca2+ flux in 
subpopulations of cortisone-sensitive thymocytes, but not in cortisone-resistant 
thymocytes and peripheral lymphocytes. Adding Ca2+-chelating EGTA to the 
extracellular medium totally abolished the DxS500 kDa-induced Ca2+ flux, implying that 
the Ca2+ rise is totally dependent on the uptake of extracellular Ca2+, thus, implicitly 
indicating that the response is unlikely to require the release of Ca2+ from intracellular 
stores. Also, inhibiting VGSC has no effect on the DxS500 kDa-induced Ca2+ flux, thus, 
eliminating these ion channels from playing a role in the response (Tellam and Parish, 
1987, Weston et al., 1991).  
 
Since cortisone-sensitive thymocytes are DP thymocytes, the same thymocyte 
subpopulation that exhibits CD8-dependent autorosetting, an attractive hypothesis was 
that DxS500 kDa may be inducing a Ca2+ flux via the CD8 molecule. Therefore, this 
Chapter describes experiments to test this hypothesis and investigate the functional 
significance of the sulfated polysaccharide-induced Ca2+ flux in lymphocytes. 
 
4.3 Results 
4.3.1 Induction of a Ca2+ flux in lymphocytes by DxS500 kDa 
Consistent with earlier reports (Tellam and Parish, 1987, Weston et al., 1991) the data 
presented in this thesis confirmed that DxS500 kDa can induce a sustained Ca2+ flux in 
thymocytes. Although heparin has been previously shown to induce a weak Ca2+ flux in 
thymocytes, here the same effect was not observed, whereas DxS5 kDa consistently failed 
to induce a Ca2+ flux in thymocytes (FIG. 4.1Ai), despite these two sulfated 
polysaccharides inhibiting autorosetting (FIG. 3.8A). The addition of 2 mM EGTA to 
the assay buffer to chelate extracellular Ca2+ totally abolished the DxS500 kDa-induced 
Ca2+ flux, thus, confirming that extracellular Ca2+ was essential for the Ca2+ flux 
observed in DxS500 kDa-stimulated thymocytes (FIG. 4.1Aii). Furthermore, titration of 
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FIG. 4.1: High but not low molecular weight sulfated polysaccharides are able to induce a 
Ca2+ flux in thymocytes that is dependent on the uptake of extracellular Ca2+. (A) 
Comparison of the ability of 100 µg/mL of heparin, DxS5 kDa and DxS500 kDa to trigger a Ca2+ flux 
in thymocytes in HEPES-buffered saline (pH 7.4) (HBS) in (i) the absence or (ii) the presence 
of EGTA (2 mM). (B) Titration of DxS500 kDa to determine the minimal concentration required to 
trigger a Ca2+ flux in thymocytes. (C) Effect of pre-treatment of thymocytes with (i) heparin or 
(ii) DxS5 kDa (100 µg/mL) on induction of a Ca2+ flux by DxS500 kDa (1 µg/mL). Ca2+ fluxes in 
Indo-1-loaded thymocytes were determined for 22 min by flow cytometry, including a 2 min 
pre-stimulation baseline for each treatment. Arrows indicate the time the sulfated 
polysaccharides were added. Data are expressed as a ratio of fluorescence (GMFI) of Ca2+-
bound Indo-1 (425 nm) vs. fluorescence of unbound Indo-I (510 nm).  	 	
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FIG. 4.2: The sulfated polysaccharide DxS500 kDa specifically induces a Ca2+ flux in 
subpopulations of thymocytes. Analysis of DxS500 kDa-induced Ca2+ flux in (A) thymic and (B) 
peripheral T cell subsets, with the Ca2+ flux in different Indo-1-loaded lymphocytes populations 
being monitored for 22 min by flow cytometry, including a 2 min pre-stimulation baseline. Data 
are expressed as a ratio of fluorescence (GMFI) of Ca2+-bound Indo-1 (425 nm) vs. fluorescence 
of unbound Indo-I (510 nm). Arrows indicate the time DxS500 kDa was added. (C) Percentage of 
different thymocyte subsets exhibiting a Ca2+ flux (upper values in each panel) vs. percentage 
failing to produce a Ca2+ flux (lower values in each panel) when unstimulated or stimulated with 
DxS500 kDa (1 µg/mL) for 20 min, when the Ca2+ flux had plateaued. Binding of Ca2+ by Indo-1 
results in an increase in 425 nm fluorescence and a decrease in 510 nm fluorescence that is Ca2+ 
concentration-dependent. ‘Total’ refers to response of total lymphocytes population, with 
lymphocyte subsets as in FIG. 3.4B.  
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the DxS500 kDa concentration showed that 0.1 µg/mL was sufficient to induce a 
substantial Ca2+ flux (FIG. 4.1B). Interestingly, it was also found that pre-treatment of 
thymocytes with 100 µg/mL of either heparin or DxS5 kDa substantially reduced the 
DxS500 kDa-induced Ca2+ flux (FIG. 4.1C), therefore, suggesting that heparin and DxS (5 
and 500 kDa) bind to the same receptor despite differences in their ability to induce a 
Ca2+ flux. 
 
Previously, it has been shown that cortisone-sensitive thymocytes are the main 
lymphocyte subset displaying a substantial Ca2+ flux following DxS500 kDa stimulation, 
whereas cortisone-resistant thymocytes and splenocytes are non-responsive to DxS500 
kDa stimulation (Tellam and Parish, 1987, Weston et al., 1991). Indeed, here it was 
confirmed that DP thymocytes and to a lesser extent, CD8 SP and CD4 SP thymocytes, 
were the DxS500 kDa-responsive subsets, whereas DN thymocytes and peripheral CD4+ 
and CD8+ T lymphocytes consistently failed to show any detectable Ca2+ flux following 
DxS500 kDa stimulation (FIG. 4.2A and B). To complement these data, it was found that 
62.8% of total thymocytes, in particular, 72.2% of DP, 32% of CD8 SP and 25.9% of 
CD4 SP thymocytes showed a noticeable Ca2+ flux following DxS500 kDa stimulation 
(FIG. 4.2C). Collectively, these data implied that only subpopulations of immature 
thymocytes could be stimulated by DxS500 kDa to produce an increase in intracellular 
Ca2+.   
4.3.2 The molecular basis of the DxS500 kDa-induced Ca2+ flux in thymocytes 
Since heparin and DxS (5 and 500 kDa) bind to the CD8αβ heterodimer and block 
autorosetting (FIG. 3.8, 3.9 and 3.10), and heparin and DxS5 kDa partially blocked the 
Ca2+ response induced by DxS500 kDa (FIG. 4.1C), it was hypothesised that the CD8αβ 
heterodimer is the receptor on thymocytes responsible for the DxS500 kDa-induced Ca2+ 
flux. To test this hypothesis, the extent of the DxS500 kDa-induced Ca2+ flux in CD8.KO 
thymocytes was evaluated. Indeed, it was found that CD8α.KO thymocytes, which 
completely lacked the CD8αβ heterodimer, displayed an almost completely impaired 
DxS500 kDa-induced Ca2+ flux, the level of impairment being closely matched by 
CD8β.KO thymocytes (FIG. 4.3Ai). Similarly, examination of different thymocyte 
subpopulations also showed that CD8β made a major contribution to the Ca2+ flux 
induced by DxS500 kDa in DP and CD8 SP thymocytes (FIG. 4.3B). Collectively, these 
data indicate that CD8β makes a major contribution to the response, but is aided by 
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CD8α. This conclusion was confirmed by the observation that the Ca2+ flux of 
CD8β.KO thymocytes that were pre-treated with an anti-CD8α mAb was comparable to 
that of CD8α.KO thymocytes (FIG. 4.3Ai lower panel). The proportion of the different 
thymocytes populations producing a Ca2+ flux in response to DxS500 kDa further supports 
this finding (FIG. 4.3C). Thus, compared to 64% of WT thymocytes, only 25.4% of 
CD8β.KO thymocytes gave a DxS500 kDa-induced Ca2+ response, this responsive 
population being further reduced to 15.9% in the presence of an anti-CD8α mAb, 
although not quite as low as with CD8α.KO thymocytes (10.4%).  
 
In contrast, the magnitude of the DxS500 kDa-induced Ca2+ flux in WT and CD4.KO 
thymocytes was comparable (FIG. 4.3Aii). At face value, this implies that CD4 does not 
contribute to the response. Intriguingly, however, DxS500 kDa induced a marginal Ca2+ 
flux in CD4 SP thymocytes (FIG. 4.2A and C) that was seemingly unaffected by CD8β-
deficiency (FIG. 4.3B), thus implying the presence of a CD8-independent response to 
DxS500 kDa. 
 
Since the DxS500 kDa-induced Ca2+ flux in thymocytes is predominantly CD8-dependent, 
it appeared likely that the response may involve components of the TCR-signalling 
pathway. To test this possibility, the extent of the DxS500 kDa-induced Ca2+ flux in DP 
thymocytes from N-ethyl-N-nitrosourea (ENU)-generated mutant mice, which lacked 
the major signal transduction proteins Zap70 (Siggs et al., 2007) and Slp76 (Siggs et al., 
2015), with Zap70 acting upstream of Slp76 (Fu et al., 2014), were evaluated. Initially, 
it was found that there were marked differences in the percentage of DN, DP, CD4 SP 
and CD8 SP thymocytes in WT, Zap70-/- and Slp76-/- mice. In particular, the 
development of Zap70-/- thymocytes appeared to be arrested at the DP stage, whereas 
Slp76-/- thymocytes showed impaired progression from the DN to the DP stage (FIG. 
4.4A), consistent with earlier reports claiming that Zap70 and Slp76 deficiencies lead to 
aberrant T lymphocyte development (Siggs et al., 2007, Siggs et al., 2015). However, 
despite CD8 being comparably expressed on WT, Zap70-/- and Slp76-/- DP thymocytes, 
the DxS500 kDa-induced Ca2+ flux was comparable in WT and Zap70-/- DP thymocytes, 
but markedly impaired in Slp76-/- DP thymocytes (FIG. 4.4B). Indeed, this finding was 
complemented by the observation that 67.5% of WT, 62% of Zap70-/- and 35.5% of 
Slp76-/- DP thymocytes showed a substantial Ca2+ flux following DxS500 kDa stimulation 
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FIG. 4.3: Contribution of CD8 molecules to the DxS500 kDa-induced Ca2+ flux in thymocytes. 
(A) DxS500 kDa-induced Ca2+ flux in (i) WT, CD8α.KO and CD8β.KO thymocytes (top panel), 
with the effect of the addition of an anti-CD8α mAb (5 µg/mL) on the DxS500 kDa-induced Ca2+ 
flux in CD8β.KO thymocytes shown (bottom panel) and in (ii) WT and CD4-/-(ENU) thymocytes. 
In (i) note the y-axis of the bottom panel has been expanded. (B) Effect of CD8β-deficiency on 
the DxS500 kDa-induced Ca2+ flux in different thymocyte subsets, with the Ca2+ flux being 
monitored for 22 min by flow cytometry, including a 2 min pre-stimulation baseline. Data are 
expressed as a ratio of fluorescence (GMFI) of Ca2+-bound Indo-1 (425 nm) vs. fluorescence of 
unbound Indo-I (510 nm). Arrows indicate the time DxS500 kDa was added. (C) Percentage of 
WT, CD8α.KO and CD8β.KO thymocytes, the latter in the absence or presence of an anti-CD8α 
mAb (5 µg/mL), exhibiting a Ca2+ flux (upper values in each panel) vs. percentage failing to 
produce a Ca2+ flux (lower values in each panel) when unstimulated or stimulated with DxS500 
kDa (1 µg/mL) for 20 min (i.e., when the Ca2+ flux had plateaued). Binding of Ca2+ by Indo-1 
results in an increase in 425 nm fluorescence and a decrease in 510 nm fluorescence that is Ca2+ 
concentration-dependent. 
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(FIG. 4.4C). Collectively, these data suggest that DxS500 kDa induces a Ca2+ flux in DP 
thymocytes via an intracellular signalling pathway that involves Slp76, but the upstream 
Zap70, which is associated with the initiation of TCR signalling, plays little or no role 
in the process. 
 
 
	
FIG. 4.4: Zap70 but not Slp76 is dispensable for the DxS500 kDa-induced Ca2+ flux in 
thymocytes. Analysis of (A) the distribution of thymocyte subsets and (B) DxS500 kDa-induced 
Ca2+ flux in WT, Zap70-/- and Slp76-/- DP thymocytes, with the Ca2+ flux in different Indo-1-
loaded thymocytes being monitored for 22 min by flow cytometry, including a 2 min pre-
stimulation baseline. Data in (B) are expressed as a ratio of fluorescence (GMFI) of Ca2+-bound 
Indo-1 (425 nm) vs. fluorescence of unbound Indo-I (510 nm). Arrow indicates the time DxS500 
kDa was added. (C) Percentage of WT, Zap70-/- and Slp76-/- DP thymocytes exhibiting a Ca2+ 
flux (upper values in each panel) vs. percentage failing to produce a Ca2+ flux (lower values in 
each panel) when unstimulated or stimulated with DxS500 kDa (1 µg/mL) for 20 min (i.e., when 
the Ca2+ flux had plateaued). Binding of Ca2+ by Indo-1 results in an increase in 425 nm 
fluorescence and a decrease in 510 nm fluorescence that is [Ca2+]-dependent. 
 
Since O-sialylation of CD8β on CD8 SP thymocytes and peripheral CD8+ lymphocytes 
impedes the ability of CD8 to interact with sulfated polysaccharides (FIG. 3.12), a 
likely possibility is that O-sialylation also impairs the DxS500 kDa-induced Ca2+ flux in 
these cells. Thus, it was predicted that neuraminidase treatment would restore the 
DxS500 kDa-induced Ca2+ flux in peripheral CD8+ T lymphocytes. Indeed, neuraminidase 
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treated peripheral CD8+ T lymphocytes showed a substantial Ca2+-flux following 
DxS500 kDa stimulation, whereas mock-treated control cells did not respond to DxS500 kDa 
(FIG. 4.5). Also, neuraminidase-treated CD8β.KO peripheral CD8+ T lymphocytes were 
non-responsive to DxS500 kDa, thus demonstrating that the DxS500 kDa-induced Ca2+ flux 
in peripheral CD8+ T lymphocytes, like with thymocytes, is highly CD8β-dependent 
(FIG. 4.5). 
 
 
	
FIG. 4.5: Neuraminidase treatment restores the CD8β-dependent DxS500 kDa-induced Ca2+ 
flux in peripheral CD8+ T cells. Analysis of the DxS500 kDa-induced Ca2+ flux in untreated and 
V. cholerae neuraminidase treated WT and CD8β.KO peripheral CD8+ T cells, with the Ca2+ 
flux in different Indo-1-loaded peripheral CD8+ cells being monitored for 22 min by flow 
cytometry, including a 2 min pre-stimulation baseline. Data are expressed as a ratio of 
fluorescence (GMFI) of Ca2+-bound Indo-1 (425 nm) vs. fluorescence of unbound Indo-I (510 
nm). Arrows indicate the time DxS500 kDa (1 µg/ml) was added.  
 
4.3.3 Contribution of sulfated polysaccharide recognition to thymocyte activation 
Based on the ability of DxS500 kDa to induce a substantial Ca2+ flux in DP thymocytes, it 
was hypothesised that this Ca2+ flux could lower the threshold required to activate T 
cells, with expression of cell surface CD69 on thymocytes being used as a marker of 
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4.6B), indicating that CD8β makes a major contribution to the induction of CD69 
expression by DxS500 kDa.  		
	
FIG. 4.6: DxS500 kDa enhances anti-CD3ε mAb-mediated thymocyte activation in a CD8β-
dependent manner. (A) CD69-expressing thymocytes (%) after 4 hr incubation at 37°C alone 
or in the presence of 1-100 µg/mL of the sulfated polysaccharides heparin and DxS (5 and 500 
kDa). (B) CD69-expression by WT and CD8β.KO thymocytes (%) following 4 hr incubation at 
37°C alone or in the presence of DxS500 kDa (1-100 µg/mL). In (A) and (B), ***, P < 0.001. ****, 
P < 0.0001 (1-way ANOVA with Dunnett’s multiple comparisons test to unstimulated control). 
(C) CD69-expressing thymocytes (%) following 4 hr incubation at 37°C alone or in the 
presence of an immobilised anti-CD3ε mAb (0.4, 2 and 10 µg/mL) with or without DxS500 kDa 
(1-100 µg/mL). **, P < 0.01. ***, P < 0.001 (1-way ANOVA with Dunnett’s multiple 
comparisons test to without anti-CD3ε mAb stimulation). (D) CD69-expressing WT and 
CD8β.KO thymocytes (%) after 4 hr incubation at 37°C in the presence of an immobilised anti-
CD3ε mAb (10 µg/mL) and with or without DxS500 kDa (1-100 µg/mL). NS, not significant. ****, 
P < 0.0001 (2-way ANOVA with Bonferroni multiple comparisons test). Data are expressed as 
mean %CD69-expressing thymocytes ± SD of triplicate samples, as measured by flow 
cytometry. 
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The ability of DxS500 kDa to independently activate thymocytes was consistent with the 
hypothesis that DxS500 kDa stimulation may synergise with and lower the threshold for an 
anti-CD3 mAb (i.e., TCR signal) to activate thymocytes. To test this hypothesis, the 
percentage of thymocytes expressing CD69 following 4 hr incubation at 37°C with an 
immobilised anti-CD3ε (145-2C11) mAb, in the absence or presence of DxS500 kDa, was 
measured by flow cytometry. Initially, it was found that the immobilised anti-CD3ε 
mAb at all concentrations used (0.4, 2 and 10 µg/mL) produced no change in the 
percentage of CD69+ thymocytes above background levels. This suggested that 
stimulation with an immobilised anti-CD3ε mAb, without the addition of DxS500 kDa, is 
insufficient to activate thymocytes after short-term culture (i.e., 4 hr). However, whilst 
incubation with 1 µg/mL of DxS500 kDa alone consistently failed to activate thymocytes, 
co-incubation with 10 µg/mL of immobilised anti-CD3ε mAb resulted in a small but 
significant increase in the percentage of CD69+ thymocytes (9.23% vs. 11.6% CD69+ 
cells, P < 0.01). The ability of DxS500 kDa to enhance thymocyte activation by 
immobilised anti-CD3ε mAb was more evident in the presence of increasing 
concentrations of DxS500 kDa, with thymocytes co-incubated with 10 and 100 µg/mL of 
DxS500 kDa showing significantly enhanced CD69 expression at all three concentrations 
of immobilised anti-CD3ε used (FIG. 4.6C). Furthermore, the ability of DxS500 kDa to 
enhance anti-CD3ε mAb-mediated activation was significantly impaired in CD8β.KO 
thymocytes (FIG. 4.6D). Collectively, these data demonstrate that DxS500 kDa can 
synergise with and lower the activation threshold required for TCR-mediated activation 
of thymocytes, this process being CD8β dependent. 
 
4.4 Discussion 
DxS500 kDa has been previously shown to induce a substantial and sustained Ca2+ flux in 
subpopulations of immature thymocytes (Weston et al., 1991) but how this occurs and 
its functional implications are not known. In this Chapter the main findings were: (i) it 
was confirmed that DxS500 kDa induces a sustained Ca2+ flux in subpopulations of DP 
thymocytes and to a lesser extent in CD8 SP and CD4 SP thymocytes, whereas 
peripheral CD4+ and CD8+ T lymphocytes are non-responsive to DxS500 kDa stimulation, 
(ii) the DxS500 kDa triggered Ca2+ flux is dependent on the CD8αβ heterodimer with 
CD8β playing a major role in the process but being aided by CD8α, (iii) sialylation of 
CD8β completely inhibits the DxS500 kDa-induced Ca2+ flux in peripheral CD8+ T 
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lymphocytes, an inhibition that can be reversed by neuraminidase treatment, (iv) the 
CD8-DxS500 kDa interaction triggers the uptake of extracellular Ca2+ by DP thymocytes 
via a signalling pathway that is independent of TCR associated Zap70 but requires 
downstream Slp76 and, finally, (v) ligation of the CD8αβ heterodimer by DxS500 kDa 
lowers the threshold required for anti-CD3ε mAb-mediated activation of thymocytes. 
 
Consistent with earlier reports (Tellam and Parish, 1987, Weston et al., 1991) DxS500 kDa 
induced a sustained Ca2+ flux (FIG. 4.1A) in subpopulations of DP thymocytes and to a 
lesser extent, in CD8 SP and CD4 SP thymocytes, whereas peripheral CD4+ and CD8+ 
T lymphocytes were non-responsive to DxS500 kDa (FIG. 4.2). Similar to autorosetting, it 
appears that the sensitivity of thymocytes to the DxS500 kDa-induced Ca2+-flux is 
developmentally controlled and, although not directly examined in this thesis, probably 
represents the subpopulation of DP thymocytes that is capable of autorosetting. It has 
been shown previously that heparin and DxS5 kDa induced smaller Ca2+ rise in 
thymocytes (Tellam and Parish, 1987) however, here the response was negligible (FIG. 
4.1A). This discrepancy may be due to the subtle differences in the batches of heparin 
and DxS5 kDa used in the two studies. In contrast, heparin and DxS5 kDa inhibited the 
ability of DxS500 kDa to induce a Ca2+ flux (FIG. 4.1C) indicating that heparin and DxS 
(5 and 500 kDa) bind to the same receptor on DP thymocytes.  
 
The ability of DxS500 kDa to substantially inhibit the binding of an anti-CD8β mAb and, 
to a lesser extent, an anti-CD8α mAb to thymocytes (FIG. 3.9), coupled with the almost 
complete lack of a DxS500 kDa-induced Ca2+ flux in CD8.KO thymocytes (FIG. 4.3Ai), 
strongly suggest that the CD8αβ heterodimer is the key DxS500 kDa receptor involved in 
triggering a Ca2+ flux. Also, consistent with autorosetting, sialylation of CD8β on CD8 
SP thymocytes and peripheral CD8+ T lymphocytes deterred the interaction of CD8 
with sulfated polysaccharides (FIG. 3.11 and 3.12) and, hence, explains why these cells 
were non-responsive to DxS500 kDa stimulation. Indeed, this inhibition was reversed by 
neuraminidase treatment (FIG. 4.5). Finally, the residual Ca2+ flux in CD8.KO 
thymocytes (FIG. 4.3Aii) and CD4 SP thymocytes (FIG. 4.3B) suggests the existence of 
a CD8-independent response to DxS500 kDa and, although not tested, possibly mediated 
by the binding of DxS500 kDa to other DxS/HS-binding cell surface receptors, including 
CD45, CD90 (Parish et al., 1988a), LFA-1 and α4β1/VLA-4 (Vermot-Desroches et al., 
1991, Schlesinger et al., 2009, Bendas and Borsig, 2012)  
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In developing thymocytes, proper engagement of the TCR by self-peptide/MHC-I 
complexes, together with the ligation of CD8 by a non-cognate region of MHC-I, leads 
to the initiation of intracellular signalling cascades including a rise in cytoplasmic Ca2+ 
(Fu et al., 2014). Earlier studies have demonstrated that Zap70 (Williams et al., 1999) 
and Slp76 (Kumar et al., 2002) are crucial for Ca2+ mobilisation during thymocytes 
development. The full extent of intracellular signalling events activated by the CD8-
DxS500 kDa interaction is not known, but the data shown in this Chapter indicate that the 
induction of the Ca2+ flux requires the adapter protein Slp76, whereas Zap70, which is 
the key transducer of TCR signalling but upstream of Slp76, apparently plays no role in 
the process (FIG. 4.4). It is most unlikely that DxS500 kDa induces the release of 
intracellularly stored Ca2+ as Zap70 did not contribute to the response and, chelation of 
extracellular Ca2+ by EGTA resulted in no intracellular Ca2+ rise, thus, unequivocally 
confirming that the DxS500 kDa-induced Ca2+ flux is totally due to the uptake of 
extracellular Ca2+ (FIG. 4.1Aii). The involvement of Slp76, in particular, in the uptake 
of extracellular Ca2+ is surprising as this has not been reported before and, as VGSC do 
not contribute to the response (Tellam and Parish, 1987), further work is required to 
delineate the intracellular signalling events involved and the mechanism of intracellular 
Ca2+ entry induced by DxS500 kDa. 
 
In the absence of TCR stimulation, based on CD69 expression thymocytes were 
substantially activated after 4 hr incubated with high concentrations (100 µg/mL) of 
DxS500 kDa with CD8β and, although not tested directly, CD8α presumably making a 
contribution to the process (FIG. 4.6A and B). Whilst TCR stimulation by an 
immobilised anti-CD3ε mAb failed to activate thymocytes after 4 hr incubation, co-
incubation with DxS500 kDa markedly augmented thymocytes activation above that 
evident with DxS500 kDa alone. Importantly, thymocytes stimulated with increasing 
DxS500 kDa concentrations required lower concentrations of immobilised anti-CD3ε mAb 
to achieve comparable levels of CD69 expression, with the augmenting effects of 
DxS500 kDa being CD8-dependent (FIG. 4.6C and D). Collectively, these data 
demonstrate that DxS500 kDa lowers the threshold required for TCR-mediated activation 
of thymocytes, particularly at early time points (i.e., 4 hr) after initiation of anti-CD3 
mAb activation. It should be noted that if anti-CD3 mAb induced CD69 expression on 
thymocytes was examined after 24 hr incubation, all concentrations of immobilised 
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anti-CD3 mAb induced a high proportion of CD69+ thymocytes and DxS500 kDa had little 
or no enhancing effect (data not shown). 
 
In summary, this Chapter describes the likely functional implications of the CD8-HS 
mediated autorosetting phenomenon observed with DP thymocytes. DxS500 kDa 
represents a HS mimetic that binds to CD8 on DP thymocytes and generates a Zap70-
independent, Slp76-dependent signalling events that induce a sustained influx of 
extracellular Ca2+ in these cells. Sialylation of CD8β on peripheral CD8+ T lymphocytes 
impedes the CD8-HS interaction and, consequently, the associated intracellular Ca2+ 
flux, but this inhibitory effect can be reversed by enzymatic desialylation. Thus, the 
CD8-HS interaction detected by autorosetting appears to trigger intracellular signalling 
events that lower the TCR-mediated activation threshold in DP thymocytes. Future 
investigations are needed to further examine the intracellular events triggered in 
thymocytes by the CD8-HS interaction, as well as the ability of this interaction to fine-
tune antigen-induced thymocyte activation. However, of more immediate importance is 
the identification of the cells in the thymus that ‘rosette’ with thymocytes and, 
presumably, provide the HS ligand that triggers a Ca2+ flux in developing thymocytes. 
Experiments described in the next Chapter (Chapter 5) attempt to address this issue. 
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Chapter Five 
 
 
 
 
 
 
 
Physiological Relevance of Murine Autorosetting 
 
 
 
 
 
 
 
5.1 Abstract 
The thymus provides unique microenvironments which enable T cell precursors to 
become functional and self-tolerant MHC-restricted TCRαβ T lymphocytes. Immature 
thymocytes migrate through distinct thymic niches and interact with stromal cells by 
scanning self-antigens in the context of MHC while progressively undergoing TCR 
rearrangements. In the cortex only TCR clones with low to intermediate affinity for 
self-peptide/MHC complexes on cTEC surfaces are positively selected to survive and 
develop into SP thymocytes, whereas strongly reactive TCR clones are negatively 
selected upon interacting with self-peptide/MHC complexes on cortical DC. The 
surviving TCR clones migrate to the medulla and face a second wave of negative 
selection against tissue-restricted antigens expressed by mTEC and DC. The data shown 
in this Chapter demonstrate that highly sulfated HS expressed on the surface of cTEC 
participates in the heterotypic interaction between cTEC and thymocytes, thus allowing 
the two cell types to form rosettes in a similar way to autorosetting (Chapter 3), this 
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process being CD8αβ-dependent and being augmented by the presence of MHC 
molecules on cTEC. Furthermore, the functional relevance of the CD8-HS interaction in 
cTEC-thymocyte rosetting is evident from the induction of a sustained Ca2+ influx in the 
rosetting thymocytes, consistent with the findings in Chapter 4. Collectively, these data 
indicate that the CD8-HS interaction facilitates the adhesion of DP thymocytes to cTEC 
and initiates a Ca2+ flux in the adherent thymocytes that lowers the threshold required 
for positive selection of DP thymocytes. 
 
5.2 Introduction 
Multipotent lymphoid progenitor cells from the bone marrow migrate to the thymus via 
the circulation to undergo intrathymic developmental processes involving tightly 
regulated interactions with thymic stromal cells, finally producing functional MHC-
restricted CD4+ or CD8+ TCRαβ T lymphocytes (Anderson and Jenkinson, 2001). In the 
thymus CD4-CD8- (DN) thymocytes arrive at the corticomedullary junction and whilst 
migrating to the subcapsular zone (Lind et al., 2001) differentiate from the DN1 stage 
into the DN2 and DN3 stages (Godfrey et al., 1993). DN3 thymocytes are screened for 
productive TCRβ chain expression (β-selection) and then undergo proliferative 
expansion and differentiate into CD4+CD8+ DP (CD3+TCRβloPre-TCRα+) thymocytes 
(Dudley et al., 1994, Hoffman et al., 1996, Kreslavsky et al., 2012). DP thymocytes 
then migrate inwards to the inner cortex and undergo TCRα chain rearrangements 
(Petrie et al., 1993), whilst scanning self-peptides in the context of MHC on cortical 
thymic epithelial cells (cTEC) (Lorenz and Allen, 1989, Anderson et al., 1994) and 
dendritic cells (DC) (Gallegos and Bevan, 2004, Ladi et al., 2008). DP thymocytes 
expressing TCRs with low to intermediate affinity for self-peptide/MHC complexes on 
cTEC are positively selected and develop towards the CD8 SP (MHC-I-restricted) or 
CD4 SP (MHC-II-restricted) lineages. In contrast, TCR clones strongly reacting with 
self-peptide/MHC complexes on DC are deleted (negative selection) (McCaughtry et 
al., 2008, Baba et al., 2009), whereas TCR clones that have little or no affinity for self-
peptide/MHC complexes are lost due to ‘death by neglect’, a process that results in the 
deletion of useless TCR clones (Hernandez et al., 2010). The TCRαβhi CD4 SP and 
CD8 SP thymocytes migrate to the thymic medulla where they are screened against 
AIRE-regulated (Liston et al., 2003) tissue-restricted antigens (TRA) (Derbinski et al., 
2001) presented by medullary TEC (mTEC) or by thymic DCs that have acquired the 
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mTEC-derived TRA (Gallegos and Bevan, 2004, Hubert et al., 2011). Strongly reactive 
TCR clones are either clonally deleted or, in the case of CD4 SP thymocytes, may 
differentiate into CD4+FoxP3+CD25+ natural regulatory T lymphocytes (Itoh et al., 
1999, Jordan et al., 2001). 
 
In addition to the TCR signals (Fu et al., 2014), cTEC are thought to express unique cell 
surface molecules that can provide ‘accessory signals’ that aid MHC-restricted positive 
selection and maturation of DP thymocytes into CD8 SP and CD4 SP thymocytes 
(Anderson et al., 1994). Moreover, cTEC can tightly interact with thymocytes, 
consequently forming rosettes (Oliveira-dos-Santos et al., 1997, Oliveira-dos-Santos et 
al., 1998), the most extreme example of this interaction being thymic nurse cells (TNC) 
that interact with large numbers of thymocytes (Wekerle and Ketelsen, 1980, Wekerle 
et al., 1980, Kyewski et al., 1982, Li et al., 1992). Earlier reports demonstrated that 
cTEC express high levels of cell surface heparan sulfate (HS) that is rich in 6-O-sulfates 
within the highly sulfated regions of the molecules. These researchers also suggested 
that this HS serves as a cell adhesion ligand that contributes to the heterotypic 
interaction between cTEC and thymocytes (Britz and Hart, 1983, Werneck et al., 1999, 
Werneck et al., 2000). 
 
In Chapter 3 of this thesis it was shown that erythrocyte surface HS, with similar 
structural characteristics to the HS on cTEC surfaces as described above, can interact 
predominantly with CD8β and, to lesser extent, with CD8α on DP thymocytes, thus 
mediating autorosetting. The data presented in Chapter 4 demonstrates the functional 
consequences of the CD8-HS interaction, HS mimetics that bind CD8 inducing a 
sustained Ca2+ flux in DP thymocytes that lowers the threshold for TCR-mediated 
thymocyte activation. Hence, it was postulated that the CD8-HS interaction contributes 
to the heterotypic interaction (rosetting) between cTEC and thymocytes, the interaction 
inducing a sustained Ca2+ flux in bound thymocytes independent of TCR-MHC 
recognition. This Chapter describes experiments that attempted to test this hypothesis. 
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5.3 Results 
5.3.1 Identification of HS-expressing cells in the murine thymus 
Earlier studies have demonstrated that TEC express high level of cell surface HS (Britz 
and Hart, 1983) with 6-O-sulfate groups being abundant in the highly sulfated, heparin-
like regions of the HS molecules (Werneck et al., 1999). Here, the expression of HS in 
murine thymus was examined in situ via immunohistochemistry of deparaffinised 
thymic sections labelled with an anti-HS (clone 10E4) mAb. Indeed, HS was weakly 
but ubiquitously expressed throughout the cortex and was less evident in the medulla. 
Strikingly, HS appeared to intensely label ‘rosette-like structures’ that were found 
exclusively in the thymic cortex. These preformed rosettes were approximately 40 µm 
in diameter and consisted of a central HS+ staining cells containing and surrounded by 
multiple (>20 cells/rosette), small (<10 µm) HS- cells that were presumably thymocytes 
(FIG. 5.1). At face value, these rosettes resemble TEC-rosettes (Oliveira-dos-Santos et 
al., 1997, Oliveira-dos-Santos et al., 1998) and TNC (Wekerle and Ketelsen, 1980, 
Wekerle et al., 1980, Nakagawa et al., 2012). 
 
The possibility that the HS-expressing cells within rosettes (FIG. 5.1) were cTEC was 
examined by flow cytometry. Pooled thymic fragments were enzymatically digested 
with collagenase/dispase to release the stromal cells before being subjected to unit 
gravity sedimentation on a cushion of FCS for 1 hr, the large preformed rosettes 
pelleting at the bottom of the tube (Kyewski et al., 1982, Oliveira-dos-Santos et al., 
1997). Light microscopy analysis revealed large rosettes averaging ~20-40 µm in 
diameter alongside smaller non-rosetting cells (i.e., 10-20 µm in diameter) (FIG. 5.2Ai). 
The published literature defines TEC as EpCAM+CD45- cells (Gray et al., 2002, 
McLelland et al., 2011, Wong et al., 2014). In this study, however, exclusion of the 
CD45+ population from EpCAM+ cells was deliberately omitted to ensure that CD45+ 
thymocyte-containing rosettes were not depleted. Indeed, the sedimented cells were 
found to be a mixed cell population, a substantial proportion being EpCAM+ TEC 
(32.5%), which could be subdivided into cTEC (i.e., Ly51interUEA-1lo cells) and mTEC 
(i.e., Ly51loUEA-1hi cells) (51% and 21.4% of EpCAM+ cells, respectively) (FIG. 5.2B 
top panel). Moreover, cTEC could be further subdivided into Ly51inter and Ly51hi (i.e., 
cTEChi) populations (42.5% and 8.5% of TEC, respectively). 
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FIG. 5.1: Immunohistochemical detection of cells expressing high levels of heparan sulfate 
(HS) in the cortex of the mouse thymus. Thymic sections (deparaffinised) from a 5 week old 
C57BL/6 mouse were incubated with an anti-HS mAb (clone 10E4) or an isotype control 
(mouse IgM), bound mAbs being detected by a HRP-conjugated secondary Ab and subsequent 
development with the AEC substrate with one cell being enlarged (inset panel, scale bar: 20 
µm). Arrows indicate the location of high HS-expressing cells in the thymic cortex and not in 
the thymic medulla. Thymic sections were counterstained with haematoxylin. Scale bars: 250 
µm (top panel) and 50 µm (bottom panel). 
 
Next, the expression of cell surface HS by sedimented preformed rosettes and thymic 
stromal cells was evaluated by flow cytometry using the anti-HS (10E4) mAb. Thymic 
stromal cells were manually enriched via magnetic-activated cell sorting (MACS) of 
anti-EpCAM mAb labelled cells from enzymatically-digested thymic fragments, as 
described above. Light microscopy revealed smaller preformed rosettes present 
alongside non-rosetting cells in the MACS-enriched cell suspensions (FIG 5.2Aii). The 
alacrity of TEC to form multicellular complexes with thymocytes most likely reflects 
the unique role of TEC in intrathymic thymocyte development (Oliveira-dos-Santos et 
al., 1998, Hare et al., 2003, Hendrix et al., 2010, Nakagawa et al., 2012). Thus, the 
exclusion of CD45+ T lymphocytes from MACS-enriched EpCAM+ TEC preparation 
was deliberately avoided here and in subsequent experiments so to include functioning 
TEC, namely those rosetting with exogenous thymocytes in vitro. 
Isotype controlAnti-HS mAb (10E4)
Cortex
Cortex
Medulla
Cortex
Medulla
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FIG. 5.2: Identification of different subsets of thymic stromal cells. Thymic fragments from 
4 thymuses of 3 week old mice were repetitively digested with collagenase/dispase. The heavier 
and denser pre-formed rosetting cells were sedimented at unit gravity on a FCS layer for 1 hour. 
Alternatively, EpCAM-expressing stromal cells were enriched via positive selection by 
magnetic-activated cell sorting (MACS) after the cells were labelled with biotinylated anti-
EpCAM mAb linked to Streptavidin-Microbeads. (A) Bright field images illustrate thymic 
stromal cells that were enriched by either unit (i) gravity sedimentation or (ii) by MACS. 
Arrows indicate the presence of pre-formed multicellular conjugates. (B) Characterisation of 
enriched thymic stromal cells by flow cytometry. After discriminating viable cells from dead 
cells and cellular debris (P1), PE-Cy7-EpCAM labelled stromal cells were gated (P2) and 
separated into different subsets based on FITC-UEA-1 lectin binding and Ly51 cell surface 
expression (P3-P6). TEC = thymic epithelial cells. Subsets: non-TEC (P3) = Ly51-UEA-1-; 
medullary-TEC, mTEC (P4) = Ly51loUEA-1hi; cortical-TEC, cTEC (P5) = Ly51interUEA-1lo; 
cTEChi (P6) = Ly51hiUEA-1lo. Percentage of cells in different gates indicated in dot plots. 
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Indeed, 98% of EpCAM+ TEC were successfully enriched via MACS using this 
approach, and were subdivided into cTEC, mTEC and non-TEC (i.e., Ly51-UEA-1-) 
populations representing 61%, 3% and 31.6% of the EpCAM+ cells, respectively (FIG. 
5.2B lower panel). Strikingly, the 10E4 mAb strongly labelled cell surface HS on both 
the sedimented (FIG. 5.3A) and the MACS-enriched (FIG. 5.3B) mTEC and cTEC 
populations. Furthermore, the sedimented preformed rosettes present in the cTEChi 
subpopulation, which most likely correspond to TNC, expressed the highest HS levels, 
whereas the non-TEC population (FIG. 5.2B lower panel) expressed little cell surface 
HS (FIG. 5.3C). 
 
 
 
	
FIG. 5.3: Heparan sulfate is highly expressed by thymic stromal cells. Representative 
fluorescence histograms depicting the background autofluoresence (grey histogram) and the 
binding of the anti-HS (10E4) mAb (open histogram) to thymic stromal cells enriched by (A) 1 
g sedimentation and (B) MACS as in FIG. 5.2. (C) Comparison of the expression of HS on the 
surface of various thymic stromal cell subsets, indicated by GMFI of anti-HS mAb-labelled 
cells minus the respective GMFI background autofluoresence in (A) and (B). Thymic stromal 
cells subset labelling as defined in FIG. 5.2B. Data in (C) are mean GMFI ± SD of triplicate 
samples. 
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5.3.2 The molecular basis of cTEC-thymocyte rosetting 
In Chapter 3 it was demonstrated that HS on the surface of erythrocytes facilitates 
autorosetting with DP thymocytes. Based on our findings that HS expression is evident 
in the thymic cortex where preformed thymic rosettes were prominent (FIG. 5.1), that 
cell surface HS is abundantly expressed by cTEC (FIG. 5.3) and that DP thymocytes, 
the main autorosetting population (FIG. 3.4), inhabit the thymic cortex alongside cTEC, 
it was hypothesised that cTEC can rosette with thymocytes ex vivo via the CD8-HS 
interaction. To test this hypothesis, the flow cytometry based autorosetting assay 
described in Chapter 3 was adapted to monitor rosetting between MACS-enriched 
thymic stromal cells and thymocytes in vitro.  
 
MACS-enriched stromal cells pre-labelled with fluorescently-conjugated anti-EpCAM 
and anti-Ly51 mAbs and lectin UEA-1 to delineate the different TEC subsets (FIG. 
5.2B), were mixed with CPD670 or CTV-labelled thymocytes (FIG. 5.4A), rosetting with 
TEC being depicted by the TEC acquiring the fluorescence profiles (CPD670 + or CTV+) 
of the labelled thymocyte, the rosetting threshold being the binding of ≥3 thymocytes 
per stromal cell. The cell mixtures were immediately analysed to determine 
%coincidence values or induced to rosette by brief centrifugation (200 g for 1 min) and 
incubation for 1 hr on ice before %uncorrected rosetting values were measured by flow 
cytometry (FIG. 5.4B). The true %rosetting values were then calculated by subtracting 
%coincidence (%C) from %uncorrected rosetting values (%Rraw). As predicted, cTEC, 
which express high levels of cell surface HS displayed a much higher level of rosetting 
with thymocytes (79.2%) than non-TEC (9.9%) that carry little cell surface HS (FIG. 
5.4C).  
 
In Chapter 3 it was shown that CD8 binds to HS to mediate autorosetting, whereas an 
earlier study implicated CD4 molecules in TEC-thymocyte rosetting in vivo (Oliveira-
dos-Santos et al., 1998). Thus, CD8α.KO, CD8β.KO, CD4.KO, and CD4/CD8β.KO 
thymocytes were tested for their ability to rosette with MACS-enriched cTEC, both in 
terms of the percentage of cTEC rosetting with thymocytes and the number of 
thymocytes bound per cTEC. Compared to WT thymocytes, rosetting by CD8β.KO 
thymocytes was partially and significantly reduced, whereas CD8α.KO thymocytes 
were the weakest to rosette with cTEC, thus confirming that CD8α and CD8β markedly 
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FIG. 5.4: Fluorometric assay for detection of thymocytes rosetting with thymic stromal 
cells. Equal volumes (50 µL) of MACS-enriched stromal cells (5x106 cells/mL) and CPD670 
labelled thymocytes (5x107 cells/mL) were mixed and either immediately analysed by flow 
cytometry to measure ‘coincidence’ or induced to rosette by brief centrifugation (200 g, 1 min) 
and incubation on ice for 60 min, prior to evaluation by flow cytometry, i.e., stromal cells 
acquiring CPD670 fluorescence. (A) Gating of rosetting thymic stromal cells. After 
discriminating viable cells from dead and cellular debris (P1), PE-Cy7-EpCAM labelled stromal 
cells were identified (P2) and subdivided into non-TEC (P3) and cTEC (P4) populations based 
on binding of the UEA-1 lectin and Ly-51 cell surface expression, as defined in FIG. 5.2B. (B) 
Representative fluorescence histograms depicting rosetting (open black histograms) and 
coincidence (grey histograms) for non-TEC and cTEC. Fluorescence histogram (open red) of 
CPD670 thymocytes alone is depicted. Gate includes thymic stromal cells associating with ≥3 
thymocytes. True rosetting values represent %Rraw - %C, i.e., non-TEC-thymocyte rosetting 
(15.3% - 0.2%) = 15.1%; cTEC-thymocyte rosetting (82.7% - 3.5%) = 79.2% in example shown. 
(C) Percentage (%) of rosetting non-TEC and cTEC, with data being mean % rosetting ± SD of 
triplicate samples. 		
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FIG. 5.5: Thymocyte CD4 and CD8 molecules, cTEC MHC and sulfated polysaccharides 
contribute to rosetting between cTEC and syngeneic thymocytes. All data presented as 
either percentage of cTEC rosetting with thymocytes (left y-axis) or the number of thymocytes 
bound per cTEC (right y-axis). (A) Comparison of the ability of WT, CD4.KO, CD8β.KO, 
CD4/CD8β.KO and CD8α.KO thymocytes to rosette with WT cTEC. (B) Comparison of the 
ability of the sulfated polysaccharides heparin and DxS (5 and 500 kDa, 100 µg/mL, pre-
incubated for 30 min) to inhibit rosetting between cTEC and thymocytes. NS, not significant. **, 
P < 0.01. ***, P < 0.001 (1-Way ANOVA with Tukey’s multiple comparisons test). (C) 
Comparison of the ability of WT and MHC-I/II.KO cTEC to rosette with WT thymocytes, in 
the absence or presence of heparin (100 µg/mL). NS, not significant. **, P < 0.01. ***, P < 
0.001 (1-Way ANOVA with Dunnett’s multiple comparisons test for within strains and 2-Way 
ANOVA with Bonferroni multiple comparisons test between WT and MHC-I/II.KO strains). 
Rosetting assays performed as in FIG. 5.4. Number of thymocyte bound per cTEC determined 
by dividing median fluorescence CPD670+ cTEC (gated to include ≥1 thymocyte per cTEC) with 
GMFI CPD670 of individual thymocyte. Data are mean % cTEC rosetting and median number of 
thymocyte bound cTEC ± SD of triplicate samples. 			
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FIG. 5.6: Synergistic contributions of MHC and HS on cTEC to thymocyte rosetting 
capacity. (A) Representative fluorescence histograms depicting number of thymocytes (3 - ≥10) 
rosetting with WT (black line) and MHC-I/II.KO (red line) cTEC, in the absence (top panel) or 
presence of heparin (100 µg/mL) (bottom panel). Gate depicts cTEC binding ≥3 thymocytes, 
with % of WT (black values) or MHC-I/II.KO (red values) cTEC rosetting values indicated. 
Thymocytes were pre-incubated with heparin (100 µg/mL) on ice for 30 min before being 
examined for rosetting with cTEC. (B) Percentage of WT (black line) or MHC-I/II.KO (red line) 
cTEC rosetting with 3-≥10 thymocytes in the absence (Control) or presence of heparin (100 
µg/mL). NS, not significant. *, P < 0.05. **, P < 0.01. ***, P < 0.001. ****, P < 0.0001 (2-Way 
ANOVA with Bonferroni multiple comparisons test between WT and MHC-I/II.KO strains). 
Data are mean % cTEC rosetting ± SD of triplicate samples. 
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contribute to thymocytes-cTEC rosetting. Despite CD4.KO thymocytes rosetted 
normally with cTEC, the extent of rosetting by CD4/CD8β.KO thymocytes was 
significantly lower than CD8β.KO thymocytes and comparable to the rosetting by 
CD8α.KO thymocytes (FIG. 5.5A). Collectively, these data indicate that CD8β is a key 
rosetting receptor on thymocytes, with CD8α and CD4 making relatively minor 
contributions to the interaction. 
 
As the treatment of MACS-enriched stromal cells with HS-degrading enzymes (i.e., 
HPSE and HPNSE) resulted in low viability of the treated cells (data not shown), the 
direct contribution of HS on the cTEC surface to cTEC-thymocyte rosetting could not 
be assessed. The sulfated polysaccharides heparin and DxS (5 and 500 kDa) were 
shown in Chapter 3 to mimic HS by binding to CD8 and inhibiting erythrocyte 
autorosetting (FIG. 3.8A and FIG. 3.10). Hence, the role of HS in cTEC-thymocyte 
rosetting was indirectly examined based on rosetting inhibition by these HS mimetics. 
Thymocytes were pre-treated heparin and DxS (5 and 500 kDa) at 100 µg/mL before 
being induced to rosette with MACS-enrich stromal cells. Remarkably, DxS500 kDa 
almost completely inhibited cTEC-thymocyte rosetting, whereas heparin and DxS5 kDa 
were partially and significantly inhibitory (FIG. 5.5B). These data are consistent with 
the hypothesis that HS is the key ligand facilitating cTEC-thymocyte rosetting. 
 
The MHC molecules on stromal cells have been previously implicated in the 
multicellular conjugation between TEC and thymocytes (Bousso et al., 2002, Hare et 
al., 2003). Also, earlier observations from the Parish Laboratory have demonstrated that 
MHC can regulate autorosetting (Sia and Parish, 1980a, Sia and Parish, 1980b). Thus, 
to investigate if MHC molecules on the cTEC surface contribute to cTEC-thymocyte 
rosetting, the extent of rosetting between WT (i.e., cTECWT) or MHC class I and II-
deficient cTEC (i.e., cTECMHC-I/II.KO) and thymocytes was evaluated. It was found that 
cTECWT and cTECMHC-I/II.KO were equally effective at forming rosettes with thymocytes, 
implying that MHC plays a minor role in cTEC-thymocyte rosetting. In parallel, 
thymocytes were pre-treated with heparin (100 µg/mL) before being induced to rosette 
with cTECWT or cTECMHC-I/II.KO to evaluate the contribution of MHC to the process 
when cTEC HS recognition is blocked. Strikingly, in the presence of heparin, the 
percentage of cTECMHC-I/II.KO rosetting with thymocytes was substantially lower than 
with cTECWT, being 17.3% and 34.5% rosetting, respectively (P < 0.01) (FIG. 5.5Ci). 
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Furthermore, a detailed cytofluorometric analysis revealed that the absence of MHC on 
cTEC reduced the number of thymocytes bound per cTEC despite cTECWT and 
cTECMHC-I/II.KO exhibiting a comparable percentage of cTEC rosetting with thymocytes 
(FIG. 5.5Cii 5.6). Similarly, the presence of heparin reduced the number of thymocytes 
bound per cTEC, this effect being further enhanced by the absence of MHC on cTEC 
(FIG. 5.5Cii and 5.6). Collectively, these results corroborate the finding that HS is the 
key rosetting ligand on cTEC, with the expression of MHC on cTEC stabilising 
thymocyte binding. 
5.3.3 Functional significance of cTEC-thymocyte rosetting 
In addition to MHC aiding thymocytes adhesion to TEC, it is also generally believed 
that MHC is responsible for the Ca2+ mobilisation observed in thymocytes interacting 
with cTEC during positive selection (Hare et al., 2003, Bhakta et al., 2005). However, 
data from previous studies (Tellam and Parish, 1987, Weston et al., 1991) and recent 
observations (Chapter 4) indicate that HS mimetics are able to trigger a sustained Ca2+ 
flux in DP thymocytes that is CD8-dependent. Hence, with HS and MHC on the cTEC 
surface and CD8 molecules on thymocytes contributing to cTEC-thymocyte rosetting, 
the relative importance of cTEC HS and MHC in the induction of a Ca2+ flux in 
thymocytes bound to cTEC was examined. To answer this question, CTV-labelled 
thymocytes were pre-loaded with intracellular Ca2+ indicator dyes (Fura-Red and Fluo-
4) before being induced to rosette with WT or MHC-I/II.KO MACS-enriched stromal 
cells at 4°C or 37°C, the increase in intracellular Ca2+ being detected by elevated Fura-
Red/Fluo-4 ratios monitored by flow cytometry.  
 
Initially, it was found that rosetting of thymocytes with cTECWT and cTECMHC-I/II.KO 
occurred rapidly (<5 min) and at comparably high levels at both 4°C and 37°C, thus 
confirming that cTEC-thymocyte rosetting is primarily an energy-independent process 
(FIG. 5.7A). 
 
As expected, intracellular Ca2+ levels remained low in non-rosetting thymocytes both at 
4°C and 37°C, providing the baseline Ca2+ level for thymocytes (FIG. 5.7B). 
Interestingly, rosetting thymocytes displayed a noticeable and sustained increase in their 
intracellular Ca2+ levels following 5, 10 and 30 min incubation at 4°C, a response that	
was markedly augmented at 37°C. 
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FIG. 5.7: Rosetting between thymocytes and cTEC induces a prolonged Ca2+ flux in 
thymocytes. (A) Analysis of rosetting between thymocytes and WT and MHC.KO cTEC after 
co-incubation for 5, 10 and 30 min, at 4°C and 37°C, respectively. Thymocytes (Fluo-4/Fura-
Red-loaded, CTV-labelled) and EpCAM+-enriched thymic stromal cells (4°C or 37°C) were 
mixed at a 10:1 thymocytes/stromal cell ratio and immediately examined by flow cytometry or 
induced to rosette, at 4°C or 37°C, respectively. Following 5, 10 and 30 min co-incubation, % 
thymocytes rosetting with cTEC was quantified by flow cytometry as in FIG. 5.4. Data are 
mean % cTEC rosetting ± SD of triplicate samples. (B) Analysis of Ca2+ flux in thymocytes 
rosetting with WT and MHC-I/II.KO cTEC after co-incubation for 5, 10 and 30 min, at 4°C and 
37°C, respectively. At each time point, a 30 sec snapshot of Ca2+ flux, depicted by real time 
GMFI ratios of Ca2+-bound Fluo-4 (530 nm) over Ca2+-unbound Fura-Red (695 nm) in rosetting 
and non-rosetting thymocytes, was measured by flow cytometry. Data are GMFI Fluo-4/Fura-
Red ratios ± SD of triplicate samples. (C) Effect of heparin (100 µg/mL) on Ca2+ flux in 
thymocytes bound to WT and MHC.KO cTEC after 10 min co-incubation at 37°C. (D) Analysis 
of Ca2+ flux in WT and CD8α.KO thymocytes bound to WT and MHC.KO cTEC after 10 min 
co-incubation at 37°C. Data are GMFI Fluo-4/Fura-Red ratios ± SD of triplicate samples. In (C) 
and (D) *, P < 0.05. **, P < 0.01. ***, P < 0.001. ****, P < 0.0001 (1-Way ANOVA with 
Tukey multiple comparisons test for within strains and 2-Way ANOVA with Bonferroni 
multiple comparisons test between WT and MHC-I/II.KO strains).  
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Furthermore, the overall magnitude and kinetics of the intracellular Ca2+ rise was 
accentuated in thymocytes rosetting with cTECWT, compared to cTECMHC-I/II.KO (FIG. 
5.7B), implying that MHC not only aids rosetting, but substantially enhances Ca2+ 
mobilisation in rosetting thymocytes. 
 
Since CD8 and HS (FIG. 5.5A and B) are key mediators of cTEC-thymocyte rosetting, 
their contribution to the Ca2+ flux in thymocytes bound to either cTECWT or cTECMHC-
I/II.KO for 10 min at 37°C was evaluated. The addition of heparin (100 µg/mL) 
significantly reduced the Ca2+ flux in thymocytes bound to both cTECWT and cTECMHC-
I/II.KO, consistent with HS making a contribution to the rosette-mediated Ca2+ flux that is 
independent of the MHC (FIG. 5.7C). Moreover, the lack of CD8 on thymocytes 
resulted in these cells giving a markedly reduced Ca2+ flux upon rosetting with both 
cTECWT and cTECMHC-I/II.KO, indicating that CD8 can act as both a key thymocyte 
rosetting receptor and a key contributor to the rosette-induced Ca2+ flux, independent of 
the contribution of the MHC to the Ca2+ flux (FIG. 5.7D). Collectively, these data 
indicate that the CD8-HS interaction plays a key role in initiating and sustaining the 
Ca2+ flux observed in thymocytes following their rosetting with cTEC.  
 
5.4 Discussion 
In previous Chapters it was shown that the CD8-HS interaction mediates the 
autorosetting phenomenon observed between DP thymocytes and erythrocytes (Chapter 
3) and that the ligation of CD8 by a HS mimetic triggers a sustained Ca2+ flux that 
lowers the threshold for TCR-mediated activation of DP thymocytes (Chapter 4). 
However, the physiological relevance of this CD8-HS interaction in the development of 
thymocytes needed to be clarified. In this Chapter the key findings were: (i) HS is 
ubiquitously expressed in the thymic cortex, particularly by multicellular complexes 
resembling TNC, (ii) flow cytometry studies established that cTEC express high levels 
of cell surface HS and revealed that these cells very efficiently rosette with thymocytes 
ex vivo, (iii) rosetting between cTEC and thymocytes is substantially blocked by HS 
mimetics and, based on studies with KO mice, is dependent on CD8β and, to lesser 
extent, CD8α and CD4 expression by thymocytes and on MHC on the surface of cTEC 
and, finally, (iv) cTEC-thymocyte rosetting triggers a sustained Ca2+ flux in the 
rosetting thymocytes that is HS, CD8 and MHC-dependent.  
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Initial in situ analysis of murine thymic sections revealed the presence of HS in the 
cortex and intense labelling of multicellular structures (FIG. 5.1), resembling TNC 
(Wekerle and Ketelsen, 1980, Wekerle et al., 1980, Kyewski et al., 1982, Li et al., 1992, 
Oliveira-dos-Santos et al., 1997, Oliveira-dos-Santos et al., 1998, Nakagawa et al., 
2012), which have been previously reported to express high levels of highly sulfated 
cell surface HS (Werneck et al., 2000). Subsequent phenotypic studies of preformed 
rosettes in thymocyte suspensions sedimented at unit gravity indicated that they 
predominantly contain cTEC. However, the enrichment of preformed rosettes by the 
sedimentation method is relatively non-selective, which may explain why only 32% of 
the sedimented cells were epithelial (EpCAM+) cells, cTEC being enriched alongside 
larger and denser non-rosetting cells and also rosettes formed by non-cTEC stromal 
cells, including mTEC and also non-TEC, such as thymic DC and macrophages 
(Brelinska et al., 1986, Shortman et al., 1989) (FIG. 5.2). Also, thymocytes released 
from preformed rosettes could lead to dilution of EpCAM+ cells in the cell suspensions. 
Importantly, flow cytometric examination of preformed rosettes by mTEC and cTEC, 
particularly cTEChi revealed high expression of cell surface HS (FIG. 5.3C). 
Presumably, cTEChi represent the multicellular structures present in the thymic cortex 
that stain strongly for HS and resemble TNC (FIG. 5.1 lower left panel), although this 
needs further experimental confirmation.  
 
It has been reported previously that the HS produced by cTEC abundantly express 6-O-
sulfate groups in its highly sulfated regions (Werneck et al., 1999) and in Chapter 3 it 
was demonstrated that the 6-O-sulfate groups of heparin are essential for heparin to 
inhibit CD8-mediated autorosetting (FIG. 3.8D). Such findings are consistent with CD8 
on DP thymocytes binding to HS rich in 6-O-sulfate groups on cTEC. Indeed, the data 
shown in this Chapter reveal a strong link between high levels of surface HS on cTEC 
(FIG. 5.3) to the ability of cTEC to rosette with thymocytes ex vivo (~80% rosetting), in 
an energy-independent manner (4°C) (FIG. 5.7A), as opposed to non-TEC, in which the 
low levels of surface HS is associated with low rosetting values (<10% rosetting) (FIG. 
5.4C). Unfortunately, the direct contribution of surface HS on cTEC to cTEC-
thymocyte rosetting could not be determined, as HPSE and HPNSE treatments appeared 
detrimental to TEC survival (data not shown). However, the striking ability of HS 
mimetics to inhibit cTEC-thymocyte rosetting, particularly the total inhibition of 
rosetting by DxS500 kDa, indirectly implicates HS as a key player in the process (FIG. 
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5.5B). Heparin and DxS5 kDa were only partially inhibitory probably due to their lower 
molecular weight resulting in a lower ability to bind multivalently to CD8 molecules on 
thymocytes than DxS500kDa and compete against an array of highly charged HS chains 
present on cTEC surfaces. Future studies should be aimed at modifying the structure of 
HS on cTEC by genetic means, especially preventing the 6-O-sulfation of HS chains, 
and observing the impact that this has on cTEC-thymocyte rosetting.  
 
Whilst earlier reports have shown that MHC molecules expressed at high levels by 
cTEC (Wekerle and Ketelsen, 1980, Yang et al., 2006) are crucial for cTEC to form 
multicellular conjugates with thymocytes (Hare et al., 2003), in this Chapter it was 
demonstrated that HS-mediated rosetting could occur in the absence of MHC molecules 
(FIG. 5.5Ci). The presence of MHC, however, markedly accentuated the number of 
thymocyte bound to each cTEC, thus establishing the additive contributions of HS and 
MHC on cTEC to expanding thymocyte rosetting capacity (FIG. 5.5Cii and 5.6). Thus, 
it appears likely that MHC stabilises rosettes via peptide-loaded MHC interacting with 
cognate TCR or non-cognate CD4/CD8 molecules on thymocytes, with cTEC HS 
securing rosettes by interacting with CD8 on thymocytes. In fact, an attractive 
hypothesis is that the CD8-HS interaction ensures that DP thymocytes are selectively 
targeted to cTEC, the subsequent TCR-MHC interactions with cTEC determining T cell 
fate. 
 
In addition to cTEC MHC recognition by TCR, it is also possible that other thymocyte 
cell surface receptors could bind HS and contribute to cTEC-CD8α.KO thymocyte 
rosetting (FIG. 5.5A). Speculatively, these molecules could be CD2 (Parish et al., 
1988b), CD4 (Parish et al., 1990, Parish and Warren, 1991) CD45 and CD90 (Parish et 
al., 1988a), all four molecules having been shown to react with polyanions resembling 
HS. Also, the cell adhesion molecules CD44 and LFA-1 have been previously 
implicated in thymic rosetting in vivo (Oliveira-dos-Santos et al., 1998).  
 
In Chapter 4 the functional significance of the CD8-HS interaction was investigated and 
shown to activate a sustained Ca2+ flux in DP thymocytes, this process being associated 
with a lowering of the threshold required for TCR mediated activation. In this Chapter, 
in addition to their substantial role in cTEC-thymocyte rosetting, HS (FIG. 5.7C) and 
CD8 (FIG. 5.7D) were shown to contribute to the induction of a Ca2+ flux in thymocytes 
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bound to cTEC (FIG. 5.7B). Heparin, however, unlike DxS500kDa could only partially 
block cTEC-thymocyte rosetting (FIG. 5.5B), which may explain why there was still a 
considerable Ca2+ flux in the presence of heparin. Thus, the impact of altering the 
structure of cTEC HS, as discussed above, is paramount to unequivocally establishing 
the contribution of cTEC HS to rosette-mediated Ca2+ mobilisation. Similarly, whilst 
CD8 plays a key role in thymocyte adhesion to cTEC, other thymocyte cell surface 
molecules, as described above, which could bind HS may be responsible for the residual 
Ca2+ flux observed in rosetting CD8α.KO thymocytes.  
 
In summary, the experimental data presented in this Chapter establishes the 
physiological relevance of the CD8-HS interaction in the heterotypic interaction 
between cTEC and DP thymocytes in the thymic cortex during the process of MHC-
restricted positive selection. Our current in vitro rosetting model proposes that CD8β 
and, to a lesser extent, CD8α on thymocytes interact with HS on cTEC to initiate 
thymocyte adhesion to cTEC. In parallel, MHC on cTEC stabilises the interaction, 
presumably via TCR and CD8/CD4 recognition.  Both MHC and HS recognition on 
cTEC independently initiate rises in intracellular Ca2+ concentrations in DP thymocytes, 
the CD8-HS interaction being particularly effective in this regard. Combined with data 
presented in Chapter 4 demonstrating that the CD8-HS interaction lowers the TCR-
mediated activation threshold in thymocytes, future studies should be aimed at 
confirming that this interaction controls selection of the TCR repertoire in DP 
thymocytes. 
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Final Discussion and Future Directions 
 
 
 
 
 
 
 
 
This Chapter provides a summary and a general discussion of the key findings 
described in Chapters 3, 4 and 5 and how this information is likely to fit into current 
concepts of T lymphocyte development and function, and impact on future research 
directions.  
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6.1 Introduction 
HS is a highly acidic linear polyanionic carbohydrate with a very variable structure. It is 
ubiquitously expressed on cell surfaces and in the ECM/BM of tissues. Synthesised 
attached to various core proteins to form HSPGs, HS is able to interact with various 
proteins and exert diverse functions. In Chapter 1 a bioinformatic analysis of 
mammalian proteins that express a heparin/HS-binding motif and are associated with 
the immune system identified 235 candidate proteins, a noticeable proportion located 
intracellularly. This simple analysis suggests HS interacts with many more components 
of the immune system than previously realised. Numerous studies have also directly 
shown that HS plays multiple prominent functional roles in the immune system, these 
include its ability to regulate leukocyte development, leukocyte migration, immune 
activation and inflammatory processes (Simon Davis and Parish, 2013). This Thesis 
provides evidence that HS also plays an important role in T cell development in the 
thymus. 
 
In summary, the key findings of this Thesis are: 
a) The CD8 heterodimer on DP thymocytes binds to highly sulfated (particularly 6-
O-sulfate rich) HS on cell surfaces, mainly via the CD8β chain of the CD8 
molecule. Developmentally linked α2-3 sialylation of CD8 on CD8 SP 
thymocytes and peripheral CD8+ T lymphocytes inhibits this interaction, with 
circulating HRG further regulating the CD8-HS interaction in the periphery by 
masking cell surface HS – Chapter 3. 
b) HS-like molecules trigger a sustained, CD8-, Slp76-dependent and Zap70-
independent, influx of extracellular Ca2+ into DP thymocytes but not other 
thymic or peripheral T cell populations, this influx being accompanied by a 
lowering of the anti-CD3-mediated activation threshold of the DP thymocytes. 
Enzymatic desialylation, however, restores the HS-induced Ca2+ flux in 
peripheral CD8+ T lymphocyte, a population that otherwise is non-responsive to 
HS – Chapter 4. 
c) Collectively, these data indicate that the HS-CD8 interaction facilitates the 
adhesion of DP thymocytes to cTEC and initiates a Ca2+ flux in the adherent 
thymocytes that lowers the threshold required for positive selection of DP 
thymocytes. – Chapter 5. 
 
Final Discussion & Future Directions 
	 117 
6.2 CD8-HS interaction: important structural consideration 
6.2.1 Location of HS binding site on CD8 molecule 
To the best of our knowledge, this study is the first to reveal a functional relationship 
between CD8 molecules and cell surface HS. This is rather an unexpected finding as 
CD8β is absent from the list of hypothetical heparin/HS-binding proteins identified by a 
bioinformatic approach (Chapter 1, Simon Davis and Parish, 2013), although HS-
binding sites that are dependent on the tertiary structure of proteins rather than linear 
amino acid sequences would not be detected by this approach (Table. 1.1). However, a 
lysine-rich and possible ‘HS-binding’ motif is located in the CD8β stalk region and 
potentially could provide the required electrostatic charge to bind HS, i.e., sequence 
146-156, motif: KKTTLKMKKK (mouse) and sequence 146-156: KKSTLKKRVCR 
(human). The mouse sequence of basic residues would not have been detected by the 
bioinformatic search that was undertaken in Chapter 1. Also, it should be noted that 
CD8β is positioned proximal to the TCR and the location of the putative ‘HS-binding’ 
motif in the stalk region means it is independent of the MHC-Iα3 binding domain of 
CD8β (Wang et al., 2009, Rettig et al., 2009) and consistent with CD8β being able to 
bind HS and MHC-I simultaneously. Moreover, CD8α very weakly binds HS, possibly 
due to the lack of apparent clusters of basic residues to suggest a potential HS-docking 
site. Hypothetically, basic residues in the stalk of CD8α could contribute to the CD8β 
HS binding site or, in CD8β deficient mice, form a weak HS binding site in the CD8αα 
homodimer. Only solving the 3D-structure of a desialylated CD8αβ-HS complex will 
resolve this intriguing issue. 
6.2.2 Sialylation of the CD8 molecule 
The stalk region of the CD8β chain on mature T lymphocytes is heavily O-glycosylated 
at multiple sites and this is thought to control its coreceptor functions (Rudd et al., 
2001). The ST3Gal-1 sialyltransferase catalyses the α2-3 sialylation of core 1-O-glycan 
Galβ1-3GalNAc structures, converting them into Siaα2-3Galβ1-3GalNAc 
glycoconjugates (Pereira et al., 1976, Kono et al., 1997, Moody et al., 2003). The 
developmentally controlled α2-3 O-sialylation of CD8β involves the expression of the 
non-sialylated CD8β glycoform on DP thymocytes and the sialylated form on CD8 SP 
and peripheral CD8+ T lymphocytes, an expression pattern that strongly correlates with 
the reduced affinity of CD8αβ for MHC-I molecules (Moody et al., 2001, Moody et al., 
2003, Daniels et al., 2001). In this study, the pattern of O-sialylation of developing 
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thymocytes matched these earlier reports, based on differential PNA (specific for 
exposed Galβ1-3GalNAc residues) and MAL-II (specific for α2-3 sialic acid residues) 
labelling of thymocyte subsets and peripheral CD8+ T lymphocytes (FIG. 3.11A and B), 
with sialylation strongly correlating with decreased HS binding by CD8 SP thymocytes 
and peripheral CD8+ T lymphocytes (FIG. 3.11C and D). Thus, α2-3 sialylation of 
CD8β confers a developmental switch on the CD8β-HS interaction, probably the 
negative charge of the attached sialic acid residues interfering with the recognition of 
the negatively charged HS. Furthermore, ST3Gal-1 is known to catalyse α2-3 
sialylation of core 1-O-glycans attached to threonine/serine residues in the stalk region 
of the CD8β chain i.e., sequence 141-149: TTAPTKKTT (mouse) and sequence 140-
149: TTAQPTKKST (human), that overlap the predicted HS-binding motif.  
 
In the periphery ST3-Gal-1-catalysed α2-3 O-sialylation of CD8αβ raises the threshold 
required to activate peripheral CD8+ T lymphocytes. During an immune response, 
however, it is possible that O-glycosialylation is reversed via cessation of ST3Gal-1 
function or via sialidase-mediated desialylation of core 1-O-glycans (FIG. 3.11A and 
B). Such a process would restore the ability of CD8αβ to bind to both MHC-I (Priatel et 
al., 2000) and HS (FIG. 4.11 and FIG. 3.12), hence lowering the activation threshold 
required for T cell activation. However, when the immune stimulus declines, ST3Gal-1 
catalytic function could be resumed to prevent cell death via apoptosis. In fact, it has 
been proposed that the resialylation of the CD8αβ heterodimer, combined with other 
signals, such as IL-7 (Kimura et al., 2013), promotes the survival and differentiation of 
peripheral CD8+ T lymphocytes into memory T cells (Priatel et al., 2000).  
 
Plasma HRG is abundant in the circulation (~100-200 µg/ml) and can strongly bind to 
HS (Lane et al., 1986, Lijnen and Collen, 1989, Poon et al., 2011). Also, HRG is a 
negative acute phase protein and, thus, its normal plasma concentration plummets 
during inflammation and recovers to normal physiological levels as inflammation 
subsides (Saigo et al., 1990). HRG readily inhibits CD8-mediated autorosetting (FIG. 
3.14) by masking HS on erythrocytes suggesting that it has a higher affinity for HS than 
the CD8αβ molecule. Thus, in addition to the regulatory role of CD8 O-sialylation, 
HRG may also prevent CD8 interacting with HS, particularly on APCs, particularly in 
the absence of immune activation. In the event of T cell activation during an infection, 
however, CD8αβ could be desialylated and HRG levels drop, thus, the ability of the 
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CD8αβ heterodimer to recognise HS and MHC-I is restored. Conversely, as the immune 
stimulus subsides, it is likely that increasing concentrations of circulating HRG prevent 
HS from binding to the ‘HS-binding’ motif of CD8. Thus, a combination of ST3-Gal-1 
catalysed α2-3 sialylation of the CD8αβ heterodimer and the masking of cell surface HS 
on APCs by HRG ensures the tight regulation of CD8-HS interaction in the periphery.  
6.2.3 Does CD4 interact with HS? 
It is unclear whether CD4 binds HS although it has been reported that CD4 carries a 
prominent polyanion-binding pocket (Parish and Warren, 1991). Certainly, CD4 
deficiency had no effect on the autorosetting of DP thymocytes (FIG. 3.5C) or the 
binding of FITC-heparin to thymocytes (FIG. 3.10), although any effect of CD4 could 
be masked by the strong interaction of CD8 with HS. In fact, CD4 appeared to 
contribute to HS-mediated TEC-thymocytes rosetting in the absence of CD8β (FIG. 
5.5A). Thus, it is possible that CD4 binds HS very weakly in a similar manner to the 
CD8α-HS interaction. A provocative hypothesis is that CD8αβ binds to linear sequences 
of monosaccharides in HS chains, analogous to an endoglycosidase, whereas CD4 
recognises terminal sugars of HS chains, analogous to exoglycosidases (Parish C.R. 
pers. comm.). If this hypothesis is correct there would be much fewer binding sites for 
CD4 than for CD8 in cell surface HS or in soluble heparin, which may explain the 
weaker interaction of CD4 with these molecules. Tetramers of heparin, prepared with 
heparin biotinylated at the reducing terminus and fluorescent streptavidin, could be used 
to test this hypothesis, i.e., the tetramer should bind strongly to DP thymocytes from 
CD8α deficient mice, a binding blocked by anti-CD4 mAbs. 
 
6.3 Implications of CD8-HS interaction: the big perspective 
The functional relevance of the CD8-HS interaction goes beyond it being a cell 
adhesion process that enhances the interaction between thymocytes and cTEC. As 
hypothesised above, HS is likely to bind strongly to the stalk region of the CD8β chain 
of the CD8αβ heterodimer to trigger a sustained influx of extracellular Ca2+ into DP 
thymocytes (FIG. 4.1). This activation event is unlikely to occur via the conventional 
TCR signalling pathway, as the Zap70 molecule was shown to be dispensable whilst 
downstream Slp76 was required (FIG. 4.4). Intriguingly, the unique signal induced by 
the CD8-HS interaction synergises with the TCR signal following anti-CD3ε mAb 
stimulation to lower the anti-CD3ε level required to activate DP thymocytes (FIG. 4.6). 
 
Chapter 6 
	 120 
In fact, it was shown that both HS-derived and MHC-derived signals contributed to the 
steady and sustained Ca2+ influx observed in thymocytes rosetting with cTEC (FIG. 
5.7). It is unknown if recognition of HS by CD8 directly enhances TCR signalling 
pathways or independently promotes the activation of transcription factors that are 
targeted by TCR signals. Hypothetically, HS may cross-link CD8 to LFA-1 and/or 
α4β1/VLA-4 to trigger a Slp-76-dependent ‘outside-in’ signals in T lymphocytes (Cimo 
et al., 2013, Baker et al., 2009). Whatever the biochemical explanation, it is likely that 
the CD8-HS interaction plays a crucial role in several phases of TCRαβ T lymphocyte 
development, selection and immune activation (FIG. 6.1).  
6.3.1  Role of CD8-HS interaction in positive selection 
TCR signals delivered by unique thymic stromal cells play a critical role in thymocyte 
development (FIG. 1.6). This study provided lines of evidence for the involvement of 
HS in T cell development, particularly at the DP stage, in which the tight interaction 
with cTEC is imperative for the positive selection of DP thymocytes (FIG. 1.5). It is 
important that pre-selection DP thymocytes gain a productive TCR signal to avoid death 
by neglect, and this requires TCR-self-peptide/MHC recognition, alongside CD8/CD4-
MHC binding to generate MHC-restriction in TCRαβ T lymphocytes (FIG. 1.7) (Van 
Laethem et al., 2007, Van Laethem et al., 2013). In the event that a pre-selection DP 
thymocyte expresses a ‘useless’ nascent TCR that fails to recognise self-peptide/MHC 
on cTEC, the ligation of CD8 by HS is likely to deliver a Ca2+ flux that augments the 
deletion of this clone by death by neglect (FIG. 6.1A). This outcome is in agreement 
with the ‘death by instruction’ model proposed by Grebe et al. (2004), albeit via an ill-
defined downstream signal induced in thymocytes by anti-CD8α and anti-CD8β mAbs 
or by MHC-I mediated CD8 ligation/cross-linking (Grebe et al., 2004). Thus, to survive 
and be positively selected, TCR on pre-selection DP thymocytes need to recognise with 
low affinity unique peptides generated in cTEC by the thymoproteosome β5t (MHC-I 
restricted peptides) (Sasaki et al., 2015) or cathepsin-L/TSSP (MHC-II restricted 
peptides) (Nakagawa et al., 1998, Honey et al., 2002, Gommeaux et al., 2009).  
 
In addition, Daniels et al. (2006) showed that CD8 substantially aids the ability of TCRs 
to bind to low affinity positive selecting self-peptide/MHC-I complexes (Daniels et al., 
2006). In this regard, the dual functionality of CD8 to bind simultaneously MHC-I and 
HS on cTEC (FIG. 6.1B) would increase the probability of low affinity TCRs being 
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positively selected. Also, it is likely that by working independently of the initial TCR 
signalling pathway, the HS-induced Ca2+ influx may augment pathways that favour 
positive selection. For example, the increase in intracellular Ca2+ could sensitise the 
ERK/AP-1 and Ca2+/NFAT pathways without involving the robust positive feedback 
loop arising from membrane localisation of the Grb2-Sos complex (FIG. 1.6) (Daniels 
et al., 2006), in a similar manner to the contribution of Tespa1 (Wang et al., 2012). 
Therefore, in the presence of a TCR signal, the CD8-HS interaction may lower the 
threshold for positive selection of low affinity TCR clones and simultaneously reduce 
the number of cells dying by neglect. This is evident with the formation of TNCs in the 
cortex (FIG. 1.5 and FIG. 5.1), with Nakagawa et al. (2012) proposing that TNC 
formation is due to the persistent interaction between cTEC and thymocytes that are 
given a ‘second’ chance to rearrange their TCRα chains (Nakagawa et al., 2012). In this 
‘facilitated’ selection process, it is not surprising that cTEC adjust weak TCR signals 
generated by nascent TCRs by offering additional aids such as Ca2+ signalling generated 
by the CD8-HS interaction, a speculation matched by the noticeably higher cell surface 
expression of HS on cTEC in TNCs (FIG. 5.1 and FIG. 5.3). It should be noted, 
however, that TNCs are not prominent in ‘tailored-affinity’ transgenic TCR strains, 
including the OT-I (OVA-specific) and P14 (LCMV-specific) TCR clones (Nakagawa 
et al., 2012), perhaps as such homogenous self-sufficient TCR pools are less reliant on 
HS-induced Ca2+ fluxes to undergo positive selection.  
6.3.2 Role of CD8-HS interaction in negative selection 
In a similar manner to positive selection, the CD8-HS interaction is likely to aid the 
deletion of potentially autoreactive TCR clones by negative selection. SIRPα+CD8α- 
migratory DCs present blood-borne self-antigens from the periphery to DP thymocytes 
(FIG. 1.5) (Baba et al., 2009, McCaughtry et al., 2008). It should be noted that, 
compared to the low affinity positive-selecting TCR ligands generated by cTEC, many 
of the ubiquitous self-antigens presented on other APCs are likely to be recognised with 
relatively high affinity by nascent TCRs (Klein et al., 2009, Klein et al., 2014). It should 
be noted that DCs express cell surface HS at high levels, similar to cTEC (unpublished 
lab observation), that may augment TCR binding to self-peptide/MHC complexes on 
DCs and promote the recruitment of RasGRP1 to the membrane-bound pLAT complex 
to accentuate the Ras/ERK cascade (FIG. 1.6) (Daniels et al., 2006, Kortum et al., 
2013). 
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FIG. 6.1. Predicted implications of the CD8-HS interaction for intrathymic MHC-I-
restricted TCRαβ CD8+ T lymphocyte development and function. (A) Death by neglect. 
‘Useless’ TCRs fail to bind self-peptide/MHC-I on cTEC. CD8αβ-HS interaction induces a 
Ca2+ flux that enhances apoptosis of pre-selection DP thymocytes. (B) Positive selection. 
HS enhances TCR/CD8 binding to low affinity (β5t-generated) self-peptide/MHC-I 
complexes on cTEC. HS-induced Ca2+ influx augments weak TCR signals to lower the 
threshold required for positive selection. The ion channel that mediates the HS-induced 
influx of extracellular Ca2+ is unknown. (C - D) Negative selection. (C) HS enhances 
TCR/CD8 binding to ubiquitous self-antigens presented on thymic DCs. HS-induced Ca2+ 
influx augments the TCR and, consequently, lowers the threshold required for deletion of 
strong self-reactive TCR clones. (D) CD8β on immature CD8 SP thymocyte is modestly 
α2-3 O-sialylated (indicated by orange star), reducing HS binding to the CD8β stalk region. 
A partial CD8-HS interaction promotes the ability of high affinity TCRs to bind AIRE-
regulated tissue-restricted antigens (TRA) or ubiquitous self-peptides/MHC-I complexes 
presented by mTEC. HS-induced Ca2+ flux augments TCR signal to lower the threshold 
required to delete TRA-reactive and strongly self-reactive TCR clones. Orange star 
indicates α2-3 sialic acid. (E – F) Immune activation and anergy. (E) Heavy α2-3 O-
sialylation of CD8β on peripheral CD8+ (pCD8) T lymphocytes (indicated by red star) fully 
impairs HS binding to the stalk region. (F) Immune activation triggers the loss of α2-3 sialic 
acid on CD8β, restoring the ability of the CD8-HS interaction to increase TCR affinity for 
peptide/MHC-I complexes on APC/DC. HS-induced Ca2+ influx augments the strength of 
the TCR signal to generate productive effector responses (CD28-co-ligated) or anergy 
(without CD28 ligation). 
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Thus, the CD8-HS interaction could lower the threshold required to delete potentially 
auto-reactive TCR clones in the first wave of negative selection in the cortex (FIG. 
6.1C). The same can be assumed to be taking place in the second wave of negative 
selection in the medulla as mTEC, like cTEC, express comparable levels of surface HS 
(FIG. 5.3). In this context, in addition to the presentation of ubiquitous self-antigens, 
mTEC also present AIRE-regulated tissue-restricted antigens (TRA) to post-selection 
CD8 SP thymocytes (FIG. 1.5) (Klein et al., 2014). As previously mentioned, CD8β on 
DP thymocytes after selection and commitment to the SP stage is gradually α2-3 O-
sialylated and this partially reduces the binding to HS (FIG. 3.11), thus resulting in a 
smaller intracellular Ca2+ influx being induced by the CD8-HS interaction compared to 
DP thymocytes (FIG. 4.2). In this scenario, it is likely that a HS-induced Ca2+ flux 
augments the TCR signal and may be the pivotal factor that determines whether 
borderline auto-reactive TCR clones are to be negatively selected (FIG. 6.1D). 
Collectively, it can be concluded that by enhancing adhesion between TEC and 
thymocytes and providing a Ca2+ flux, the CD8-HS interaction contributes to the fine-
tuning of TCR signals that expand the positively selected TCR repertoire but at the 
same time increases the efficiency of the filtering process involved in deleting 
potentially autoreactive TCR clones. Such a process results in a TCR repertoire that is 
less likely to mediate autoimmunity in the periphery. It is assumed that this process is 
less important for the CD4 lineage, as in addition to clonal deletion, differential TCR 
tuning results in the generation of regulatory T cells (Hsieh et al., 2012). 
6.3.3 Role of CD8-HS interaction in the periphery 
As discussed in Section 6.2.2, in the periphery the CD8αβ heterodimer on dormant 
peripheral CD8+ T lymphocytes is maximally α2-3 O-sialylated to maintain normal cell 
homeostasis (FIG. 6.1E). High levels of circulating plasma HRG ensure that there are 
no residual CD8-HS interactions occurring between APC/DC and dormant peripheral 
CD8+ T lymphocytes, thereby maintaining peripheral tolerance and avoiding the risk of 
developing autoimmune responses. Following immune activation and an established 
inflammatory environment the α2-3 sialic acid residues could be lost from the CD8αβ 
molecules and, in the absence of HRG, CD8αβ molecules could now regain full 
coreceptor functions. Similarly, it is likely that the CD8-HS interaction induces the 
uptake of extracellular Ca2+ (FIG. 4.5) that promotes the Ca2+/NFAT pathway (Macian, 
2005) and also augments TCR signalling arising from recognition of foreign 
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peptides/MHC-I complexes presented on APC/DC to produce robust peripheral CD8+ T 
lymphocyte effector responses. Of course, in the periphery the activation of T cells 
requires costimulatory signals, such as T cells CD28 interacting with CD80/CD86 
expressed by APCs, the absence of costimulation resulting in T cell anergy (FIG. 6.1F). 
Thus, collectively the CD8-HS interaction may not only be important at the intrathymic 
lymphopoietic level, but also may contribute to the generation of robust CD8+ T 
lymphocyte effector responses and the maintenance of CD8+ T lymphocyte peripheral 
tolerance.   
 
6.4 Future research directions 
6.4.1 Establishing the structural requirements for the CD8-HS interaction 
The studies described in this Thesis provide many lines of evidence supporting the view 
that there is a direct interaction between HS and the CD8β chain. Nonetheless, the true 
nature of this interaction will only be resolved when the crystal structure of the CD8-HS 
interaction has solved, as discussed in Section 6.2.1.  
 
Future work should also be aimed at confirming the structural features of the HS 
expressed by thymic stromal cells that are recognised by the CD8 molecule. It should be 
noted that the synthesis of HS chains is a highly complex process involving diverse HS 
synthesising and modifying enzymes. In fact, earlier studies have shown that germline 
ablation of genes encoding HS-synthesising and modifying enzymes, such as extose 
(Ext), N-deacetylase/N-sulfotransferase (Ndst), D-glucuronyl C5-epimerase (Glce), HS 
2-O-sulfotransferase (Hs2st) and HS 6-O-sulfotransferase (Hs6st) (this order being 
reflective of their sequential roles in the synthesis and modification of HS chain) are 
either embryonically lethal or result in perinatal death (Lin et al., 2000, Ringvall et al., 
2000, Li et al., 2003, Stickens et al., 2005, Habuchi et al., 1998, Wilson et al., 2002). 
This issue, however, can be overcome via tissue-specific ablation using the Cre-LoxP 
recombination system. In this approach, specific alterations in the HS chains expressed 
by TEC and DCs can be generated by crossing a mouse strain carrying a floxed allele of 
the gene encoding a particular HS synthesising/modifying enzyme with a syngeneic 
mouse strain that carries Cre recombinase under control of the promoter for FoxN1 or 
Itgax (CD11c) expression, these promoters being specific to TEC and DCs, respectively 
(Gordon et al., 2007, Caton et al., 2007). The impact of such genetic alterations, 
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particularly Hs6st-deficiency in TEC and DCs which would result in HS chains lacking 
6-O-sulfates, on CD8 binding using the TEC/DC-thymocyte rosetting assay or on the 
Ca2+ flux in DP thymocytes rosetting with TEC or DCs will be of particular interest. In 
parallel, these assessments can be done simultaneously with MHC-I and MHC-II 
deficient HS-variant TEC and DCs to exclude the contribution of MHC molecules to 
thymocytes rosetting and induction of an intracellular Ca2+ flux. Mouse strains that 
carry a floxed allele of Ndst, Hs2st and Hs6st are already available as well as 
appropriate Cre recombinase strains that are required for the proposed experiments (Qu 
et al., 2011, Wang et al., 2005). 
6.4.2 Establishing the role of the CD8-HS interaction in positive and negative 
selection of DP thymocytes 
Several laboratories have established in vitro assays to monitor positive and negative 
selection of DP thymocytes (Daniels et al., 2006). These systems can be used to assess 
whether the CD8-HS interaction can lower the signalling threshold required for 
peptide/MHC-I complexes to induce either positive or negative selection of DP 
thymocytes. Usually TCR transgenic DP thymocytes are used from TAP deficient mice 
and hence the thymocytes are arrested at the pre-selection DP stage due to the TAP 
deficiency preventing the peptide loading of endogenous MHC-I molecules on 
TEC/DCs. Peptide variants that have a range of affinities for the transgenic TCR also 
may be used to determine whether there are changes in the affinity of the TCR that is 
positively or negatively selected when pulsed on WT or HS-variant TEC/DCs (Section 
6.4.1) are used. To determine DP thymocyte selection a number of parameters can be 
measured, such as number of surviving DP thymocytes, CD69 up-regulation as a 
general marker for thymocyte activation (FIG. 4.6) (Hare et al., 1999), TCR 
downregulation, as a correlative marker for positive versus negative selection 
(Mariathasan et al., 1998) and CD5 surface expression as a correlate of the signalling 
capacity of the TCR (Azzam et al., 1998). Also, DP thymocytes from TCR transgenic, 
TAP-deficient mice that are Bcl-2 transgenic could be used, as the presence of Bcl-2 
allows negatively selected T cells to survive and be more accurately quantified on the 
basis of Bim expression (Daley et al., 2013).  
 
In addition to cellularity and phenotypic changes as outlined above, the intracellular 
signalling pathways influenced by the CD8-HS interaction, with respect to positive and 
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negative selection, require further experimental examinations. In this regard, an 
unbiased approach to identifying signalling proteins that are phosphorylated in DP 
thymocytes following HS (DxS) stimulation can be achieved by utilising the Phospho 
Explorer Antibody Array system (Full Moon, Biosystems) that consists of a microarray 
with 1318 site-specific antibodies against unique phosphorylation sites in signalling 
proteins. Thus, this system can be used to assess the phosphorylation status of signalling 
molecules in DP thymocytes exposed to HS-like ligands, such as DxS, compared to 
unstimulated and TCR stimulated DP thymocytes. Also, of considerable interest will be 
the effect of simultaneous DxS and TCR stimulation on signalling pathways, 
particularly TCR signalling. Eventually, Phosphoflow and Western blotting analysis 
may be used to confirm the most informative phospho-proteins involved in DxS (HS) 
signalling and in TCR signalling in the presence of the DxS-induced Ca2+ flux. 
Appropriate KO mice, if available, can be used to confirm the importance of any 
identified signalling proteins, particularly those involved in the DxS-induced Ca2+ flux. 
Finally, an important issue to be resolved regarding the major Ca2+ influx induced by 
HS/DxS in DP thymocytes is the nature of the Ca2+ channel(s) involved. 
6.4.3 Establishing the role of the CD8-HS interaction in peripheral CD8+ T 
lymphocyte effector function 
Future studies will examine under what circumstances CD8 molecules become 
desialylated in the periphery and regain HS and MHC-I binding. Such a process would 
potentially lower the activation threshold of peripheral CD8+ T lymphocytes, thereby 
enhancing their capacity to respond to foreign antigens. Theoretically, there are two 
ways by which CD8 molecules can become desialylated. First, pre-existing CD8 
molecules could simply be desialylated by sialidases present in the local, presumably 
inflammatory, environment. Second, as is the case with DP thymocytes, peripheral 
CD8+ T lymphocytes could cease producing the ST3Gal-1 sialyltransferase, in this 
situation all newly synthesised CD8 molecules lacking α2-3 sialic acid residues.  
 
There are four known mammalian sialidases (neuraminidases), NEU1, NEU2, NEU3 
and NEU4, (Miyagi and Yamaguchi, 2012) that could potentially desialylate CD8. 
Scanning the publically available transcriptome databases (e.g., BioGPS), however, it is 
clear that NEU-2 and -4 have extremely narrow expression profiles and are not detected 
in the immune system. NEU1 is expressed by immune cells but exclusively by activated 
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macrophages at very high levels (Seyrantepe et al., 2010). In human DCs NEU3 
expression is upregulated following LPS-induced activation although it is unknown if a 
similar response occurs in murine DCs. Thus, initially the ability of recombinant mouse 
NEU1 and NEU3 to desialylate CD8 on peripheral T lymphocytes and restore FITC-
heparin binding, rosette formation with DCs and DxS-induced Ca2+ fluxing could be 
examined. These experiments have a very high chance of success as NEU1 and NEU3 
have a similar substrate specificity (i.e., high affinity for α2-3 sialic acid) (Miyagi and 
Yamaguchi, 2012) to the V. cholera neuraminidase used in this Thesis to desialylate 
CD8. Whether macrophages and DCs expressing high levels of NEU1 (and NEU3?) in 
inflammatory sites can desialylate CD8 on T lymphocytes infiltrating the site will be of 
considerable interest. Of course, an alternative possibility is that proliferating CD8+ T 
lymphocytes downregulate expression of the ST3Gal-1 sialyltransferase, as occurs in 
DP thymocytes. However, a preliminary study provided no evidence of desialylation of 
CD8 on proliferating OT-I T lymphocytes in vivo, based on FITC-heparin binding (data 
not shown). An attractive hypothesis, however, is that memory CD8+ T lymphocytes 
downregulate the ST3Gal-1 sialyltransferase to render them more responsive to antigen. 
Contrary to this hypothesis, it has been suggested that resialylation of CD8αβ promotes 
CD8+ memory T cells (Priatel et al., 2000). Standard in vitro and in vivo methods for 
generating TCR transgenic (OT-I) memory CD8+ T cells (Miyakoda et al., 2012, Berg 
et al., 2003) could be used to resolve this issue.  
 
6.5 Concluding remarks 
Based the future directions outlined in this Chapter it is clear that, although the research 
reported in this Thesis has identified a new mechanism controlling thymic T cell 
selection and possibly peripheral CD8+ T lymphocyte function, many new questions 
have been raised that need to be addressed. Also, at the general biological level, the 
studies reported in this Thesis have provided an elegant example of the importance of 
HS recognition in a subtle, sophisticated and highly complex biological process, the 
positive and negative selection of T cells in the thymus. Thus, HS can no longer be 
considered as a widely expressed polyanion that merely provides a structural scaffold 
for most tissues and, due to its negative charge, non-specifically binds numerous 
proteins. The remarkable structural diversity of HS within and between tissues has 
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study, one hopes, will provide an excellent example of the biological importance of this 
remarkable family of molecules. 
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